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Abstract 
Peptide inhibitor of trans-endothelial migration (PEPITEM) is a B cell-secreted 
peptide which inhibits T cell trafficking across cytokine-stimulated endothelium. This 
homeostatic mechanism is lost in autoimmune and chronic inflammatory diseases, 
leading to inappropriate T cell trafficking with pathological consequences, e.g. in 
type-1 diabetes and rheumatoid arthritis. We aimed to investigate the structure and 
function of PEPITEM in vitro and in vivo to establish its pharmacokinetics, therapeutic 
potential, and underlying molecular mechanisms. 
The efficacy of PEPITEM was verified, showing the same regulatory control of 
T cell trafficking as previously reported. Nuclear magnetic resonance (NMR) studies 
revealed PEPITEM to be a linear peptide lacking secondary structure. Intravenous 
administration of radiolabelled native PEPTEIM in wild-type mice showed rapid 
clearance by the renal circulation, conferring a circulatory half-life of <2 minutes. 
Common conjugation strategies employed to modify PEPITEM, e.g. PEGylation, did 
not affect peptide function, demonstrating its potential for therapeutic development. 
The evolution of PEPITEM from its parent protein, 14-3-3ζ was investigated. 
PEPITEM is probably cleaved from 14-3-3ζ by matrix metalloproteinase 9 
extracellularly after exocytosis from B cells. Interestingly, this generates a 17aa 
peptide which requires additional proteolytic processing to evolve a smaller 
biologically active pharmacophore. 
These observations add to our current knowledge of the PEPITEM paradigm, 
which appears central to regulated trafficking of T cells. Future work will formulate 
new PEPITEM versions with suitable pharmacological profiles, and screen them for 
function in vitro and in vivo to develop suitable therapeutic agents. 
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1.1. An overview of the Immune system 
 
As early as 430 BC, the principle of immunity was observed by Athenian 
historian Thucydides, who noted that only nurses who had successfully recovered 
from the offending Plague of Athens were able to tend to the sick without subsequent 
infection (Thucydides et al., 1910). Innovative scientists such as Edward Jenner, 
Louis Pasteur, Robert Koch and Elie Metchnikoff have since pioneered immunology 
as we know it today.  
In this general introduction, the immune system and the process of 
inflammation will be explored in the context of both health and disease. This thesis 
will interrogate the structure, function and pharmacokinetics of a novel peptide 
termed PEPITEM, which inhibits T cell transmigration. Its relevance in immunity and 
potential for therapeutic application in immunological disease will be explored. 
The immune system is a multifaceted, highly specialised and intricately co-
ordinated network of tissues, cells, molecules and proteins. Evolved over millions of 
years, it works dynamically to provide defence against disease, and this is essential 
for host survival.  
 
1.1.1. The function of the immune system 
The two principle activities of the immune system are recognition and 
response to malady. Immune recognition is the ability to determine ‘self’ from ‘non-
self’. Through this aptitude, the immune system is able to distinguish pathogens such 
as bacteria or parasites from our own cells, self-molecules from non-self molecules 
 3 
 
such as bacterial toxins, and even our own virally infected or cancerous cells, from 
healthy cells. The immune response is the ability to neutralise a threat to the host. 
This ability to respond to threats enables us to eliminate pathogens including viruses, 
bacteria and parasites, neutralise molecules such as toxins and bacterial proteins, 
and carefully remove our own diseased cells (Owen et al., 2007). 
 
1.1.2. Leukocytes 
 
“Leukocyte” is the collective term for a white blood cell (WBC). Leukocytes, 
along with red blood cells (RBC) and platelets, are produced in the bone marrow 
through haematopoiesis. During this process, haematopoietic stem cells can give rise 
to lymphoid progenitor cells or myeloid progenitor cells, eventually differentiating 
down several lineages (Figure 1.1). While the lymphoid lineage produces B and T 
lymphocytes and natural killer (NK) cells , the myeloid lineage results in erythrocytes, 
platelets, basophils, eosinophils, neutrophils and monocytes. Both lineages have the 
capacity to produce dendritic cells (DC), (Owen et al., 2007). 
 
1.1.3. Innate and adaptive immunity 
The immune system can be separated into two distinct yet allied systems; 
innate and adaptive immunity. The main differences are summarised in Table 1.1. 
The innate immune system can be considered the first line of defence, which kicks 
into action immediately following an insult. Although specificity is limited, innate 
immunity is crucial for defence against bacterial pathogens. This is highlighted in  
 4 
 
 
 
 
 
 
 
 
 
Figure 1.1. Leukocyte production by haematopoiesis.  
Self-renewing hematopoietic stem cell progenitors can differentiate down the 
myeloid or lymphoid lineages. These discrete lineages can give rise to a number 
of cell types, each with their own specific immunological functions. Adapted from 
Owen et al. (2007). 
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diseases such as chronic granulomatous disease, where phagocytic cells 
including neutrophils have a genetic defect in the oxidative pathway used to generate 
reactive oxygen species (ROS), such as hydrogen peroxide (Owen et al., 2007). This 
defect leads to an inability to kill phagocytosed pathogens, and therefore persistent 
bacterial and fungal infections. The innate immune system responds to antigens 
through a series of pattern recognition receptors (PRRs) which recognise pathogen-
associated molecular patterns (PAMPs) and danger-associated molecular patterns 
(DAMPs). These molecular patterns are highly conserved structural motifs expressed 
by pathogens or released following damage for PAMPs and DAMPs respectively 
(Newton and Dixit, 2012). 
The adaptive immune system supports the innate immune system with a more 
tailored immune response. This response, although slower, is more specific and thus 
Feature: Innate immunity: Adaptive immunity: 
Response time Hours Days 
Main components 
Physical barriers, 
phagocytes 
Lymphocytes 
Soluble factors 
Cytokines, complement, 
acute phase proteins 
Cytokines, antibodies 
Specificity Limited Diverse and improving 
Response to 2o 
infection 
Same as response to initial 
infection 
Faster, more specific 
 
Table 1.1. Innate vs Adaptive Immunity. 
The immune system can be divided into two distinguished parts. Here, the main 
differences between these two allied systems are compared. Adapted from 
Owen et al. (2007). 
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more effective at clearing pathogens. In adaptive immunity, B cells and T cells play a 
central role and this will be discussed further in sections 1.2 and 1.3. The importance 
of adaptive immunity is emphasised by research in athymic “nude” mice, which under 
normal living conditions have a high mortality rate. This is due to the lack of thymus 
(Flanagan, 1966), and thus T cells (De Sousa et al., 1969), leading to a deficiency in 
cell-mediated immunity and antibody production. 
Antigen presenting cells (APC) bridge innate and adaptive immunity. They 
provide a means by which the innate immune compartment can communicate with 
the adaptive compartment, activating T cells and B cells and initiating the adaptive 
immune response (Owen et al., 2007). Ultimately, for a fully functional immune 
system, both the innate and adaptive counterparts are required. 
 
1.2. T cells 
 
T cells form an essential part of adaptive immunity, providing cell-mediated 
defence against disease. With a whole host of T cell subsets, these lymphocytes are 
dedicated to the eradication of a multitude of diseases and the regulation of immune 
responses. Here, the role of T cells will be explored in more detail. 
 
1.2.1. Generation 
T cells originate in the bone marrow from haematopoietic progenitor cells, and 
differentiate down a lymphoid lineage before migrating to the thymus, a primary 
lymphoid organ. Here, they mature and are educated by the thymic stroma through 
positive and negative selection. During this process, T cells are tested according to 
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their integral ability to distinguish self from non-self, thus ensuring self-tolerance 
(Moroy and Karsunky, 2000, Owen et al., 2007).  
Upon maturation, T cells express the T cell receptor (TCR) cluster of 
differentiation 3 (CD3), and either the co-receptor cluster of differentiation 4 (CD4) or 
cluster of differentiation 8 (CD8). They are released into the periphery as naïve T 
cells where they recirculate every 12-24 hours (Owen et al., 2007). These T cells are 
poor at responding to antigen, but are able to migrate well to lymphoid organs such 
as lymph nodes. 
Naïve T cells circulate continuously between the lymphatic system consisting 
of complex structures where immune cell trafficking, meetings and surveillance takes 
place. The lymphatic system comprises a network of vessels and capillaries which 
carry fluid called lymph formed when plasma, under blood pressure, leaves 
capillaries, permeates tissues and then drains into lymphatic vessels and is 
eventually returned to the blood. This extensive network of vessels connects 
lymphoid organs, allowing movement of T cells and other WBC between the lymph 
and the blood. Naïve T cells express adhesion molecule L-selectin (CD62L), C-C 
chemokine receptor type 7 (CCR7) and the β2 integrin lymphocyte function-
associated antigen 1 (LFA-1). Expression of these molecules aids specific homing to 
the glycoprotein peripheral node addressin (PNAd), chemokine (C-C motif) ligand 21 
(CCL21) and intercellular adhesion molecule-1 or 2 (ICAM-1/2) respectively, 
expressed by post-capillary high endothelial venues (HEVs), facilitating entrance to 
lymph nodes (Weninger et al., 2001). 
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1.1.2. Activation and recruitment 
During circulation, T cells continuously survey the body for specific antigens. 
Antigen presenting cells such as DCs and macrophages constitutively take up 
antigen from inflamed tissue, process them, and bring them back to secondary 
lymphoid organs (SLOs) such as lymph nodes (LNs), the spleen and mucosa-
associated lymphoid tissue (MALT), where T cell traffic is frequent. Antigen-specific T 
cells recognise cognate non-self antigens presented to them by APCs in the context 
of major histocompatibility complex (MCH) class I and II for CD8+ and CD4+ T cells 
respectively. Subsequent activation is triggered via two signals – (i) through the 
binding of CD3 to an MHC-antigen complex, and (ii) through the binding of co-
stimulatory molecule CD28 on T cells to cognate receptors on activated APCs such 
as CD86 or CD80 (Jensen, 2007). Following activation, T cells up-regulate the 
expression of proliferation-promoting cytokine interleukin (IL)-2, undergo clonal 
expansion and differentiate into memory and effector cells. Memory T cells and 
effector T cells have distinct trafficking patterns achieved through differential 
expression of specific cell adhesion molecules such as selectins (Ley and Kansas, 
2004). This enables T cells to be recruited to the right place at the right time, and 
perform desired effector or regulatory functions. 
 
1.1.3. T cell subsets and function  
Following activation, T cells can be divided in to 2 main groups; effector T cells 
and memory T cells. These subsets have specific functions, and their characteristics 
reflect this. Other T cell subsets include regulatory T cells, and their functions will be 
discussed below. 
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1.1.3.1. Effector T cells 
Effector T cells conduct specialist functions and can be further divided into 
CD4+ T helper (TH) cells (TH1 or TH2), and CD8
+ cytotoxic T cells (CTL). TH1 play a 
key role in cell-mediated immunity and CTL activation, and can polarise the immune 
response towards defence against pathogens through the secretion of IL-2, interferon 
gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α), (Owen et al., 2007). These 
cytokines are then able to activate other leukocytes such as neutrophils and 
macrophages (Broere et al., 2011). On the other hand, TH2 provide the response to 
extracellular pathogens and provoke allergic responses through secretion of IL-3, IL-
4, IL-5 and IL-6, and are able to co-ordinate humoral immunity through the activation 
of B cells (Owen et al., 2007). CTL possess cytotoxic killing activity and are important 
in the removal of damaged or virus infected cells by their ability to recognise 
abnormal self-antigens presented to them in MHC class I-antigen complexes. 
Following recognition of a damaged cell e.g. a cancer cell, CTLs destroy the target 
cell either though cell lysis via the release of cytotoxic proteins, or through the 
induction of apoptosis mediated by the binding of CTL Fas ligand to target cell Fas 
receptors (Owen et al., 2007). 
 
1.1.3.2. Memory T cells 
Following the restoration of homeostasis, most T cells undergo apoptosis. 
However, a small proportion remain and differentiate into memory T cells (Kaech et 
al., 2002). This memory T cell (TM) population of antigen-experienced cells have the 
capacity to mount faster and more specific secondary immune responses following 
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subsequent recognition of the same antigen. These cells can be divided into two 
types with distinct functions; central memory (TCM) and effector memory T cells (TEM).  
TCM reside in secondary lymphoid organs and despite having limited effector 
function, are capable of expert proliferation and differentiate into effector cells in 
response to antigen. Reflecting this, these cells have high expression of L-selectin 
and C-C chemokine receptor type 7 (CCR7), required for re-circulation, and can 
produce pro-proliferative cytokine IL-2 but are poor at producing pro-inflammatory 
cytokine IFN-γ (Kaech et al., 2002). Conversely, TEM occupy the periphery, and 
possess advanced effector functions in inflamed tissues in response to antigen 
(Sallusto et al., 2004).  Again, this is reflected by the low expression of L-selectin and 
the absence of CCR7. Instead, these cells are highly capable of producing IFN-γ, but 
poor at producing IL-2 (Kaech et al., 2002). 
 
1.1.3.3. Regulatory T cells 
Regulatory T cells (Treg), as the name suggests, represent a population of T 
cells which regulate the function of many immune cells and play an important role in 
the maintenance of self-tolerance within the immune system. Tregs can be induced in 
the periphery (iTreg) following activation, or develop naturally in the thymus (nTreg), 
and recognise self-antigens to facilitate the maintenance of self-tolerance 
(Pacholczyk and Kern, 2008). They express the surface marker CD25 (Sakaguchi et 
al., 1995) also present on activated T cells, but a more specific marker of Treg is the 
transcription factor forkhead box P3 (FoxP3, Hori et al. (2003)). Upon activation, Treg 
suppress other T cells (Tang and Bluestone, 2008) by mopping up available pro-
proliferative cytokine IL-2 produced during inflammation, secreting anti-inflammatory 
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cytokines such as IL-10 and transforming growth factor beta (TGF-β), and inducing 
apoptosis in responding T cells (Shevach, 2009). T cells can also act indirectly on T 
cell performance by down-modulation of APC function, for example by, suppressing 
antigen presentation (Sakaguchi et al., 2009). 
 
1.3. B cells 
 
B cells, defined by their expression of the B cell receptor (BCR), play a 
fundamental role in the humoral immune response, with their primary functions being 
to produce antibody and serve as APCs. The role B cells play in adaptive immunity 
will be explored in more detail here. 
 
1.3.1. Generation 
B cells, like T cells, are derived from haematopoietic progenitor cells in the 
bone marrow. However, unlike T cells, B cells remain there during initial stages of 
maturation. The generation of B cells requires the unique microenvironment provided 
by the bone marrow stroma, which supports the maturation of B cells through the 
secretion of cytokines such as IL-7 (Engel et al., 2011). 
Developing B cells express surface antibodies in the form of surface 
immunoglobulin (Ig) IgM (Engel et al., 2011). This Ig is produced through the 
rearrangement of the genes coding for the heavy chain and light chains of the Ig to 
produce a unique, functional BCR complex, capable of recognising antigen 
presented by APCs in MHC I (Owen et al., 2007). During development, deletion of 
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auto-reactive B cells by negative selection occurs in the bone marrow, mediated by 
the stroma and helps to prevent autoimmunity (Engel et al., 2011). However 
evidence has suggested that B cells can also arrest and re-arrange the light chain 
genes of their B cell receptor (Shevach, 2009). After successful passage of this 
checkpoint, B cells are released into the periphery at a rate of approximately 5 million 
per day, and begin to circulate, maturing into naïve B cells expressing CD19, IgM, 
and, after entering SLOs, IgD on their surface (Engel et al., 2011, LeBien, 2000). 
 
1.3.2. Activation and recruitment 
Naïve or resting B cells can be activated in a thymus-dependent or thymus 
independent manner; that is, in the presence or absence of T cells respectively. An 
example of the latter is the activation of B cells by lipopolysaccharide (LPS), a 
component of the cell wall of gram-negative bacteria. LPS binds both its receptor toll-
like receptor 4 (TLR4) and the BCR on the B cell surface. The ligation of these two 
receptors causes the subsequent activation of the B cell and differentiation into short-
lived plasma cells which secrete IgM, but are low-affinity and cannot generate 
memory cells (Fagarasan and Honjo, 2000). Despite this, these B cells are integral to 
fast immune responses against pathogens. 
T cells play an essential role in B cell responses to antigen, which occur in 
SLO such as LN (Engel et al., 2011). Following the recognition of specific antigen by 
the BCR, the BCR-antigen complex is internalised by receptor-mediated endocytosis 
(Owen et al., 2007). It is subsequently processed into smaller peptides, which are 
presented at the membrane as peptide-MHC II complexes. The co-stimulatory 
molecule B7 is also up-regulated, as well as MHC II. This initial signal causes the B 
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cells to migrate to follicles in the periphery of SLOs (Engel et al., 2011), where they 
interact with TH to become fully activated. 
Initially, antigen-specific TCR on T cells recognises cognate antigen presented 
by the B cell in the context of MHC II. This interaction, along with the ligation of B cell 
CD80/CD86 to T cell CD28 as described in section 1.1.2, activates the TH cell. Once 
activated, TH cells express the ligand for B cell costimulatory molecule CD40 (CD40-
L), (Noelle et al., 1992). Interaction of B cell CD40 with T cell CD40L provides a 
second signal to the B cell (Engel et al., 2011), which begins to up-regulate receptors 
for TH1 cytokines such as IL-2, IL-4 and IL-5 (Owen et al., 2007). The activated TH 
cell secretes these cytokines, which bind to the B cell and stimulate complete B cell 
activation, inducing proliferation and differentiation into effector B cells (Engel et al., 
2011). These short-lived B cells secrete IgM and IgG (Owen et al., 2007). 
Some of the activated B cells form germinal centres within follicles (Engel et 
al., 2011). The importance of germinal centres in the humoral immune response is 
highlighted by the fact that three key processes take place there. The first of these 
processes is affinity maturation, where rapid B cell division and somatic 
hypermutation of B cell Ig genes leads to the production of B cells with high-affinity 
membrane Ig (MacLennan et al., 2003, Owen et al., 2007). Class switching 
subsequently occurs, where B cell Ig can improve further through changing the 
isotype of the constant region of the antibody, improving the biological effector 
activity of the antibody while maintaining antigen specificity (Owen et al., 2007). 
Finally, germinal centres support the vital process of B cell differentiation into plasma 
and memory cells (MacLennan et al., 2003). This is influenced heavily by TH, and the 
cytokines that they secrete such as IL-2, IL-4 and IL-5 (Owen et al., 2007). 
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1.3.3. B cell subsets and function 
Like T cells, B cells can be subdivided into an effector subset cells known as 
plasma cells, and a memory subset. The functions of these cells will be outlined here. 
 
1.4.3.1. Plasma B cells 
Both short-lived and long-lived plasma cells have been identified in mice and 
humans, depending on the context of B cell activation and interactions with TH 
(Bortnick and Allman, 2013). The primary role of these effector B cells is to produce 
large amounts of high affinity antibodies. Upon differentiation, plasma cells migrate to 
the medullary cord and secrete antibodies into the lymph (Shapiro-Shelef and 
Calame, 2005). Antibody function is primarily mediated by their binding affinity to a 
specific epitope. Through this interaction, antibodies are able to bind specifically to 
their target antigen, triggering a series of down-stream effects. These include 
immobilisation, neutralisation and opsonisation of pathogens, antibody mediated 
cytotoxicity and activation of other compartments of the immune system including the 
complement system and effector cells (Owen et al., 2007). 
 
1.4.3.2. Memory B cells 
Formed within germinal centres after a primary immune response, memory B 
cells are capable of existing for long periods of time, recirculating between peripheral 
lymphoid tissues via vascular and lymphatic vessels (Crotty et al., 2003, Tangye and 
Tarlinton, 2009). This subset of B cells classically express CD19 and CD27, and 
respond efficiently to antigens. Compared to naïve B cells, memory B cells express 
much higher levels of co-stimulatory molecules such as CD80 and CD86, needed for 
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complete T cell activation (Good et al., 2009). Central to their role, memory B cells 
possess the capacity to rapidly proliferate and differentiate into antibody-secreting 
plasma cells following re-exposure to a previously encountered antigen. Succeeding 
this secondary immune response, these antigen-experienced B cells are more 
specialised at producing antibodies, which are of high affinity due to affinity 
maturation (Engel et al., 2011). 
 
1.1.4.2. Regulatory B cells 
The existence of immunosuppressive B cells has been speculated for some 
years, however studies defining this controversial subset have been more recent. 
Regulatory B cells (Breg) represent a B cell subset with suppressive or regulatory 
functions. Like Treg, Breg are also important in maintaining self-tolerance. As a 
consequence of class switching, Breg express additional Ig on their surface including 
IgG, IgA and IgM (Owen et al., 2007). Although Breg have been identified in mice 
(Mauri and Ehrenstein, 2008), the existence of a counterpart in humans continues to 
be debated (Jamin et al., 2008). One such way by which Breg have been speculated 
to regulate immune responses is through the production of anti-inflammatory cytokine 
IL-10 (Yang et al., 2013). 
 
1.4. T cell trafficking in inflammation 
 
In order to fulfil their immunological roles, T cells must be capable of selective 
migration to sites of inflammation in tissues, facilitated by the expression of a variety 
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of cell adhesion molecules. T cell trafficking during inflammation involves a multi-step 
paradigm, summarised in Figure 1.2, known as the leukocyte adhesion cascade. This 
is similar for neutrophils, monocytes and lymphocytes, and enables leukocyte 
extravasation out of the vasculature (Schmidt et al., 2013). There, they perform a 
number of functions leading to the elimination of any hazards, and the resolution of 
inflammation.  
 
1.4.1. T cell extravasation at sites of inflammation. 
Endothelial cells lining post-capillary venules express a diverse range of cell 
adhesion molecules and chemokines to orchestrate the recruitment of T cells during 
inflammation (Aird, 2005). The main stages in T cell recruitment from the blood can 
be summarised into several sequential steps. These steps are tissue specific, and 
involve different cell adhesion molecules depending on the context and tissue in 
which migration is occurring. 
 
(i) Capture from flow 
T cell capture by endothelial cells is highly dependent on cytokines such as 
TNF-α and IFN-γ (Springer, 1995), secreted primarily by WBC during inflammation. 
Effector and memory T cells circulate in the blood during an inflammatory response 
and are subsequently captured by cytokine-activated endothelium. In this process, 
initial margination of cells occurs due to the physiological and kinetic properties of 
flowing blood; the larger RBC accumulate in the centre of the lumen, forcing the 
smaller T cells towards the periphery (Munn et al., 1996). This facilitates close- 
proximity interactions between T cell and endothelial cell adhesion molecules, 
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allowing the proceeding steps in the cascade.  
 
(ii) Rolling 
When in close proximity to inflamed vascular endothelium, T cells roll along 
the surface of the blood vessel. This phenomenon is mediated by a group of cell 
adhesion molecules known as selectins, which bind a family of mucin-like cell 
adhesion molecules, such as P-selectin glycoprotein-1 (PSGL-1), via their lectin 
domain (Ley, 2003). Several selectins are involved in T cell rolling, including E-
selectin, P-selectin and L-selectin. E-selectin and P-selectin are both expressed on 
the surface of endothelial cells, and were originally identified on endothelial cells and 
platelets respectively. P-selectin plays a key role in mediating T cell capture and 
Figure 1.2. T cell recruitment and transmigration. 
Initially, T cells are recruited from flow and roll along the endothelium via selectin-
mediated interactions. For example, activated T cells use PSGL-1 to roll on 
endothelial cell P-selectin (Ley and Kansas, 2004). T cells undergo chemokine-driven 
integrin activation through inside-out signalling, and arrest on the endothelium. 
Following a final signal from PGD2 and engagement of DP2, T cells cross the 
endothelial cell layer and move into the tissue by paracelluar or transcelluar migration. 
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rolling (Luscinskas et al., 1995b), whereas E selectin is essential for TM cell adhesion 
(Shimizu et al., 1991). L-selectin expression is exclusive to leukocytes, but is not 
present on effector memory T cells (Ley et al., 2007, Springer, 1994, von Andrian et 
al., 1993). Selectins bind their ligands with low affinity leading to the rapid breaking 
and re-forming of weak bonds between the molecules. These low affinity interactions 
enable rolling to occur and are important in reducing velocity, allowing sufficient time 
for the leukocyte to examine endothelial cell moieties such as chemokines (Schmidt 
et al., 2013). Mounting evidence has suggested that very late antigen-4 (VLA-4) is 
also able to support T cell rolling on vascular cell adhesion molecule-1 (VCAM-1), 
(Alon et al., 1995, Johnston et al., 1996, Luscinskas et al., 1995b). 
 
(iii) Activation 
Upon sensing an appropriate signal from the endothelium, T cells will become 
activated and cease to roll. Activation signals occur through the binding of 
chemokines, synthesised by inflamed endothelial cells, to receptors on the surface of 
T cells. Chemokines are a group of chemoattractant cytokines of around 8 to 16kDa, 
and are comprised of 4 families classified by the position of two conserved cysteine 
residues within the amino acid sequence; C, CC, CX3C and CXC (Rollins, 1997). 
IFN-γ, a cytokine commonly produced at the site of inflammation, induces the 
expression of chemokines CXCL9, CXCL10 and CXCL11 on the endothelial cell 
surface (Mazanet et al., 2000, Piali et al., 1998). These chemokines are able to bind 
to the G-protein coupled receptor (GPCR) CXCR3, expressed highly on the surface 
of effector and memory T cells (McGettrick et al., 2009, Piali et al., 1998), and GPCR 
signalling in turn leads to T cell activation.  
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(iv) Arrest 
Chemokine binding to T cell GPCRs induce a rapid intracellular signalling 
cascade leading to a change in conformation of T cell transmembrane receptors 
known as integrins. Through a process known as “inside out signalling”, structural 
changes in T cell integrin LFA-1 render it active, facilitating high-affinity binding to the 
endothelial cell ligand VCAM -1 (Hogg et al., 2011, Ley et al., 2007). This strong 
binding interaction leads to T cell arrest and firm adhesion on the endothelial cell 
surface. 
 
(v) Transmigration 
In the final stage of the leukocyte adhesion cascade, T cells initially migrate on 
the surface of the endothelium (Middleton et al., 2002). Recent evidence 
demonstrated the requirement of TM cells for a final signal, which is provided by 
endothelial cell prostaglandin D2 (PGD2) binding to the D-prostanoid receptor (DP2) 
on the TM surface (Ahmed et al., 2011).  
Other mechanisms regulating this final step in T cell migration have been 
suggested in the literature. For example, IL-15 has been attributed to enhanced T cell 
activation and transmigration in vitro (Sancho et al., 1999) and ex vivo in T cells from 
multiple sclerosis (MS) patients (Broux et al., 2015). Matrix metalloproteinase (MMP) 
activation in T cells, for example through Wnt signalling (Wu et al., 2007), also 
facilitates T cell migration by permitting passage through the basement membrane. 
Interestingly, the prostaglandin analogue PGD3 was shown to inhibit neutrophil 
transmigration via antagonism of the DP2 receptor in neutrophils (Tull et al., 2009), 
however this same mechanism has not yet been established in T cells.  
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The process of transmigration, whereby T cells cross the endothelial cell layer 
via diapedesis, can occur in two different ways. The most common of these ways is 
known as paracellular migration, where T cells migrate between gaps in cells via tight 
junctions, and use endothelial cell adhesion molecules such as PECAM-1, LFA-1, 
junctional adhesion molecules (JAMs) and vascular endothelial (VE)-cadherin (Ley et 
al., 2007, Muller, 2003). The less common way, termed transcellular migration, is 
where T cells migrate directly through the endothelial cells via formation of vesiculo-
vacuolar organelles, creating intracellular endothelial cell channels (Ley et al., 2007, 
Millan et al., 2006). 
 
1.4.2. Memory T cell recruitment to inflamed tissues 
Antigenic stimulation of naïve T cells leads to the reinstatement of 
homeostasis, and the generation of TEM and TCM. TEM circulate in the periphery, 
providing immune surveillance of tissues, while TCM reside in SLOs, waiting for their 
cognate antigen (Kaech et al., 2002). During inflammation, TM are recruited to the 
tissues by adhesion molecules up-regulated on inflamed vascular endothelial cells 
following cytokine activation. Enrichment of TM subsets during inflammation has been 
reported both in vivo during peritoneal inflammation (Roberts et al., 2009), and in 
vitro (Ahmed et al., 2011, Chimen et al., 2015).  
As briefly mentioned previously, the generation of PGD2 from arachidonic acid 
(AA) by EC cyclooxygenases (COX), and its receptor DP2 on the surface of T cells, 
has been implicated in the migration of CD4+ TM cells across inflamed endothelial 
cells (Ahmed et al., 2011). PGD2 binding to DP2 enhanced CD4
+ TM cell trafficking 
following activation by chemokine receptor CXCR3. Evidence supporting this model 
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of TM cell trafficking includes the observation of decreased inflammatory responses 
following DP2 inhibition in mouse models of allergic inflammation (Stebbins et al., 
2010). 
 
1.5. The role of T cells in autoimmune and chronic 
inflammatory diseases 
 
The primary role of T cells in inflammation is to respond to the presence of 
non-self material known as antigens. The T cell response is a highly complex 
biological response involving an impressive multitude of inflammatory mediators and 
immune cells under tight regulation. Under normal physiological circumstances, T cell 
trafficking is beneficial to the elimination of the antigenic trigger and the resolution of 
acute inflammation. However, when this highly co-ordinated system fails, disease 
can result. 
 
1.5.1. Chronic inflammation 
Chronic inflammation occurs when acute inflammation does not resolve and 
persists for long periods of time. During this process, an accumulation of leukocytes 
such as T cells occurs in tissues due to excessive trafficking, local proliferation or 
delayed egress. Once in the tissues, inflammatory cells release a multitude of 
mediators causing a continuous cycle of inflammation, cell recruitment and activation. 
Ultimately, tissue damage results which in turn leads to the development of a variety 
of chronic inflammatory diseases, usually with a T cell element. Often, T cell 
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mediated chronic inflammation is tissue specific (Luster et al., 2005), highlighting the 
ability of T cells to home distinctively to specific tissues. The aetiology of chronic 
inflammatory disease remains a subject of fierce debate. However most speculate 
the cause to be dysregulation of pro-inflammatory or anti-inflammatory processes 
that regulate the extent of inflammation and resolution. For example, perhaps 
dysregulation in the production of IL-10, a key anti-inflammatory cytokine (Kubo and 
Motomura, 2012), or the suppressive function of Treg (Lindley et al., 2005). 
 
1.5.2. Type 1 Diabetes 
Type 1 Diabetes (T1D) is an autoimmune endocrine disorder resulting from 
the inability of pancreatic beta cells to produce the metabolic hormone insulin 
(Daneman, 2006). Currently affecting around 400,000 people in the UK (Juvenile 
Diabetes Research Foundation, 2010), T1D is characterised by an increased blood 
glucose level which can be life threatening if left untreated. 
It is widely agreed that the pathogenesis of T1D is due to insulitis and 
subsequent beta cell destruction, mediated by the infiltration of auto-reactive T cells 
specific for a self-antigen, which to date is still unknown. Evidence supporting this 
includes the identification of CD4+ and CD8+ T cells in insulitic lesions (Figure 
1.3),(Imagawa et al., 1999), however the presence of B cells and macrophages has 
also been reported (Itoh et al., 1993). Many popular hypotheses involve a viral 
element, with some scientists suggesting pro-autoimmune infection triggering 
autoimmunity, and others implicating molecular mimicry of human antigens (Filippi 
and von Herrath, 2008). Contributing factors to the onset of T1D include the failure of 
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Treg to suppress CD8
+ T cells through Treg expression of TGF-β (Lindley et al., 2005), 
or the sensitivity of T cells to TGF-β (Gregori et al., 2003, Lawson et al., 2008). 
 
 
                          Patient with T1D                    Healthy control 
 
 
 
 
 
1.5.3. Rheumatoid Arthritis 
Rheumatoid Arthirits (RA) is a chronic autoimmune disease involving 
persistent synovial inflammation. Affecting between 0.5 and 1% of adults, RA can 
lead to decreased mobility resulting from joint damage (Scott et al., 2010). Like T1D, 
RA is also triggered by an unknown antigen recognised by autoreactive T cells, 
leading to excessive immune cell trafficking. CD4+ T cells play a primary role in the 
Figure 1.3. Infiltration of T cells into pancreatic islets in type 1 diabetes. 
A section of the pancreatic islets from (a) a patient with T1D and (b) a healthy 
control.  Insulin is stained in red and T cells are stained in green, identified by 
cluster of differentiation 3 (CD3). Infiltration of T cells can be seen in the pancreas 
of the type 1 diabetes patient leading to insulitis and autoimmune destruction of 
beta cells, however T cells are absent in the healthy control. (Imagawa et al. 
(1999) copyright license number: 2814290215519). 
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establishment of RA, and have been found in the synovium along with the presence 
of autoantibodies (Komatsu and Takayanagi, 2012). The involvement of both TEM and 
TCM under the regulation of the T cell mitogen IL-12, has been implicated in the 
pathogenesis of RA (Kohem et al., 1996, Zhang et al., 2005). Furthermore, synovial 
inflammation is exacerbated through immune cell production of IL-1, IL-6 and TNF-α, 
facilitating the continuous recruitment and activation of immune cells (Komatsu and 
Takayanagi, 2012, Scott et al., 2010). 
 
1.5.4. Atherosclerosis 
Atherosclerosis is one of the most prevalent cardiovascular diseases (CVD) in 
the UK, resulting from accumulation of lipid within the arterial walls. Atherosclerosis 
involves a complex multi-factorial process initially involving endothelial cell activation, 
inflammation and the recruitment of leukocytes (Falk, 2006). Macrophages 
phagocytose deposited lipids, becoming foam cells and contributing to the 
atherosclerotic plaque. T cells also contribute to the development and maintenance 
of chronic inflammation in atherosclerosis. The involvement of both TH1 and TH2 
responses in atherosclerosis has been examined (Ait-Oufella et al., 2009), with T 
cells playing an important part in the progression of disease. TH1 cells predominate, 
contributing to the exacerbation of inflammation through the production of high levels 
of pro-inflammatory cytokines such as IFN-γ, sustaining the inflammatory response 
through the further recruitment of monocytes and DCs, thus progressing plaque 
formation (Mallat et al., 2007). Atherosclerotic plaques are susceptible to rupture due 
to arterial shear stress, which can lead to coronary complications such as stroke, and 
even death. 
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1.6. PEPITEM: a novel inhibitor of T cell transmigration 
 
T cell recruitment during inflammation is normally highly regulated, controlled 
by antigen specificity, Treg and regulatory cytokines. From early on, T cells are 
controlled for auto-reactivity by negative selection in the thymus. However, during 
certain diseases including those discussed above, T cell trafficking can become 
dysregulated, causing excessive migration of T cells into tissues with pathological 
consequences. Recently, our laboratory has demonstrated that B cells regulate T cell 
trafficking in response to adiponectin stimulation (Chimen et al., 2015). This 
homeostatic mechanism, mediated by a peptide termed Peptide Inhibitor of Trans-
Endothelial Migration (PEPITEM), represents a novel paradigm and forms the basis 
on which this thesis centres. Here, PEPITEM and its molecular mechanism will be 
discussed in further detail. 
 
1.6.1. Anti-inflammatory properties of Adiponectin 
Adiponectin is an adipokine primarily secreted by adipocytes (Ouchi et al., 
2011). The adiponectin receptors, AdipoR1 (AR1) and AdipoR2 (AR2), represent 
ubiquitously expressed GPCRs capable of binding globular and full length 
adiponectin respectively (Yamauchi et al., 2003). Adiponectin plays an important role 
in energy homeostasis, metabolism and the regulation of insulin sensitivity. 
Physiological levels of adiponectin vary between 3 and 30µg/ml, but generally are 
high (Arita et al., 1999, Ouchi et al., 2011). However, adiponectin levels are severely 
decreased in obesity and the protective roles of adiponectin against obesity-related 
diseases have been demonstrated by the correlation of low levels of adiponectin with 
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higher risk of CVD, metabolic syndrome and type II diabetes (Kadowaki and 
Yamauchi, 2005, Ouchi et al., 2011, Rabe et al., 2008).  
Adiponectin has pleiotropic effects within the immune system (Kadowaki et al., 
2006, Ouedraogo et al., 2007) and is capable of exerting anti-inflammatory effects 
and mediating immune responses, such as the inhibition of TNF-α production and the 
stimulation of anti-inflammatory cytokine IL-10 production by macrophages (Ouchi et 
al., 2011). Conversely, adiponectin has also been reported to exhibit pro-
inflammatory effects through the induction of pro-inflammatory cytokines including IL-
6, IL-8 and TNF-α by monocytes and macrophages (Haugen and Drevon, 2007, 
Peake and Shen, 2010, Tsatsanis et al., 2005) . Perhaps the differences in 
adiponectin function may be attributed to the different forms of adiponectin 
(Neumeier et al., 2006), or indeed the inflammatory context.  
The importance of adiponectin in inflammation is demonstrated by studies in 
adiponectin-deficient mice, who were found to have greater levels of the pro-
inflammatory cytokines TNF-α and IL-6, reversible by the addition of exogenous 
adiponectin (Ouchi et al., 2011). These mice were also more susceptible to vascular 
diseases such as atherosclerosis, and involve chronic inflammatory infiltrates 
(Matsuda et al., 2002, Okamoto et al., 2002). Furthermore, increased rolling and 
adhesion of leukocytes has been reported in adiponectin-deficient mice, along with 
the upregulation of key endothelial cell adhesion molecules involved in leukocyte 
trafficking (Cao et al., 2009, Ouedraogo et al., 2007). However, the mode of action of 
these effects remains unclear, and the immunological role of adiponectin has not yet 
been fully established. 
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1.6.2. Sphingosine-1-phosphate in T cell trafficking 
Sphingosine-1-phosphate (S1P) is a sphingolipid produced in the cytosol 
through the phosphorylation of sphingosine by the enzymes sphingosine kinase 1 
and sphingosine kinase 2 (SPHK1/2), which are expressed by vascular endothelial 
cells (Hla et al., 2001). It has a short half-life in plasma of 15 minutes (Venkataraman 
et al., 2008). S1P is exported across the EC membrane into the blood by the S1P 
transporter protein spinster homolog 2 (SPNS2), where it exerts its effects by binding 
to one of five GPCRs (S1PR1–S1PR5). However, S1P signalling is mainly limited to 
S1PR1 and S1PR4 in T lymphocytes (Reviewed by Garris et al. (2014)). 
The major role of S1P has been well reported, regulating the egress of 
recirculating lymphocytes from secondary lymphoid organs such as LN into efferent 
lymphatics (Matloubian et al., 2004). However recent studies have revealed the 
ability of S1P to inhibit T cell migration from tissues into afferent lymphatics, mediated 
by high levels of S1P in tissues during inflammation (Ledgerwood et al., 2008, 
Roviezzo et al., 2011). Furthermore, the role of S1P in T cell trafficking is highlighted 
by the effect of deletion of endothelial cell SPNS2 in mice, which resulted in 
dysregulated lymphocyte trafficking (Fukuhara et al., 2012). 
Although high SPHK expression has been reported in high endothelial venules, 
not much research has been done into other vascular beds (Pham et al., 2010). 
Interestingly, sphingosine kinase activity has been reported to be induced in 
endothelial cells by adiponectin through the activation of nuclear factor kappa beta 
(NF-κβ) (Kase et al., 2007). 
Mounting evidence for the role of S1P in T cell trafficking has led to the 
development of pharmacological agent Fingolimod in 2010, an immunomodulatory 
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S1P receptor agonist used in the treatment of multiple sclerosis (MS), (U.S. Food and 
Drug Administration, 2010). 
 
1.6.3. PEPITEM; a novel inhibitor of T cell transmigration 
In 2015, using a well-characterised in vitro model of transmigration, Chimen 
and colleagues described PEPITEM for the first time, initially observing that 
adiponectin treatment of lymphocytes inhibited their transmigration across cytokine-
stimulated human umbilical vein endothelial cells (HUVEC), (Chimen et al., 2015). 
However, the fact that few T cells expressed adiponectin receptors implied that 
adiponectin was not performing this effect through direct interaction with T cells. On 
the other hand, B cells do express adiponectin receptors, and depletion of B cells 
from the in vitro model of transmigration freed lymphocytes from adiponectin-
mediated inhibition, suggesting that adiponectin acted directly on B cells. The 
analysis of supernatants from adiponectin-stimulated B cells revealed that a B cell-
secreted agent was regulating the trafficking of T cells across inflamed endothelium. 
Through proteomic screening using mass spectrometry, the mystery agent was 
identified as PEPITEM, named Peptide Inhibitor of Trans-Endothelial Migration, 
according to its function. Further investigations found that PEPITEM inhibited the 
transmigration of T lymphocytes, but not monocytes or neutrophils (Chimen et al., 
2015). 
 
PEPITEM is a 14-amino acid peptide, proteolytically derived from its parent 
protein, 14-3-3 zeta (14-3-3ζ). PEPITEM represents an exciting and novel 
adiponectin-mediated paradigm for the regulated trafficking of T cells, beginning with 
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the binding of adiponectin to its receptors on the surface of B cells. Following this 
interaction, B cells are stimulated to release PEPITEM which interacts with cadherin-
15 (CDH15), a cell adhesion molecule expressed on the surface of endothelial cells, 
triggering an intracellular signalling cascade involving the phosphorylation of 
sphingosine to S1P by SPHK1. S1P is subsequently released by the endothelium, 
and binds to its receptors S1PR1/4 on the surface of T cells. This binding alters the 
activation state of integrin LFA-1, inhibiting T cell transmigration across the 
endothelium (Figure 1.4). However, much still remains to be determined about 
PEPITEM, such as its pharmacokinetics and plasma concentration in vivo in healthy 
individuals, but also the export mechanism and amount secreted by B cells following 
adiponectin stimulation. 
 
 
 
 
 
 
Figure 1.4. Novel homeostatic regulation of T cell migration during 
inflammation.  
In the current model of T cell recruitment, T cells are recruited by inflamed endothelial 
cells and arrest on the endothelium, preparing to transmigrate. Chimen et al. (2015) 
described a novel paradigm in the regulation of T cell migration. Initially, B cells are 
stimulated by adiponectin to release PEPITEM. Through interaction with CDH15, 
PEPITEM induces the endothelial cell synthesis and release of S1P by sphingosine 
kinase-1 (SPHK1). S1P binds to its receptors on the T cell surface, inhibiting 
transmigration. 
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1.6.4. 14-3-3ζ is the parent protein of PEPITEM 
The 14-3-3 family of proteins in mammals consists of seven isoforms; beta 
(β), epsilon (ε), gamma (γ), eta (η), sigma (σ), tau (), and zeta (ζ), classified based 
on their chromatographic elution profiles. 14-3-3 alpha (α) and delta (δ) represent the 
phosphorylated forms of β and ζ respectively (Fu et al., 2000). Remarkably, these 
proteins are highly conserved between all eukaryotic cells and are 100% homologous 
between mammalian and avian species. Expressed in almost all mammalian tissues 
(Celis et al., 1990), this family of dimeric proteins were demonstrated to interact with 
binding partners via a phosphorylated serine motif (Muslin et al., 1996). The location 
of PEPITEM in 14-3-3ζ protein spans residues 28 to 41 (Chimen et al., 2015). This 
positioning makes PEPITEM accessible to other molecules at the protein’s outer 
surface, and potentially reflects a requirement for interaction with other proteins, for 
example with proteases enabling proteolytic cleavage of PEPITEM from 14-3-3ζ 
(Figure 1.5). 
14-3-3 proteins interact with a large number of intracellular proteins, with 
reports suggesting interaction with over 200 ligands (Pozuelo Rubio et al., 2004), 
modulating their function (Fu et al., 2000) and regulating various cellular processes 
including protein trafficking, the cell cycle, DNA repair, apoptosis, differentiation, cell 
adhesion and motility (Bridges and Moorhead, 2005, Dougherty and Morrison, 2004, 
Fu et al., 2000, Wilker and Yaffe, 2004). As a result of this varied function, it is no 
surprise that altered expression or function of 14-3-3 proteins can manifest as 
disease, and associations between 14-3-3 isoforms and human diseases are 
beginning to emerge. 
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a) 
                      ------PEPITEM------ 
1- MDKNELVQKAKLAEQAERYDDMAACMK SVTEQGAELSNEER NLLSVAYKNVVGARRSSWRVVSS 
IEQKTEGAEKKQQMAREYREKIETELRDICNDVLSLLEKFLIPNASQAESKVFYLKMKGDYYRYLAEVAA
GDDKKGIVDQSQQAYQEAFEISKKEMQPTHPIRLGLALNFSVFYYEILNSPEKACSLAKTAFDEAIAELDT
LSEESYKDSTLIMQLLRDNLTLWTSDTQGDEAEAGEGGEN  -245 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: The amino acid sequence and crystal structure of 14-3-3ζ 
(a) The 14-3-3ζ isoform is composed of 245 amino acids. The position of 
PEPITEM is located from residues 28 to 41, highlighted in red. (b) The crystal 
structure of a 14-3-3ζ dimer, with each monomer (blue and pink) consisting of 9 
anti-parallel α-helices. In this structure taken from Ottmann et al. (2007), the 14-
3-3ζ dimer is shown binding hydrophobically to the exoenzyme S peptide 
(highlighted in green and brown). The dimer has been modelled to demonstrate 
the exposed PEPITEM residues (highlighted in yellow). 
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A role for 14-3-3 proteins has been established in human cancer and some 
14-3-3 binding partners have been identified as products of oncogenes (Lodygin and 
Hermeking, 2005), or are involved in processes which impact tumour growth, such as 
the cell cycle and apoptosis, supporting this connection. 14-3-3σ is down-regulated in 
breast carcinoma, consistent with hypermethylation of the 14-3-3σ gene, suggestive 
of gene silencing (Ferguson et al., 2000, Umbricht et al., 2001). Furthermore, the 
14-3-3ζ isoform has been identified in the secretome of tumour associated 
monocytes and macrophages from ascites of patients with epithelial ovarin cancer 
(Kobayashi et al., 2009). 
In addition to cancer, 14-3-3 proteins have also been correlated with 
neurological diseases (Layfield et al., 1996), consistent with their high expression in 
the brain. For example, several isoforms of 14-3-3 are upregulated in the brain in 
Alzheimer’s disease (Wilker and Yaffe, 2004), and in down syndrome patients (van 
Heusden, 2005). Additionally, the gene encoding 14-3-3ε is consistently deleted in 
patients with Miller-Dieker syndrome (van Heusden, 2005). 14-3-3 isoforms have also 
been identified in cerebrospinal fluid (CSF) from individuals with Creuzfeldt-Jakob’s 
disease (CJD) and cattle with bovine spongiform encephalopathy (BSE), (van 
Heusden, 2005), and are currently being tested as diagnostic markers for these prion 
diseases.  
Currently, none of the 14-3-3 isoforms have been directly implicated in the 
regulation of T cell trafficking. However, some studies have suggested a function for 
14-3-3β and 14-3-3ζ in cell spreading (reviewed by Mhawech (2005)). Reports have 
identified the binding of 14-3-3β to β1 integrin, assisting cell spreading and migration 
(Han et al., 2001, Rodriguez and Guan, 2005). 14-3-3ζ can also mediate integrin 
signaling through binding to the integrin signaling adaptor Cas (Garcia-Guzman et al., 
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1999) in fibroblast cell lines and T cells (Nurmi et al., 2006). 14-3-3 interaction with 
the signaling protein apelin-13 in HUVEC was shown to increase monocyte adhesion 
(Li et al., 2010), however this study had limitations due to the use of the THP-1 
monocyte cell line which may not resemble primary monocytes in vivo, and ECV304 
endothelial cells which are not considered to resemble HUVEC. 
Despite these studies, the role of 14-3-3ζ in immunity remains unclear. Its 
expression has been confirmed in monocytes, CD4+ and CD8+ T cells, B cells and 
NK cells (Su et al., 2004). 14-3-3 proteins have been shown to mediate T cell 
function through binding to pathways involved in T cell stimulation or activation (Di 
Bartolo et al., 2007, Liu et al., 1996, Meller et al., 1996). Conversely, one study 
revealed that interaction of 14-3-3θ with protein kinase C (PKC) inhibited T cell 
activation (Meller et al., 1996). However, this area of study has been scarcely 
researched and provides no indication of 14-3-3 isoforms giving rise to functionally 
active peptides regulating the immune system, and the importance of this protein in 
the PEPITEM pathway remains to be examined.  
 
1.6.5. PEPITEM; a therapeutic agent? 
Chronic inflammation encompasses a large range of clinical diseases affecting 
many organs of the body. Most, if not all, have a T cell element. The PEPITEM 
paradigm represents a homeostatic, lymphocyte-specific regulatory pathway which 
may be compromised in disease, and holds therapeutic potential for diseases 
resulting from inappropriate T cell trafficking across inflamed endothelium. Indeed 
recently it has been shown that the expression of adiponectin receptors 1 and 2 on B 
cells as well as PEPITEM production diminishes with age, suggestive of immune 
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senescence of this homeostatic pathway. Chimen et al. (2015) showed that inhibition 
of T cell trafficking was dysregulated in chronic inflammatory diseases including T1D 
and RA, with circulating levels of PEPITEM in patient serum reportedly reduced when 
compared to healthy donors. Moreover, regulation could be re-established using 
exogenous PEPITEM both in vitro and also in vivo using animal models of chronic 
inflammation. 
The use of PEPITEM in T cell-mediated diseases represents a more specific 
therapeutic agent than adiponectin or S1P. Adiponectin is highly pleotropic, 
regulating a host of homeostatic processes, including lipid and glucose metabolism. 
Therefore, the use of adiponectin to inhibit T cell transmigration during inflammation 
may result in a variety of off-target effects on metabolism. Similarly, S1P regulates T 
cell trafficking within LN and mediates T cell egress from SLOs (Cyster, 2005). Again, 
using S1P as a therapeutic agent may cause significant and undesirable effects on 
immune function. The potential of PEPITEM development as a treatment for chronic 
T cell-mediated immune disease must now be addressed. 
 
1.7. Aim and objectives 
 
The PEPITEM paradigm represents a highly novel and innovative area of 
biomedical science, contributing not only to the basic biology of human beings, but 
also to the knowledge of chronic inflammatory diseases, and how we may treat them. 
However, much remains to be discovered regarding the basic biology of PEPITEM 
and its related paradigm. For example, adiponectin stimulates B cells to secrete 
PEPITEM, although the rate of PEPITEM production remains unknown. While much 
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is known about the structure of the parent protein 14-3-3ζ, currently nothing is known 
about the structure of PEPITEM other than its amino acid sequence.  
 When considering the use of PEPITEM to treat T-cell mediated chronic 
inflammatory diseases, it is essential to understand the pharmacokinetics of the 
peptide first, and optimise the appropriate dose for administration in animal models. 
Additionally, many of the steps in the PEPITEM paradigm have not yet been 
fully elucidated, including the mechanism of PEPITEM release from B cells. 
Furthermore, it is unclear how PEPITEM is processed from its parent protein 14-3-3ζ, 
into a functional 14 amino acid peptide. 
We aim to investigate further the molecular mechanisms underlying the 
PEPITEM paradigm, and whether it can be exploited to treat T cell-mediated 
inflammatory disease. We intend to do this using the following specific objectives: 
1. Confirm the reproducibility of PEPITEM-mediated inhibition of PBL 
transmigration in vitro 
2. Examine the structure of PEPITEM and its interactions, and investigate the 
development of a high-throughput assay for PEPITEM function in vitro 
3. Assess the potential of PEPITEM development for therapeutic use in the 
treatment of chronic T cell-mediated immune disease 
4. Determine the role of 14-3-3ζ in the PEPITEM paradigm. 
 
 
 
 
 36 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 
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2.1. Materials 
Table 2.1. List of main reagents used. 
Reagent Manufacturer Catalogue 
number 
Working 
concentration 
Application 
EDTA Sigma-Aldrich 93302 1x Cell culture, cell 
sorting 
Histopaque 1077 Sigma-Aldrich 10771 1x PBMC isolation 
Histopaque 1119 Sigma-Aldrich 11191 1x PBMC isolation 
PBS without calcium or 
magnesium 
Sigma-Aldrich P4417 1x cell sorting, flow 
cytometry 
Medium M199 Gibco Invitrogen 31150 1x Cell culture, 
PBL assays 
Fetal calf serum (FCS) Sigma-Aldrich F9665 20% v/v Cell culture 
Gentamycin Gibco G1272 35 µg/ml HDBEC cell 
culture 
Trypsin (cell culture grade) Gibco Invitrogen 25200056 2.5mg/ml HDBEC cell 
culture 
TNF-α R&D systems 210-TA-010 100U/ml Cell culture 
IFN-γ Peprotech 300-02 10ng/ml Cell culture 
Adiponectin Enzo Life Sciences ALX-522-063 10µg/ml PBL assays 
BSA Fraction V Sigma-Aldrich A7030 0.15% w/v Cell culture, 
PBL assays 
Formaldehyde Sigma-Aldrich F1635 2-10% v/v PBL assays, 
confocal 
microscopy, 
histology 
DSC-18 columns Sigma-Aldrich 52602-U N/A Mass 
spectrometry 
Acetonitrile VWR Chemicals 23595.328 1x Mass 
spectrometry 
Trifluoroethanoic acid Sigma-Aldrich 302031 0.1-1% v/v Mass 
spectrometry 
Water (HPLC grade) Merck Millipore 100030 1x Mass 
spectrometry 
Formic acid Sigma-Aldrich zero6450 1% v/v Mass 
spectrometry 
RNeasy Mini Kit Qiagen 74104 n/a RNA extraction 
Ethanol Fisher Scientific BP2818 70-100% v/v RNA extraction, 
DNase 
treatment 
RNase-free dH2O Qiagen 129112 1x RNA extraction 
Random primers Promega C1181 0.5µg Reverse 
transcription 
dNTP Promega U1201 10mM Reverse 
transcription 
Trypsin (sequencing grade) Promega V5111 1x Mass 
spectrometry 
Promocell media Promocell C-220202 N/A HDBEC cell 
culture 
14-3-3ζ SignalChem Y92-30N-20 20ng/ml PBL assay, 
western blotting 
14-3-3ζ -His Fitzgerald 80R-1064 25µg/ml PBL assay, 
Biacore 
CDH15-FC R&D 4096-MC-050 12.5-200µg/ml Biacore 
Thrombospondin-1 R&D 3074-TH 10-100µg/ml Biacore 
CD19 microbeads Miltenyi Biotech 130-050-301 n/a Cell sorting 
RQ1 RNase-Free DNase Promega M6101 1U DNase 
treatment 
Phenol/chloroform/isoamyl 
alcohol (25:24:1) 
Sigma-Aldrich S77617 1x RNA 
purification 
NaAc Sigma Aldrich S7899 3M RNA 
purification 
M-MLV Reverse transcriptase 
(with buffer) 
Promega M1701 200U Reverse 
transcription 
PVDF membrane Millipore IPVH00010 n/a Western 
blotting 
ECL G E Healhcare RPN2109 N/A Western 
blotting 
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EC medium MV3h Promocell C-22020 1x HDBEC cell 
culture 
RNasin Plus RNase Inhibitor Promega N2111 25U Reverse 
transcription 
Protease inhibitor cocktail Sigma Aldrich P2714-1BTL 1:100 Western 
blotting 
CryoSFM Promocell C-29912 N/A Cell Culture 
Penicillin/streptomycin Gibco 10378016 100U/ml and 
100µg/ml 
Jurkat T cell 
culture 
RPMI Gibco Invitrogen 21875 1x Jurkat T cell 
culture 
GM6001 Santa Cruz SC-203979 10nM PBL assay 
CD19 microbeads Milteni Biotech 130-050-301 N/A PBL assay 
PBL with /without calcium and 
magnesium 
Sigma Aldrich D8662/D5773 1x PBL assay 
B cell enrichment kit Stem Cell 19054 n/a B cell isolation 
Hbs-P buffer GE Healthcare BR100368 1x Biacore 
CaCl2 Sigma Aldrich C1016 5mM Biacore 
EDC GE Healthcare BR-1000-50 0.4M Biacore 
NHS sigma 130672 0.1M Biacore 
Streptavidin sigma S-4762 0.5mg/ml Biacore 
Ethanolamine-HCL BIAcore life sciences BR-1006-33 1M Biacore 
CDH15 R&D 4096-MC 25µg/ml Biacore 
Fluo 4 NW Calcium Assay Kit Invitrogen F36206 N/A Calcium Flux 
assay 
Calcium Ionophore Santa Cruz 74267-27-9 0-1µM Calcium flux 
assay 
S1P Cayman chemicals 62570 0-100µM Calcium flux 
assay 
Scintillant Perkin Elmer 1200-437 1x Radioactivity 
counting 
CPDA Sigma Aldirch C4431 1x Blood collection 
Oil Red O Sigma Aldrich O0625 N/A Histology 
DPX mounting media Leica Biosystems 3808600ED 1x Histology 
Isopropanol Sigma Aldrich W292907 70-100% v/v Histology 
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Table 2.2. List of PEPITEM derivatives used. 
All peptides were synthesised by Alta biosciences, Birmingham, UK, except tritiated 
PEPITEM, which was synthesised by Cambridge Biosciences. *Glycine was not D-
isomerised as it does not have an enantiomer. 
Peptide ID Peptide sequence Working 
concentration 
Application 
Native PEPITEM (Pure 
synthesis) 
SVTEQGAELSNEER 20ng/ml Migration assay 
Scrambled PEPITEM TAVLENSREGESQE 20ng/ml Migration assay 
PEPITEM-AF680 SVTEQGAELSNEER-AF680 100µg/ml IVIS imaging 
3
H PEPITEM SVTEQGAELSNEER (tritiated)  0.1-10ng Mass spectrometry, 
in vivo 
pharmacokinetics 
Biotinylated PEPITEM BIOTIN-SVTEQGAELSNEER 25µg/ml Biacore 
Biotinylated scrambled BIOTIN-TAVLENSREGESQE 25µg/ml Biacore 
Native PEPITEM (crude 
synthesis) 
SVTEQGAELSNEER 2-200ngml Migration assay 
Alanine substitutions AVTEQGAELSNEER 20ng/ml Migration assay 
Alanine substitutions SATEQGAELSNEER 20ng/ml Migration assay 
Alanine substitutions SVAEQGAELSNEER 20ng/ml Migration assay 
Alanine substitutions SVTAQGAELSNEER 20ng/ml Migration assay 
Alanine substitutions SVTEAGAELSNEER 20ng/ml Migration assay 
Alanine substitutions SVTEQAAELSNEER 20ng/ml Migration assay 
Alanine substitutions SVTEQGAALSNEER 20ng/ml Migration assay 
Alanine substitutions SVTEQGAEASNEER 20ng/ml Migration assay 
Alanine substitutions SVTEQGAELANEER 20ng/ml Migration assay 
Alanine substitutions SVTEQGAELSAEER 20ng/ml Migration assay 
Alanine substitutions SVTEQGAELSNAER 20ng/ml Migration assay 
Alanine substitutions SVTEQGAELSNEAR 20ng/ml Migration assay 
Alanine substitutions SVTEQGAELSNEEA 20ng/ml Migration assay 
N-term peg 352 PEG -SVTEQGAELSNEER 20ng/ml Migration assay 
N/C block Acetyl – SVTEQGAELSNEER - amide 20ng/ml Migration assay 
D isomer REENSLEAG*QETVS (D amino acids) 20ng/ml Migration assay 
C-terminal PEG SVTEQGAELSNEER-352 PEG-amide 20ng/ml, 
1.75µg/ml 
Migration assay, 
Mouse model of 
atherosclerosis 
C-terminal PEG 
scrambled 
TAVLENSREGESQE-352 PEG-amide 1.75µg/ml Mouse model of 
atherosclerosis 
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Table 2.3. List of antibodies used in flow cytometry, western blotting, 
confocal microscopy and Biacore. 
Reagent Manufacturer Catalogue 
number 
Working 
concentration 
Application 
CD3-PECy7 
(conjugated) 
eBioscience 25-0031 1:50 Flow cytometry 
CD19-APC  
(conjugated) 
eBioscience 17-1093 1:50 Flow cytometry 
14-3-3ζ 
(unconjugated) 
R & D MAB2669 1:2000/12µg/ml Western blot,/ 
Confocal 
microscopy 
Goat anti-mouse-
FITC (conjugated) 
Dako F0479 1:30 Confocal 
microscopy 
Donkey anti-mouse 
HRP (conjugated)  
Santa Cruz SC-2318 1:2000 Western blot  
Anti-human IgG 
(unconjugated)  
Abcam Ab109489 25µg/ml Biacore  
 
 
 
 
Table 2.4. TaqMan gene expression assays used for real-time qPCR.  
All primers were purchased from Invitrogen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Gene Catalogue number 
18s Hs03003631_g1 
ICAM-1 Hs0016932_m1 
VCAM-1 Hs00365486_m1 
CXCL9 Hs00171065_m1 
CXCL10 Hs00171042_m1 
CXCL11 Hs00171138_m1 
14-3-3ζ Hs03044281_g1 
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2.2. Methods 
2.2.1. Gene measurement 
 
2.2.1.1. RNA extraction  
Total mRNA from human dermal blood microvascular endothelial cells 
(HDBEC), or lymphocytes was extracted using the RNeasy Minikit (Qiagen) 
according to manufacturer’s instructions. Initially, cells were lysed in RLT buffer, 70% 
v/v ethanol was added and each sample was vortexed to disrupt cell membranes. 
The sample was then added to a spin column for centrifugation at 15,000x g. 
Appropriate buffers were added and the flow-through discarded as per the 
manufacturers protocol. mRNA was eluted from the spin column using RNAse-free 
dH2O and the RNA concentration was determined using Nanodrop 
Spectrofluorimeter 3300 (LabTech). RNA was subsequently stored at -80oC until 
further use. 
 
2.2.1.2 DNase treatment 
Genomic material was removed from mRNA following isolation. 1µg RNA 
samples were treated with 1 unit RNAse-Free DNAse (Promega) as per 
manufacturer’s instructions and incubated at 37oC for 30 minutes before being 
transferred to ice for 5 minutes. 150µl dH2O and 200µl phenol/chloroform/isoamyl 
alcohol were added to the reaction and vortexed before centrifugation at 15,000x g 
for 5 minutes at 4oC. The top layer of the reaction was transferred to a fresh tube. 
15µl 3M pH 5.5 NaAc and 375µl 100% v/v ethanol was added to the reaction, 
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vortexed and incubated at -80oC for 2 hours. The reaction was defrosted until viscous 
and centrifuged at 15,000x g for 15 minutes at 4oC. Supernatant was removed and 
the pellet was re-suspended in RNase-free dH2O. 
 
2.2.1.3 Reverse transcription 
Isolated mRNA was converted to cDNA by reverse transcription. 0.5µg of 
random primers (Promega) were annealed to 1µg RNA by incubation at 70oC for 5 
minutes, and then transferred immediately to ice. A master mix of 5µl M-MLV 5x 
buffer, 5µl 10mM dNTPs, 25U RNasin Plus RNase Inhibitor, 200U M-MLV reverse 
transcriptase (all Promega) and dH2O to 25µl per reaction was added to each tube 
and incubated at 37oC for 1 hr. For each reverse transcription, a negative control was 
included by omitting reverse transcriptase from the master mix. All cDNA was stored 
at -20oC. 
 
2.2.1.4 Real-time qPCR 
Quantitative PCR (qPCR) was performed on a 7500 HT Real Time PCR 
Machine (Applied Biosciences). All qPCR was performed in duplicate reactions. In 
each reaction, 10µl of Taq Universal Master Mix (Invitrogen), 1µl of TaqMan gene 
expression assay kit (Invitrogen, see table 2.4) and 1µl of mRNA along with water to 
a final volume of 20µl was added to each well of a 96 well qPCR plate. 18S was used 
as an endogenous control. All TaqMan gene expression kits utilised FAM reporter-
labelled probes. qPCR employed 40 cycles of: 50°C for 2 minutes, 95°C for 10 
minutes, 95°C for 15 seconds, 60°C for 1 minute, with the final holding at 10°C. Gene 
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expression was calculated relative to endogenous 18s expression using the ΔΔCt 
method. Results are expressed as fold change relative to 18S. 
 
2.2.2. Protein expression 
 
2.2.2.1. Generation of lysates for western blotting 
Cell pellets were lysed in RIPA buffer (pH 8.0) containing protease inhibitor 
cocktail (PIC; Sigma-Aldrich) used according to manufacturer’s instructions and 
incubated for 30 minutes at 4oC with agitation. Lysates were centrifuged to remove 
debris at 15,000x g for 5 minutes and supernatant was transferred to a fresh 
Eppendorf. Lysates were stored at -20oC until ready for use. 
 
2.2.2.2. Generation of supernatants for western blotting 
B cells were isolated as described in section 2.2.4.2 and stimulated with or 
without 10µg/ml adiponectin (Enzo Life Sciences) for 1 hour at room temperature 
with agitation. Cells were pelleted at 600x g for 10 minutes and supernatant was 
transferred to a fresh Eppendorf. A vacuum centrifuge was used to lyophilise 
supernatant samples before incubation with RIPA buffer (pH 8.0) containing PIC. 
Samples were stored at -20oC until ready for use. 
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2.2.2.3. SDS-PAGE and western blotting for protein 
Samples were diluted 1:1 in 2x Lamelli buffer and 20µl of each lysate was 
electrophoresed on 8% polyacrylamide gels for 1 hour at 200V before being 
transferred onto PVDF membranes (Millipore) for 1 hour at 100V. Membranes were 
blocked in 20% w/v non-fat powdered milk in PBS tween (0.1% v/v) for 1 hour at 
room temperature with agitation. After washing with PBS tween (0.1% v/v), 
membranes were then incubated with primary antibody (see table 2.3) diluted in PBS 
tween (0.1% v/v) at 4oC overnight with agitation. Membranes were washed with PBS 
tween (0.1% v/v) and incubated with secondary antibody (see table 2.3) diluted in 
PBS tween (0.1% v/v) at room temperature for 1 hour with agitation. After final 
washes with PBS tween (0.1% v/v), chemifluorescence was detected using the ECL 
kit (G E Healthcare). X-ray film was exposed to the membrane for 2-5 minutes and 
developed using a Compact X4 Xograph imaging system. Antibody specificity was 
confirmed using 10ng recombinant 14-3-3ζ protein. HeLa cell lysates of 
undetermined protein concentration were used as an additional positive control. 
 
2.2.2.4. Flow cytometry 
 1x105 cells were transferred into a 5ml polypropylene tube (BD Falcon). Cells 
were pelleted at 400 x g for 5 minutes and re-suspended in 100μl PBS containing 
BSA (0.15% w/v, PBSA). Cells were stained with antibody (see table 2.3) for 20 
minutes in the dark at 4oC. Tubes were topped up to 4ml with cold PBSA, pelleted at 
400g for 5 minutes, re-suspended in 300μl PBSA and kept on ice in the dark until 
ready for cytometry. Flow cytometry was performed using a CyAn flow cytometer 
(Dako) with Summit software. At least 10,000 total events were acquired per sample 
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where possible. Flow cytometry plots were created using Flow Jo software employing 
the gating strategy described in section 6.2. 
 
2.2.2.5. Confocal microscopy 
 2.5x104 HDBEC were seeded in a µ-Slide (Ibidi) and stimulated with 100U/ml 
TNF-α + 10ng/ml IFN-γ for 24 hours. Cells were fixed in 2% v/v formaldehyde and 
blocked with rabbit serum (Sigma Aldrich) for 30 minutes. HDBEC were stained with 
primary antibody (see table 2.3) overnight at 4oC with agitation. Cells were then 
washed in PBS and stained for 1 hour with secondary antibody (see table 2.3). For 
negative controls, the primary antibody was omitted and PBS used it its place. Cells 
were stained with bisBenzimide (1µg/ml, Sigma Aldrich) for 5 minutes before being 
washed for a final time. Images were captured using confocal microscopy, with an 
inverted Zeiss LSM-510 UV confocal microscope at x20 or x40 magnifications. 
 
2.2.3. In vitro adhesion and migration assays 
 
2.2.3.1 Cell culture 
Human dermal blood microvascular endothelial cells (HDBEC, PromoCell) 
were cultured in low-serum medium 2% w/v (Endothelial cell growth medium; 
PromoCell) with 35µg/ml gentamycin (Gibco). At passage 4, cells were frozen down 
in CryoSFM (PromoCell) and stored in liquid nitrogen. Prior to use, cells were thawed 
at 37oC and cultured in a 25cm2 cell culture flask. After 24 hours the media was 
replaced. 
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Jurkat T cells were cultured in 25cm2 cell culture flask with RPMI (Gibco) 
supplemented with 10% v/v FCS, 100U/ml penicillin and 100µg/ml streptomycin (all 
Sigma-Aldrich). 
 
2.2.3.2. PBL isolation 
Peripheral blood mononuclear cells (PBMC) were isolated from the whole 
blood of healthy donors collected in EDTA (Sigma-Aldrich) using a two-step density 
gradient created with Histopaque 1119 and Histopaque 1077 (Sigma-Aldrich). 
Adherent monocytes were removed by seeding PBMC onto tissue culture plastic for 
30 minutes and incubating at 37oC (Rainger et al., 2001). The remaining peripheral 
blood lymphocytes (PBL) were then re-suspended at 1x106 cells/ml in M199 (Life 
Technologies) with 0.15% w/v bovine serum albumin (BSA; Sigma-Aldrich). Blood 
was collected under approval from the University of Birmingham Local Ethical Review 
Committee (ERN_07-058). 
 
2.2.3.3. Static adhesion and migration assay 
HDBEC were seeded at 1x105 per well in 12 well plates and left to adhere. 
After 24 hours, confluent endothelial cell (EC) monolayers were cytokine-stimulated 
with 100U/ml TNF- and 10ng/ml IFN- for 24 hours at 37oC. PBL were treated with 
10µg/ml adiponectin for 1 hour at room temperature with agitation and washed before 
use. For peptide treatment of PBL, peptides (see Table 2.2) were added to PBL 
immediately before use. Prior to addition of PBL, EC were washed with M199 BSA 
(0.15% w/v) to remove residual cytokines and treatments. 1x106 PBL, different 
lymphocyte fractions or Jurkat T cells were added to each well and incubated at 37oC. 
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After 6 minutes, EC were washed with M199 BSA (0.15% w/v) to remove non-
adherent PBL. Cells were fixed with 2% v/v formaldehyde (Sigma-Aldrich) and 
imaged using an inverted bright field microscope (Zeiss) at x20 magnification. 
To examine the effect of EC pre-treatment with 14-3-3ζ on transmigration, 
recombinant 14-3-3ζ (20ng/ml) was incubated with EC in M199 BSA (0.15% w/v) 
containing 100U/ml TNF- and 10ng/ml IFN- for 1 hr before or immediately before 
performing the migration assay. 
The broad-spectrum matrix metalloproteinase inhibitor GM6001 was used to 
investigate the cleavage of 14-3-3ζ into PEPITEM. GM6001 (Santa Cruz, 10nM) was 
pre-incubated with EC in M199 BSA (0.15% w/v) containing 100U/ml TNF- and 
10ng/ml IFN- and also with PBL for 1 hr prior to migration. After all treatments, EC 
were washed and the transmigration assay was performed as previously described. 
 
2.2.3.4. Analysis 
PBL migration was imaged and analysed using ImagePro 6.2 software (Media 
Cybernetics). Adherent and migrated PBL from microscope images were counted 
and the average from 8 randomly selected fields was taken. The number of adherent 
cells was calculated by multiplying the calibrated microscope field by the surface 
area of EC in mm2 and dividing this by the known total number of PBL added, to 
obtain the percentage of the PBL that had adhered. This was used to calculate the 
percentage of transmigrated PBL. Adherent cells were classed as phase-bright and 
surface adherent. Transmigrated cells were classed as phase-dark and appeared 
spread under the endothelial cell monolayer (Figure 2.1). 
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Figure 2.1. Diagrammatic representation of in vitro T cell transmigration assay.  
(a) Schematic of in vitro transmigration assay. HDBEC are grown to confluence and 
cytokine stimulated before the addition of PBL, including B cells and T cells. In this 
assay, it is the T cells that predominantly transmigrate. (b) Example of a field of view 
imaged using an inverted light microscope. Firmly adherent phase bright PBL (light 
blue) remain round and on top of the endothelium, while transmigrated phase dark 
PBL (dark blue) appear underneath the endothelial cell layer appearing flattened and 
irregularly shaped. 
 
(a) 
Transmigrated 
 T cells 
B cell                T cell 
HDBEC 
(b) 
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2.2.4. Cell sorting 
 
2.2.4.1. T cell isolation 
PBL were isolated from healthy donors as previously described. B cells were 
depleted using CD19 beads (Miltenyi Biotec) according to manufacturer’s instructions. 
9x106 PBL were incubated with 80μl MACs buffer (1x PBS, 2mM EDTA, 5mg/ml 
BSA), and 20μl CD19 magnetic beads at 4oC for 20 minutes. Cells were then washed 
and re-suspended in 500μl MACs buffer. Magnetic LD columns (Miltenyi Biotec) 
placed in a MidiMACS Separator magnet (Miltenyi Biotec) were rinsed with 1ml 
MACs buffer before addition of cells for magnetic separation. 1ml MACs buffer was 
added, and this step was repeated for maximum elution. Flow cytometry was used to 
confirm B cell depletion, and purity of at least 99% CD3+ T cells was deemed 
acceptable. 
 
2.2.4.2. B cell isolation  
PBMC were isolated as previously described and B cells were enriched using 
an EasySep kit (StemCell) and following manufacturer’s instructions. Human 
antibody cocktail was incubated with PBMC at 50μl per 1x107 cells for 10 minutes at 
room temperature in a 15ml centrifuge tube. Magnetic beads were added to the 
solution at 75μl per 1x107 cells for 5 minutes at room temperature. The total volume 
was brought to 9ml with MACs buffer and the tubes were placed in an EasySep 
magnet (StemCell) for 5 minutes at room temperature. Enriched cells were then 
poured off into a fresh 15ml centrifuge tube, re-incubated in the magnet for 5 minutes 
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and poured into a final 15ml centrifuge tube to enhance purity. Flow cytometry was 
used to confirm B cell enrichment and purity of at least 95% was deemed acceptable. 
 
2.2.5. Identification of PEPITEM in samples 
 
2.2.5.1. Demonstrating the production of PEPITEM from 14-3-3ζ  
10µl of recombinant 14-3-3ζ protein (100µg/ml, Fitzgerald) re-suspended in 
PBS was aliquotted into Eppendorf tubes giving 10µg/tube. 40µg/ml HPLC-grade 
trypsin (Promega) prepared in in 10% v/v acetonitrile (ACN, VWR chemicals), 90% 
v/v HPLC dH2O and 0.1% v/v TFA (trifluoroacetic acid, Sigma-Aldrich) was used to 
digest the 14-3-3ζ protein for 1 h at 37°C. As described in section 2.2.5.2 and 2.2.5.3, 
samples were purified on C18 columns with 10-100% v/v ACN + 0.1% v/v TFA as the 
final elution, and analyzed using mass spectrometry and database searching. 
 
2.2.5.2. Preparation of samples for mass spectrometry 
All samples were spiked with 10ng tritiated (3H) PEPITEM (Alta Biosciences) 
as an internal mass standard for relative intensity quantification by mass 
spectrometry. C-18 solid phase extraction columns (Supelco, Sigma-Aldrich) were 
used to purify samples. Initially, columns were conditioned with 1ml 100% ACN + 
0.1%v/v TFA. Columns were then washed with 1ml HPLC-grade dH2O (Sigma-
Aldrich) + 0.1% TFA to equilibrate.  Samples containing 0.1% v/v TFA were added to 
the column and, like all additions, were allowed to percolate by gravity. Columns 
were washed again with 1ml dH2O + 0.1% v/v TFA, and finally eluted with 1ml 10-
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100% ACN. Eluent containing purified samples was collected in Eppendorf tubes, 
dried in a vacuum centrifuge at 37oC and re-suspended in 30µl 2% v/v ACN 
containing 0.1% v/v formic acid (Sigma-Aldrich).  
 
2.2.5.3. Mass spectrometry 
10µl of each purified sample was analysed by liquid chromatography–tandem 
mass spectrometry (LC-MS/MS) as illustrated in Figure 2.2. A gradient of 2−36% v/v 
ACN in 0.1% v/v formic acid over 30 min at 350nl/min was run in a Dionex Ultimate 
3000 HPLC system. The initial low concentration of solvent enables peptides to bind 
to the column before being eluted by the increasing solvent gradient. This facilitates 
peptide separation on the basis of hydrophobicity, with highly hydrophobic peptides 
being retained longer on the column. The HPLC instrument was connected to an 
Electron Transfer Dissociation (ETD) amazon ion-trap mass spectrometer (Bruker) 
with a nanospray source. Here, samples were sprayed into the mass spectrometer 
and electrostatic attraction of the sample now in gas-phase draws the peptides into 
the ion-trap. This separates the ions basis of their mass to charge ratio (m/z). A mass 
spectrometry survey scan from 350 to 1,600 m/z was performed and the five ions of 
highest intensity per survey scan were selected for fragmentation by ETD, usually at 
the peptide bond. M/z is then determined, and this process is named MS/MS. Raw 
data was processed using the Bruker ProteinScape software package to select 
peaks which were subsequently searched using the Mascot search engine (version 
2.1) with the SwissProt protein database.  
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Endogenous and synthetic 3H PEPITEM elute at the same position on the 
gradient owing to their identical chromatographic properties, enabling comparison in 
the same mass spectrum. However, due to their different physical properties, these 
versions were resolved as separate peaks within this mass spectrum (Table 2.5), 
thereby allowing a comparison of intensity of 10ng radiolabelled standard within 
extracted ion chromatograms (EIC) to endogenous PEPITEM in samples. Within the 
field of analytical science, this method of quantification is time-honoured (Eidhammer 
et al., 2012). 
 
 
 
 
 
 
Figure 2.2. Schematic representation of the proteomic approach employed to 
detect PEPITEM in biological samples. 
(a) Initially, peptides were purified on C18 LD columns. (b) Peptides were then 
separated based on hydrophobicity using HPLC. (c) The sample exits the HPLC 
system and enters the mass spectrometer, where the peptides are subsequently 
given charge by electro-spray ionisation and (d) separated by m/z in an ion trap. (e) 
Finally, ions are detected and their abundance measured, (f) and the data analysed 
via computer. 
 
 
 
 
a) 
LD 
column
s 
b) 
HPLC 
c) 
Electrospray 
ionisation 
e) 
Ion detector 
f) 
Computer 
analysis 
d) 
Ion trap 
Mass spectrometer 
 53 
 
Table 2.5. M/z of endogenous and 3H PEPITEM. 
Quantification was made possible owing to the different m/z of radiolabelled 
(3H) PEPITEM and endogenous PEPITEM. 
PEPITEM VERSION: TOTAL SIZE (m/z) 
Endogenous PEPITEM 774.88 ± 0.05 
Radiolabelled (3H) PEPITEM 
standard 
780.88 ± 0.05 
 
 
2.2.6. Investigating PEPITEM interactions using Biacore binding 
assays 
 
Biacore binding assays monitor real-time molecular interactions by utilising the 
principle of surface plasmon resonance (SPR) (Figure 2.3). All Biacore assays were 
performed with the kind help of Dr. Carrie Willcox (University of Birmingham Cancer 
sciences, UK) using a Biacore 3000 SPR system (G E Healthcare). HBS-P buffer 
(GE Healthcare) containing 5mM CaCl2 was used for all reagent dilutions and binding 
experiments, except when using a Sensor Chip NTA cassette (GE Healthcare), 
where CaCl2 was omitted. Regeneration of the chips as described by the 
manufacturer was carried out between all experiments. 
To test biotinylated PEPITEM binding to recombinant CDH15, a Sensor Chip 
CM5 cassette (GE Healthcare) was first activated with EDC (0.4M N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride, G E Healthcare) mixed 1:1 
with NHS (0.1M N-hydroxysuccinimide, Sigma-Aldrich). Streptavidin (0.5mg/ml,  
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Figure 2.3. Surface plasmon resonance in BIAcore binding assays. 
(a) The receptor molecule is immobilised on the sensor surface while analyte 
ligand solution is injected into the flow cell. Polarised light is directed from a laser 
through a prism to the sensor surface. The refraction of light off the surface at 
particular angle, known as the incidence angle (α), causes light absorption and 
oscillation or “resonance” of electrons also known as surface plasmons on the 
chip surface. This causes a decrease in intensity of the reflected light detected, 
which varies following binding interactions at the surface. (b) Illustration of 
BIAcore sensorgram measuring changes in SPR. Interactions between 
immobilised molecules, such as receptors, with injected cognate ligand alters the 
refractive index at the surface, increasing resonance measured as response units 
(RU). An association phase represents binding site engagement by ligand (kon). 
When saturation is achieved, the maximum RU can be used to measure binding 
affinity (KD). Following cessation of ligand injection, a dissociation phase follows 
where (koff). The sensorchip surface can then be regenerated ready for the next 
investigation. (Adapted from Patching (2014)). 
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Sigma-Aldrich) was coupled to the chip and unreacted esters were then blocked with 
1M ethanolamine-HCl (Biacore Life Sciences). 25µg/ml N-terminal biotinlyated 
PEPITEM or Scrambled control was then immobilised onto the chip at 5µl/min. 12.5-
100µg/ml (0.10-0.82µM) recombinant CDH15 or 50µg/ml (0.30µM) recombinant 
thrombospondin-1 (both R & D) was subsequently flowed over the chip at 10µl/min.  
To test binding in the opposite orientation, 25µg/ml anti-human IgG antibody 
(Abcam) was immobilised onto a CM5 Sensor Chip cassette following activation as 
previously described. FC-tagged CDH15 (25µg/ml, R & D) was immobilised onto the 
chip at 5µl/min. A solution of 10-50µg/ml (6.7-33.33µM) PEPITEM and 10-50µg/ml 
(0.06-0.30µM) TSP-1 (pre-incubated at 37oC for 1 hr to promote potential complex 
formation) was then flowed over at 10µl/min. 
  Finally, to investigate any interactions between 14-3-3ζ and potential binding 
partners, a Sensor Chip NTA cassette (G E Healthcare) was regenerated with 
nickel(II)chloride solution and 14-3-3ζ-His tagged recombinant protein (25µg/ml, 
Fitzgerald) was immobilised at 5µl/min. 50-100µg/ml TSP-1 (0.30-0.60µM) or 50-
200µg/ml CDH15 (0.80-1.60µM) was flowed over at 10µl/min. 
Blank flow cells or scrambled PEPITEM were used as controls in case of any 
non-specific binding. Binding was measured in response units (RU) and the data 
traces were analysed using BiaEvaluation software (G E Healthcare). 
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2.2.7. Examining PEPITEM structure using Nuclear Magnetic 
Resonance Spectroscopy 
 
Nuclear magnetic resonance (NMR) occurs when the nuclei of atoms are 
placed into a stable magnetic field and subsequently exposed to a second oscillating 
magnetic field. NMR spectroscopy is based on the principle that subatomic particles 
i.e. protons, neutrons and electrons, have “spin”. In 1H, commonly used for NMR 
investigations, two energy states (m) are possible, m = +½ (a) and m = −½ (β), as 
depicted in Figure 2.4. The difference in energy states gives rise to a population 
difference with more nuclei in the lower energy state. This gives rise to a single signal. 
All NMR investigations were performed with the help of Dr. Mark Jeeves at the 
HWB-NMR facility, University of Birmingham. 1.2mg PEPITEM (>90% purity) was 
initially dissolved into 50mM sodium phosphate buffer. 50mM 5N NaOH was added 
until PEPITEM was dissolved. The pH of the solution adjusted to pH 6.0 by addition 
of 5M HCl. The final salt and PEPITEM concentrations were determined based on 
the amount of NaOH and HCl added. A final solution of 5mM PEPITEM in a 50mM 
sodium phosphate buffer containing 50mM sodium chloride at pH 6.0 was used for 
NMR investigations.  
NMR data was collected on a Bruker 600 MHz spectrometer equipped with a 
1.7mm triple resonance cryogenic probe as summarised in Figure 2.5. A one 
dimensional 1H spectrum was collected to assess peptide purity and solubility. A two 
dimensional TOCSY (Total correlation spectroscopy) spectrum was collected using a 
spin-lock mixing period of 100 ms to identify nuclei in the same spin system.  Two 
ROESY (Rotating frame nuclear Overhauser effect spectroscopy) spectra were 
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collected using mixing times of 100 and 200 ms in order to generate distance 
restraints for structural determination. 
Data was processed using NMRpipe (Delaglio et al., 1995) and analysed 
using CcpNmr Analysis (Vranken et al., 2005). Structures were calculated using 
Crystallograpy and NMR System (CNS) software (Brunger, 2007). Structural 
alignment and figures were created using PyMOL software (Schrödinger). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. 1H spin states in an external magnetic field. 
Depending on the strength of the external magnetic field, nuclei absorb and 
re-emit electromagnetic energy at a specific frequency. 
1
H nuclei take on 
either a low energy (α) or high-energy (β) state. Nuclei with lower energy 
spin in alignment with the external magnetic field, whereas nuclei with 
higher energy spin against the external magnetic field. (Adapted from 
Keeler (2013)). 
Magnetic field 
Spin (m) = +½(α) 
Energy 
Spin (m) = -½(β) 
Δ Energy 
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2.2.8. Intracellular calcium flux assay 
 
HDBEC were seeded at 5x103 per well in a 96-well clear bottom black-sided 
assay plate (Greiner Bio One) and grown to confluence. HDBEC were stimulated with 
100U/ml TNF- and 10ng/ml IFN- for 24 hours at 37oC. Calcium flux was measured 
a) Magnets 
 
c) RF transmitter d) Receiver e) Digitiser 
f) Pulse programmer 
Figure 2.5. Schematic of NMR spectrometer. 
A stable magnetic field is generated using (a) a 600MHz magnet. (b) A 
1.7mm triple resonance cryogenic probe was used to excite the sample 
placed in it and detect magnetisation. (c) A transmitter generated short pulses 
of radio frequency (RF) energy and (d) a receiver amplified small NMR 
signals from the probe. (e) A digitiser converts these signals from voltage into 
binary numbers. (f) Pulse programmer hardware controls spectrometer 
function, delivering precise pulses. Finally, (g) a computer controls the whole 
experiment and facilitates data processing (Adapted from Keeler (2013)). 
b) Probe 
g) 
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using a Fluo-4 NW Calcium Assay Kit (Invitrogen) according to manufacturer’s 
instructions. Briefly, calcium dye was reconstituted with HEPES buffer solution, and 
2.5mM probenecid was added to prevent calcium leakage. Cells were washed with 
100µl warm PBS without calcium and magnesium, and then incubated with the 
calcium dye solution for 30 minutes at 37oC in the dark followed by 30 minutes at 
room temperature in the dark. 
A compound plate containing 270µl per well of each treatment was prepared 
so that the final concentration once injected into the assay plate was as follows: 
calcium ionophore (0-10-6M, Sigma-Aldrich), sphingosine-1-phosphate (S1P; 0-10-1M, 
Cayman Chemicals), PEPITEM or scrambled peptide (0-10-1mg/ml). 50µl of each 
compound was injected into the respective wells of the assay plate. The plate was 
read at room temperature every 2 seconds for 180 seconds per well using a 
FlexStation plate reader (Molecular Devices, Eex 488nM, Eem 525nM) with SoftMax 
Pro software (Molecular Devices). To calculate percentage maximal increase in 
relative fluorescent units (RFU), data was normalised by subtracting the average 
baseline reading before treatment (measured over the first 12 seconds) from the 
maximal RFU after treatment, and then dividing by the average baseline. Data 
represents the mean of 4 experiments all performed in triplicate. 
 
2.2.9. In vivo studies using PEPITEM 
 
2.2.9.1. Mice 
Apolipoprotein E-deficient (apoE-/-) C57BL/6 mice (Jackson Laboratories) and 
wild-type (WT) BALB/c mice (bred in-house) were nurtured  
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 under specific pathogen-free (SPF) conditions. All 
animals were fed a normal chow diet (LabDiet) unless otherwise stated. All 
experiments were performed in accordance with United Kingdom Home Office 
regulations. To study the in vivo effects of PEPITEM in a model of atherosclerosis, 6 
week-old apoE-/- C57BL/6 mice were placed on a high fat diet containing 0.15% w/w 
supplementary cholesterol (HFD, Special Diet Services) for a further 6 weeks. 
Weights of all mice used in this study were recorded weekly and before procedures. 
All tissue was collected under the appropriate home office (40/3659) and PIL 
(40/10768) licenses.  
 
2.2.9.2. In vivo pharmacokinetics of PEPITEM 
Initially, varying concentrations of 3H PEPITEM were spiked into mouse blood 
in vitro and measured by scintillation counting to test optimal detection of radioactivity. 
Several ratios of 3H PEPITEM:scintilllant were also measured to determine optimal 
measurement conditions.  
Male 8-10-week old WT C57BL/6 mice were weighed and injected 
intravenously (IV) via the tail vein with 100µl radiolabelled (3H) PEPITEM at 1ng/g. 
After 2-60 minutes, mice were anaesthetised with isofluorane and culled by cardiac 
puncture followed by cervical dislocation. Approximately 800µl blood was collected 
into CDPA and centrifuged at 15,000x g for 10 minutes. Serum was transferred into a 
fresh Eppendorf. 50µl of serum was placed into scintillation counting tubes in 
triplicate with 2ml of Optiphase Hisafe 3 scintillant cocktail (Perkin Elmer) per tube, 
and counted using a Packard Tri-Carb 2500TR scintillation counter. Samples were 
counted for 10 minutes and radioactivity was measured as disintegrations per minute 
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(DPM1). Quench correction was automatically applied using internal 3H standards. 
For time point 0, mice were not injected but instead culled as described above for 
baseline radioactivity measurements. For 100% radioactivity measurements, mice 
were not injected. Instead, whole blood was collected and spiked with 1ng/g 3H 
PEPITEM prior to RBC removal by centrifugation and processed as described above. 
 
2.2.9.3. Determining the endpoint of PEPITEM in vivo. 
PEPITEM was conjugated to SAIVI Alexa Fluor 680 dye (Life Technologies) 
via the amide group by Alta Biosciences, Birmingham, UK, according to 
manufacturer’s instructions. Initially, the conjugated peptide was tested in vitro for 
functionality using the adhesion assay described in section 2.2.3. Optimum dosage 
for in vivo imaging was determined using a black 96-well plate and 0-150µg 
PEPITEM-AF680 diluted in PBS. 
100µg of PEPITEM-AF680 was injected IV via the tail vein into 3 male 6-8 
week old BALB/c mice, which were fasted 16 hours prior to imaging to minimise 
dietary autofluorescence. 3 age and sex-matched mice were injected with PBS as a 
control. After 15 minutes, mice were sacrificed by schedule 1 procedure. All major 
organs (stomach, gut, liver, heart, lungs, spleen, and kidney) were excised 
immediately and arranged in a petri dish. Organs were imaged using an In Vivo 
Imaging System (IVIS Spectrum, Perkin Elmer) using 675nm excitation filters and 
720nm emission filters. Regions of interest (ROIs) were set for each organ and 
fluorescent signal was measured as radiant efficiency using Living Image software 
(Perkin Elmer). Data was normalised to the ROI area using the sum of the radiance 
from inside the ROI divided by the number of pixels, and background was subtracted. 
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Data is expressed as photons per second per centimetre squared per steradian 
(p/s/cm2/sr). 
 
2.2.9.4. In vivo effects of PEPITEM in apoE-/- mice on high fat diet  
6 male C57BL/6 mice were fed HFD for 6 weeks. In addition from 6 weeks of 
age, mice received intra-peritoneal (IP) injections of 1.75mg/ml C-terminal PEGylated 
PEPITEM or C-terminal PEGylated scrambled control in 200µl sterile PBS twice a 
week for 6 weeks (350µg/injection).  After 6 weeks, mice were culled by cardiac 
exsanguination under isofluorane anaesthesia. Approximately 200µl blood was 
collected in CPDA (Sigma Aldrich) for blood counts, and the rest was stored in an 
Eppendorf tube at -80oC for serum analysis later. Liver, hearts and all major organs 
were collected for future analysis. 
 
2.2.9.5. Tissue preparation and histology. 
Livers were fixed in 10% v/v formaldehyde for 24 hours, paraffin embedded 
and sectioned into 4µm sections using a microtome. Hearts were frozen and 
cryosectioned into 6µm cross-sections of the aortic root, ensuring visibility of the 
bicuspid valves. Sections were mounted on Xtra glass slides (Leica Biosystems, UK). 
Standard histological assessment of tissue morphology was performed using 
haematoxylin and eosin (H&E) staining of formalin-fixed paraffin embedded (FFPE) 
tissue sections. De-waxed sections were stained using a routine protocol. Sections 
were raised in dH2O, stained in Mayers haemotoxylin for 4 minutes, incubated in 0.3% 
v/v acid alcohol for 30 seconds and stained in eosin for 2 minutes with intermittent 5 
minute incubations in dH2O between each step. Sections were then dehydrated 
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rapidly in alcohol, cleared and mounted in DPX mounting media (all Leica 
Biosystems). 
Oil red O staining was performed to visualise lipid accumulation within the 
aortic root. Frozen sections were allowed to equilibrate to room temperature. Gently, 
sections were then fixed in 4% v/v formaldehyde for 10 minutes, submerged in dH2O, 
rinsed in 70% v/v isopropanol (Sigma-Aldrich) and incubated in Oil red O solution 
(Sigma-Aldrich), for  30 minutes. Oil Red O solution and was prepared fresh using 
0.5g in 100ml isopropanol. Sections were then briefly submerged in 70% v/v 
isopropanol and then in PBS before allowing to air dry at room temperature. Stained 
sections were imaged using brightfield microscopy and subsequently analysed using 
Image J software. 
 
2.3. Statistical analysis 
  
 All data are expressed as mean ± standard error of the mean (SEM) unless 
otherwise specified. Differences were analysed using GraphPad Prism statistical 
software package (GraphPad software Inc., USA), by linear regression analysis, 
unpaired t-test or by one way analysis of variance (ANOVA), followed by post-hoc 
analysis for multiple group comparison either to the control (Dunnett) or between all 
conditions (Bonferroni). The Kolmogorov-Smirnov normality test was used to test for 
normal distribution. P≤0.05 was considered statistically significant. 
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CHAPTER 3: EXAMINING PEPITEM INHIBITION 
OF PBL TRANSMIGRATION IN VITRO 
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3.1. Introduction 
 
T cell trans-endothelial migration represents a complex physiological response 
to non-self or altered-self antigens. This tightly-controlled and multi-step paradigm is 
essential for the elimination of the antigenic trigger, and ultimately the resolution of 
acute inflammation.  
Although released by a multitude of white blood cells (WBC), TNF-α is 
predominantly produced by activated macrophages and T cells. IFN-γ is the classical 
T cell cytokine, crucial for the orchestration of the adaptive immune response (Frucht 
et al., 2001, Sen, 2001). These pro-inflammatory cytokines are able to activate 
endothelial cells (EC) during inflammation, an essential step for the recruitment and 
transmigration of immune cells from the circulation and into the tissues where they 
are required. TNF-α is able to induce ICAM-1 and VCAM-1 expression in EC, 
increasing the adhesion of both lymphocytes and polymophonuclear cells (PMN). On 
the other hand, IFN-γ induces only ICAM-1 expression in EC and increases adhesion 
of lymphocytes but not PMN (Thornhill et al., 1991). However, in vivo, it is more likely 
that EC will be subject to stimulation by a combination of cytokines as opposed to 
individual ones. 
The synergistic use of TNF-α and IFN-γ to induce recruitment and 
transmigration of T cells has been validated in a number of studies (Ahmed et al., 
2011, McGettrick et al., 2009, Piali et al., 1998). Of the PBL recruited by TNF-α and 
IFN-γ stimulated EC, CD4+ and CD8+ CD45RA-/RO+ memory T cells predominantly 
migrate, however exact proportions have varied between experiments (Ahmed et al., 
2011, Brezinschek et al., 1995, McGettrick et al., 2009, Pietschmann et al., 1992). 
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In chronic inflammation, the regulatory mechanisms underlying selective 
recruitment of immune cells and preferential migration of T lymphocytes are 
dysregulated. This results in persistent T cell trafficking into inflamed tissues. Such 
inappropriate T cell trafficking can manifest with pathological consequences, 
highlighted by diseases such as rheumatoid arthritis (RA) and type 1 diabetes (T1D) 
(Imagawa et al., 1999, Komatsu and Takayanagi, 2012). 
Lipid mediators are synthesised from lipid precursors released from cell 
membranes, via conserved biosynthetic enzymes. The bioavailability of fatty acids 
has been previously shown to regulate both T cell and neutrophil migration (Ahmed 
et al., 2011, Tull et al., 2009). Following integrin activation, T cells receive a final 
signal from PGD2, which binds to the PGD2 receptor (DP2) on the T cell surface, 
promoting migration. The availability of different fatty acids, for example, 
eicosapentaenoic acid (EPA), can also effect leukocyte migration. EPA can act as 
alternative substrate for COX enzymes, generating a PGD2 analogue, PGD3 which 
can subsequently antagonise the DP2 receptor (Tull et al., 2009). 
More recently, our lab identified a novel pathway in the homeostatic regulation 
of T cell trafficking (Chimen et al., 2015). T cell trafficking is dysregulated in chronic 
inflammatory diseases and recent findings suggested that this is due, at least  in part, 
to impairment of the adiponectin-PEPITEM axis as a result of decreased expression 
of B cell adiponectin receptors (Chimen et al., 2015).  
In this chapter, the reproducibility of results previously obtained in our lab will 
be initially evaluated to ensure comparability between historical and new experiments. 
The data presented here suggested this was indeed the case. 
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3.2. Results 
 
3.2.1 Establishing optimal cytokine concentrations for lymphocyte 
adhesion and transmigration across endothelium. 
 
The in vitro transmigration assay first described by McGettrick et al. (2009) 
was developed in our lab for measuring the migration of T cells across cytokine 
stimulated endothelium. This well-established technique was central to the research 
conducted by Chimen et al. (2015). In succession of this original research, the in vitro 
migration assay forms a key part in the generation of fresh data to be described in 
this thesis. Therefore, the reproducibility of the recruitment and transmigration of PBL 
under static conditions was initially investigated to ensure historical comparability, as 
variables such as new investigators or reagent batches can cause undesired 
discrepancies in results. 
 
HDBEC were stimulated for 24 hours with varying concentrations of pro-
inflammatory cytokines, TNF-α and IFN-γ. The adhesion and migration of PBL from 
healthy donors was assessed using the in vitro transmigration assay. Unstimulated 
EC were unable to support the substantial recruitment and transmigration of PBL, 
with the adhesion of only 32 cells/mm2/1x106 and the transmigration of just 2% PBL 
(Figure 3.1a). However, stimulation with increasing concentrations of TNF-α + 
10ng/ml IFN-γ lead to an increase in both adhesion and transmigration of PBL.  
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EC stimulated with 100U/ml TNF-α + 10ng/ml IFN-γ demonstrated significant 
recruitment of 181 cells/mm2/1x106 PBL, and transmigration of 37% PBL compared 
to the unstimulated control. 
Again in experiments where EC were stimulated with 100U/ml TNF-α + 
10ng/ml IFN-γ, adhesion was increased from 7 cells/mm2/1x106 to 197 
cells/mm2/1x106, and transmigration from 0% to 41% (Figure 3.1b), however 
increasing the concentration of IFN-γ to 100ng/ml did not lead to an additive effect, 
with the number of adherent cells being 190mm2/1x106 and transmigration at 43%. 
 
To further confirm the ability of EC to recruit PBL, gene expression of key 
endothelial cell adhesion molecules and chemokines involved in the recruitment and 
migration of T cells were measured as evidence of endothelial cell activation after EC 
treatment with the confirmed optimal concentrations of 100U/ml TNF-α and 10ng/ml 
IFN-γ. Cytokine stimulation lead to an increase in relative gene expression of ICAM-1 
and VCAM-1 (Figure 3.2a), and the IFN-γ inducible chemokines CXCL9-11 (Figure 
3.2b). These data demonstrated the ability for 100U/ml TNF-α and 10ng/ml IFN-γ to 
induce EC cell adhesion molecules and chemokine expression, and thus facilitate the 
transmigration of PBL. 
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Figure 3.1. The effects of TNF-α and IFN-γ on PBL adhesion and migration.  
HDBEC were synergistically stimulated with varying concentrations of TNF-α and 
IFN-γ. The levels of PBL total adhesion and transmigration across the 
endothelium were assessed under static conditions. (a) EC were stimulated with 
increasing concentrations of TNF- α, or (b) IFN-γ. Data represents mean ± SEM 
of 3 independent experiments, analysed by one-way ANOVA with Dunnett’s post-
test compared to unstimulated controls (Clear bars). *P≤0.05, **P≤0.01 and 
***P≤0.001. 
b) 
IFN-γ (ng/ml)        0                 10              100 
TNF-α (U/ml)        0                100             100 
 
IFN-γ (ng/ml)        0                 10              100 
TNF-α (U/ml)        0                100             100 
 
TNF-α (U/ml)     0            1            10         100 
IFN-γ (ng/ml)     0           10           10          10 
TNF-α (U/ml)     0            1            10          100 
IFN-γ (ng/ml)     0           10           10          10 
 
a) 
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Figure 3.2. Chemokine and cell adhesion molecule expression in HDBEC 
following cytokine stimulation. 
HDBEC were stimulated with 100U/ml TNF-α + 10ng/ml IFN-γ for 24 hours. 
mRNA was isolated and converted to cDNA. The expression of (a) cell 
adhesion molecules and (b) chemokines was measured by qPCR, relative to 
the endogenous control 18S. Data represent mean ±SEM of 2 independent 
experiments. 
a) 
b) 
Unstimulated      Stimulated Unstimulated      Stimulated 
Unstimulated      Stimulated Unstimulated      Stimulated 
Unstimulated      Stimulated 
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3.2.2. Investigating the reproducibility of the inhibitory effects of 
Adiponectin and PEPITEM in vitro, and the involvement of 
exogenous lipids. 
 
After confirming optimal cytokine conditions for the in vitro migration assay, we 
next assessed the reproducibility of the inhibitory effects of adiponectin and 
PEPITEM first described by Chimen et al. (2015).  
Adiponectin (AQ) was used at 10µg/ml, validated initially in preliminary 
experiments (data not shown), while PEPITEM was synthesised and tested at 
10ng/ml and 20ng/ml for inhibitory function. AQ or PEPITEM treatment did not 
significantly affect adhesion (Figure 3.3a). Conversely, a significant decrease in 
transmigration was observed for adiponectin and PEPITEM-treated conditions. While 
10µg/ml adiponectin reduced PBL transmigration from 33% to 17%, the addition of 
10ng/ml and 20ng/ml of PEPITEM to the migration assay decreased PBL 
transmigration to 20% and 19% respectively. 20ng/ml scrambled peptide exhibited 
similar levels of transmigration as the control (34% compared to 33% respectively), 
demonstrating that the inhibitory effect is specific to PEPITEM. 
To determine the effectiveness of PEPITEM inhibition of PBL transmigration at 
different extents of inflammation, EC were stimulated with 10-100U/ml TNF-α + 
10ng/ml IFN-γ for 24 hours. The adhesion and transmigration of PBL across the 
endothelium was measured following the addition of 20ng/ml PEPITEM (Figure 3.3b). 
Consistent with Figure 3.1a, increasing TNF-α concentrations increased both 
adhesion and transmigration of PBL. Again, PEPITEM did not affect the adhesion of 
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Control     AQ      Scr  PEPITEM PEPITEM 
                        (10ng/ml) (20ng/ml) 
TNF-α (U/ml) 0     10     10    50    50   100  100  
PEPITEM        -      -        +      -      +       -       + 
 (20ng/ml) 
 
b) 
Figure 3.3. Inhibition of PBL transmigration across cytokine-stimulated 
endothelium by adiponectin and PEPITEM.  
HDBEC were (a) stimulated with 100U/ml TNF-α + 10ng/ml IFN-γ for 24 
hours. PBL adhesion and transmigration was examined following treatment 
with 10µg/ml adiponectin (AQ) or 10-20ng/ml PEPITEM or scrambled (Scr) 
control. (b) EC were stimulated with 0-100U/ml TNF- α + 10ng/ml IFN-γ 
before examining the effects of 20ng/ml PEPITEM on PBL adhesion and 
transmigration. *P≤0.05, ***P≤0.001, ns=not significant by one way ANOVA 
followed by Dunnett’s or Bonferroni post-tests. Data represent mean ± SEM of 
≥3 experiments. 
Control     AQ      Scr   PEPITEM PEPITEM 
                        (10ng/ml) (20ng/ml) 
TNF-α (U/ml) 0    10    10    50    50   100   100  
PEPITEM        -      -      +      -      +       -       + 
 (20ng/ml) 
 
a) 
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PBL. However, PEPITEM treatment lead to the significant inhibition of PBL 
transmigration across EC stimulated with 100U/ml TNF-α + 10ng/ml IFN-γ (21% 
migration compared to 33%), but not at lower TNF-α concentrations. 
 
Fatty acids are common precursors for the synthesis of cell mediators. PGD2 
is a prostanoid derived from the fatty acid arachidonic acid via COX enzymes 
(O'Banion, 1999). PGD2 has previously been shown to mediate memory T cell 
transmigration across cytokine-simulated endothelium (Ahmed et al., 2011). 
Therefore, the availability of fatty acid precursors has the potential to interfere with T 
cell migration in our in vitro migration assay. To certify that the inhibitory effect of 
PEPITEM was not influenced by the presence of exogenous fatty acids present in 
media and BSA, the assay was repeated in the presence or absence of fatty acids. 
No significant differences in adhesion were noted between treatments in the 
presence (Figure 3.4a) or absence (Figure 3.4b) of exogenous fatty acids. 
Adiponectin and PEPITEM maintained their abilities to significantly inhibit PBL 
transmigration across cytokine-stimulated EC. The presence or absence of fatty 
acids did not significantly affect the inhibitory properties of AQ and PEPITEM (Figure 
3.4c), with adiponectin inhibiting transmigration by 51% and 64%, and PEPITEM 
inhibiting PBL transmigration by 58 and 65% with and without fatty acids respectively. 
Interestingly, in the absence of fatty acids, fewer PBL were recruited under 
control conditions (221cells/mm2/1x106 compared to 303cells/mm2/1x106 in the 
presence of fatty acids). Similarly, fewer PBL transmigrated in the absence of fatty 
acids (19%) compared to with fatty acids (28%). 
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Figure 3.4. The effect of exogenous fatty acids on the inhibitory function 
of PEPITEM.  
PBL adhesion and transmigration across cytokine-stimulated HDBEC following 
treatment with 20ng/ml PEPITEM or 10µg/ml adiponectin (AQ) was examined in 
the presence or absence of exogenous lipids using either (a) M199 + 0.15% w/v 
BSA, or (b) PBS with Ca2+ + Mg2+. (c) The percentage inhibition of PBL 
transmigration by PEPITEM and AQ was compared in M199-BSA or PBS. 
***P≤0.001, ns=not significant by one way ANOVA followed by Dunnett’s or 
Bonferroni post-test. Data expressed as mean ±SEM of 4 independent assays. 
a) and b) represent matched data sets. 
Control     AQ       Scr   PEPITEM  Control    AQ       Scr   PEPITEM 
Control     AQ       Scr   PEPITEM Control     AQ       Scr   PEPITEM 
 AQ   PEPITEM  AQ   PEPITEM 
M199-BSA               PBS 
a) 
b) 
c) 
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These data confirmed the effects of adiponectin and PEPITEM reported 
previously, and implies that while the absence of fatty acids decreased PBL 
recruitment and transmigration, it did not affect the ability of adiponectin or PEPITEM 
to inhibit PBL transmigration. 
 
3.2.3. Tryptic release of PEPITEM from 14-3-3ζ protein. 
 
14-3-3ζ is a highly conserved and ubiquitous protein. However currently, little 
is known about the production of PEPITEM by B cells, or the cleavage of PEPITEM 
from 14-3-3ζ. 
To demonstrate proteolytic release of PEPITEM from 14-3-3ζ in vitro, 
recombinant 14-3-3ζ protein was digested for 1 hour at 37oC with HPLC-grade 
trypsin. Samples were purified on C18 columns and eluted with increasing 
concentrations of ACN which in turn decreases column retention. Samples were 
analysed by mass spectrometry and database searching as described. 
No PEPITEM was detectable in samples eluted with 10% ACN (Table 3.1), 
indicated by the lack of PEPITEM score and the lack of identification of the peptide 
fragment sequence of PEPITEM. Unfortunately, some samples became lost during 
transit to the mass spectrometry facility, however PEPITEM was detected in all 
measured samples eluted with 20% v/v ACN and above. The same 14-amino acid 
sequence was detected in all measured samples and the m/z ratio for the parent ion 
was consistently 774.88. The PEPITEM scores indicate a significant match between 
the mass of the peptide from mass spectrometry analysis and the real mass of the 
fragment stored in the database. While the score varied between 86.8 and 111.2, the 
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scores all remained highly significant as scores ≥30 are considered statistically 
significant according to the software manufacturer. These data show the ability of 
PEPITEM to be enzymatically produced from 14-3-3ζ protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Enzymatic release of PEPITEM from its parent protein 14-3-3ζ. 
Recombinant 14-3-3ζ was incubated for 1 hour at 37
o
C with HPLC-grade 
trypsin. Following purification, samples were eluted with increasing 
percentages of acetonitrile (ACN).  Samples were analysed by mass 
spectrometry with Mascot database searching. The PEPITEM score 
represents the score given by the search engine indicating the quality of the 
match between the mass of the peptide from mass spectrometry analysis and 
the real mass in the database. Scores ≥30 indicate significant matches. 
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3.3. Discussion 
 
Lymphocyte migration has been studied in vitro under both static and flow 
conditions. Human umbilical vein endothelial cells (HUVEC), which are 
macrovascular in origin, and human dermal microvascular endothelial cells (HDMEC), 
which are microvascular in origin, have been used to study T cell trafficking in vitro 
(Ahmed et al., 2011, Chimen et al., 2015, Luscinskas et al., 1995a, McGettrick et al., 
2009). We chose to employ the use of human dermal blood microvascular 
endothelial cells (HDBEC), as they more closely replicate in vivo conditions, being of 
microvascular origin. T cell recruitment occurs mostly in the peripheral 
microvasculature such as post-capillary venues, with some exceptions, for example, 
in the lungs where recruitment occurs in capillaries. The use of both HUVEC and 
HDMEC has been validated by Chimen et al. (2015) to investigate the inhibitory 
effects of AQ and PEPITEM on PBL transmigration. HDBEC resemble the same 
population of dermal-derived microvascular EC cells as HDMEC, with the batch used 
here consisting of a purified population of blood microvascular EC. This was 
confirmed by PromoCell with immunohistochemical staining and flow cytometry using 
EC marker PECAM-1 (99% positive), lymphatic EC marker podoplanin (99.7% 
negative) and stromal cell marker CD90 (96% negative), (PromoCell, 2015). 
 
In order to confirm the reproducibility of PBL transmigration in vitro using 
HDBEC, pro-inflammatory cytokines TNF-α and IFN-γ were examined for their ability 
to facilitate the recruitment and transmigration of PBL by EC. While EC treated with 
increasing concentrations of TNF-α exhibited an increasing trend of both PBL 
 78 
 
adhesion and recruitment, IFN-γ reached a maximal effect at 10ng/ml, with PBL 
adhesion and migration across stimulated EC remaining essentially the same as 
treatment with 100ng/ml IFN- γ. These observations are consistent with other reports 
using 100U/ml TNF-α + 10ng/ml IFN-γ to study PBL transmigration (Chimen et al., 
2015, McGettrick et al., 2009). 
 
TNF-α and IFN-γ mediate EC upregulation of key molecules such as E-
selectin, P selectin, ICAM-1 and VCAM-1, required for leukocyte recruitment and 
migration (Bahra et al., 1998, Bevilacqua et al., 1989, Lidington et al., 1999). 
Additionally, IFN-γ induces the chemokines CXCL9-11 which are key for T 
lymphocyte migration. These chemokines represent ligands for the T cell chemokine 
receptor CXCR3 (Cole et al., 1998, Loetscher et al., 1996). Following ligand binding 
to CXCR3, integrin activation is triggered via inside out signalling, and permits T cell 
firm adhesion required for subsequent trans-endothelial migration (Hogg et al., 2011). 
To confirm endothelial cell activation and upregulation of these key molecules 
in HDBEC following cytokine stimulation, we examined mRNA expression by qPCR. 
Indeed following 24hr stimulation, these adhesion molecules and chemokines were 
all upregulated in HDBEC, of which CXCL9-11 demonstrated the greatest increase in 
mRNA expression. Here, we confirm that 100U/ml TNF-α + 10ng/ml IFN-γ provides 
adequate stimulation of HDBEC to facilitate the measurement of PBL transmigration 
in our in vitro transmigration assays. 
 
Although others have used flow-based assays to study the behaviour of PBL 
in vitro, the static adhesion assay used here has been validated previously by 
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Chimen et al. (2015) who saw no difference in the inhibitory function of AQ between 
flow and static conditions. We wished to validate the reproducibility of this recently 
published work demonstrating that AQ and PEPITEM significantly inhibits the 
transmigration of PBL. In that study, both HUVEC and HDMEC were used however 
here, we use HDBEC. Nevertheless, our findings were consistent with that of Chimen 
et al. (2015), displaying significant levels of inhibition by both AQ and PEPITEM.  
Interestingly, studies have demonstrated preferential recruitment of 
CD45RA-/RO+ memory T cells under static conditions following EC stimulation with 
TNF-α + IFN-γ (Ahmed et al., 2011, Lichtman et al., 1997, McGettrick et al., 2009, 
Pietschmann et al., 1992). Additionally, Chimen et al. (2015) revealed that PEPITEM-
mediated inhibition was mainly of CD4+ and CD8+ memory T cells. Therefore, in 
subsequent chapters, though we refer to PBL we may assume that it is the memory T 
cells forming the majority of transmigrating PBL, and also the majority of PBL 
inhibited by these agents. 
No difference in inhibition of PBL transmigration was seen between 10ng/ml 
and 20ng/ml PEPITEM. We therefore used 20ng/ml PEPITEM in subsequent 
experiments to ensure that maximal inhibition could be observed and measured. 
Remarkably, PEPITEM demonstrated enhanced inhibitory function at higher levels of 
inflammation, modelled using 10-100U/ml TNF-α + 10ng/ml IFN-γ in section 3.2.2. 
Although inhibition of PBL transmigration was observed at 50U/ml TNF-α, this was 
not deemed statistically significant. Perhaps the interacting receptor on the EC, 
thought to be CDH15 (Chimen et al., 2015), is not upregulated sufficiently by low 
concentrations of TNF-α, leading to a reduction in intracellular signalling and in turn, 
a decrease in S1P production required to inhibit T cell transmigration (see Figure 1.4). 
Chimen et al. (2015) reports upregulation of CDH15 in HDMEC only at 100U/ml 
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TNF-α + 10ng/ml IFN-γ by immunohistochemical staining and real-time qPCR. 
CDH15 expression needs to be quantified following EC stimulation with increasing 
concentrations of TNF-α to address this possibility. Additionally, It would be 
interesting to see if PEPITEM retains its inhibitory function when stimulating EC with 
different concentrations and combinations of cytokines such as IL-4, which is known 
to recruit PBL (Thornhill et al., 1991). 
 
Fatty acids and lipids are present in both media and BSA, although the 
amount probably varies between batches. Fatty acids and lipids typically present in 
media include free (i.e. unesterified) fatty acids, triglycerides, phospholipids and 
cholesterol (Brunner et al., 2010), while the majority of lipid impurities in serum 
albumin are free fatty acids (Chen, 1967). The bioavailability of fatty acids such as 
arachidonic acid, required for the biosynthesis of PGD2, has been shown to affect 
both T cell and neutrophil migration (Ahmed et al., 2011, Tull et al., 2009). For this 
reason, we investigated the effect of exogenous fatty acids on PEPITEM function to 
ensure that the inhibitory effect we saw was independent of this. 
Lack of exogenous fatty acids still led to significant AQ or PEPITEM inhibition 
of PBL transmigration, and this did not significantly differ in the presence or absence 
of fatty acids. These data imply that fatty acid availability does not influence the 
inhibitory effect that we see in the PEPITEM paradigm.  
Interestingly, a reduction in adhesion and transmigration of PBL was noted in 
the absence of exogenous fatty acids. Fatty acids serve as fuel for cells, and also 
constitute cellular components such as membrane phospholipids as well as 
precursors for bioactive lipid mediators. Cells require nutrients contained in media for 
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energy and component synthesis, including fatty acids and glucose, to enable basic 
cellular functions and promote growth. The reduction in adhesion and transmigration 
seen in conditions absent of such nutrients (i.e. in PBS only) may reflect the lack of 
substrates available to support the energy requirements of cell adhesion and 
migration. Additionally, the reduction in transmigration may be attributed in part to the 
lower numbers of PBL recruited in the first place. Although PGD2 promotes T cell 
transmigration, it is unlikely that absence of fatty acids lead to a reduction in PGD2 
synthesis by EC and reduced T cell transmigration due to the short 6-minute 
incubation of PBL with EC. In light of these results, the volume of media M199 and 
concentration of BSA will be kept consistent to minimise variability in PBL adhesion 
and migration. 
 
Finally, PEPITEM was shown to be cleavable from 14-3-3ζ recombinant 
protein in vitro using HPLC-grade trypsin. In all measured samples eluted with 20% 
v/v ACN or more, a fragment belonging to the 14-3-3ζ protein was correctly identified 
by mass spectrometry and the 14-amino acid sequence was confirmed as PEPITEM. 
Vascular EC such as HUVEC have been shown to express trypsin (Koshikawa et al., 
1997) but currently, the mechanisms surrounding the release of PEPITEM from 14-3-
3ζ in vivo are unknown. Investigations into the protease(s) responsible for the 
cleavage of 14-3-3ζ into PEPITEM are required to elucidate this process. 
 
3.4. Conclusions 
Like others, we show that synergistic stimulation of EC with TNF-α and IFN-γ 
is sufficient to simulate EC to express important cell adhesion molecules and 
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chemokines, resulting in the significant recruitment and migration of PBL. We confirm 
that in our assays, 100U/ml TNF-α and 10ng/ml IFN-γ were optimal for our studies. 
Additionally, synergistically stimulation of EC with TNF-α + IFN-γ was more 
physiological relevant, mimicking multiple cytokine stimulation seen in vivo. 
Here, we reiterate the inhibitory effects of AQ and PEPITEM on PBL 
transmigration. This is important as the reproducibility of AQ and PEPITEM inhibition 
is key to the subsequent work presented here. Interestingly, the effect of PEPITEM 
was greater when there is more inflammation, modelled using increased 
concentrations of TNF-α. We have also shown that while adhesion was reduced, the 
AQ-PEPITEM axis was not dependent on exogenous lipids. 
Finally, we have demonstrated the ability for PEPITEM to be released from the 
14-3-3ζ parent protein. This finding is interesting as it raises questions about the 
production of PEPITEM by B cells; How does it occur? Where does it occur? What 
regulates this process? These questions will be addressed in subsequent chapters. 
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CHAPTER 4: INVESTIGATING PEPITEM 
STRUCTURE, INTERACTIONS AND HIGH-
THROUGHPUT MEASUREMENT OF FUNCTION 
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4.1. Introduction 
  
A physiological role for PEPITEM had not been specified until earlier this year 
(Chimen et al., 2015). Prior to this, the only mention of this peptide in the literature 
has been as a tryptic peptide used for identifying 14-3-3ζ protein in mass 
spectrometry samples (Kobayashi et al., 2009, Mohammad et al., 2013). Though one 
study reported the PEPITEM sequence as a peptide presented by human leukocyte 
antigen (HLA)-DQ8, transgenically expressed in NOD mice (Suri et al., 2005), this 
study detailed only that this peptide is naturally processed and preferentially 
presented by APCs. 
Due to its originality, the structure of PEPITEM has not yet been elucidated. 
PEPITEM represents 14 amino acids located at residues 28 to 41 in the 14-3-3ζ 
protein. These residues are not covert, but instead appear exposed on the protein 
surface (Figure 1.5). The relevance of this is uncertain, but it may have some 
physiological bearing on subsequent processing into PEPITEM. Although PEPITEM 
appears linear as part of 14-3-3ζ, it is unknown what conformation it takes following 
enzymatic release.  
 
Nuclear magnetic resonance spectroscopy (NMR) is a powerful tool for 
studying the chemical structure of molecules. It exploits the absorption and emission 
of radio frequency energy by protons subject to a magnetic field.  The Nuclear 
Overhauser effect (NOE) is a quantum phenomenon which occurs following the 
magnetisation of a proton affecting its spin (Figure 2.4), influencing the spin of 
another nearby proton approximately 4-5 angstroms (Å) apart and causing an 
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increase or decrease in chemical shift, differing according to a proton’s local 
chemical environment. This series of interactions or “coupling” between protons 
along the length of a peptide can occur through bonds or through space, creating 
detectable NMR signals. These signals convey spatial information about protons 
used to decipher the structure and stereochemistry of molecules (Jacobsen, 2007). 
The related ROE (rotating-frame NOE) is used in mid-sized molecules (1000-
3000 Da) where the conventional NOE is close to zero. The use of the rotating frame 
negates the effect of the tumbling rate of the peptide meaning that even when the 
NOE is zero the ROE is not. 
Amino acids are made up of separate chemical groups each with their own 
spin system. Total correlation spectroscopy (TOCSY) exploits the scalar coupling 
between protons to provide us with information about the chemical shift of protons 
within the same spin system of an amino acid following magnetism. Associations 
between spin systems within an amino acid provide information about intra-residue 
interactions (Keeler, 2013). Rotating-frame nuclear Overhauser effect spectroscopy 
(ROESY) provides through-space information via ROEs. Often used when examining 
small peptides, ROESY delivers information about through-space associations of 
protons within the context of the rotating frame (Jacobsen, 2007, Keeler, 2013). This 
gives overlapping information with the TOCSY as protons in the same spin system 
are usually close in space but also give information about protons on different 
residues which lie within 5 Å of each other. 
 
In addition to a lack of understanding of the structure of PEPITEM, little is 
known about the interactions which take place on the EC surface leading to 
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PEPITEM-mediated EC synthesis and secretion of sphingosine-1 phosphate (S1P). 
Chimen et al. (2015) identified the EC-borne receptor for PEPITEM using biotinlyated 
PEPITEM as “bait” in a pull-down assay with EC lysates, followed by mass 
spectrometry of bound candidates. Cadherin 15 (CDH15) was recognised as the 
strongest match by Mascot database searching, however interestingly, 
thrombospondin-1 was also identified, but demonstrated a much lower Mascot match 
(unpublished observations). CDH15 is a transmembrane glycoprotein belonging to 
the cadherin superfamily of proteins. Originally identified in skeletal muscle, CDH15 
(aka M-cadherin) is involved in cell-cell interactions and its expression has been 
demonstrated in endothelial cells (Chimen et al., 2015). Thrombospondin-1 (TSP-1) 
is a matricellular glycoprotein with numerous physiological roles. As well as being 
involved in cell adhesion, TSP-1 plays a role in immune regulation and interacts with 
a wide range of proteins (reviewed by Lopez-Dee et al. (2011) and Resovi et al. 
(2014)). 
Compellingly, knockdown experiments targeting EC CDH15 abrogated the 
inhibitory effects of PEPITEM on T cell transmigration, suggesting a central role in 
the paradigm (Chimen et al., 2015). Although S1P kinase 1 (SPHK1) was 
subsequently identified downstream of cell-surface interactions, it remains unclear 
what connects CDH15 to that pathway. 
Biacore binding assays provide a means to measure ligand-receptor 
interactions and involve measurement of surface plasmon resonance (SPR). The 
refraction of a light source off a solid phase chip at particular angle, known as the 
incidence angle, causes the oscillation or “resonance” of electrons also known as 
surface plasmons on the chip surface (Figure 2.3). Interactions of immobilised 
molecules with ligands cause a detectable change in SPR recorded in the Biacore 
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sensorgram, providing kinetic information about binding events. Disappointingly, 
previous interrogation of PEPITEM interactions with CDH15 conducted through 
Biacore binding assays was inconclusive and lacked appropriate controls (Chimen et 
al., 2015). 
The in vitro migration assay represents a validated functional read-out for the 
measurement of inhibition of PBL transmigration by PEPITEM. Nevertheless, this 
assay requires multiple blood donors for the fresh isolation of PBL, which is time 
consuming. Jurkat T cells are an immortalised T cell line used in the investigation of 
T cell biology. Jurkat T cells have previously been used to study T cell transmigration 
in vitro (Kitani et al., 1998, Ma and Ma, 2014, Ticchioni et al., 2002), and would eliminate 
the need for fresh PBL in transmigration assays.  
Many studies into receptor agonists and antagonists utilise calcium signalling 
assays, which enable high-throughput measurement of drug-induced calcium 
signalling, for example via GPCR. (An Haack et al., 2011, Luo et al., 2011, Valentine 
and Tigyi, 2012). These plate-based assays are high-throughput and would eliminate 
the time consuming and highly subjective job of analysing surface adherent and 
transmigrated cells in the migration assay. 
S1P is a sphingolipid produced by endothelial cells in response to PEPITEM 
stimulation (Chimen et al., 2015), and is also involved in T cell egress from lymph 
nodes (Pham et al., 2008). S1P released from EC in the PEPITEM paradigm binds to 
the surface of T cells via the S1P receptors 1 and 4 (S1PR1/4), leading to the 
inhibition of T cell transmigration. However, S1P has also been reported in the 
literature to bind to S1P receptors expressed by EC, and lead to intracellular calcium 
flux (Itagaki et al., 2007, Seol et al., 2005). If this secondary feature could be 
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exploited, the time-consuming analysis process following migration assays could be 
eliminated, along with the requirement for fresh PBL altogether. 
In this chapter, we initially investigate the chemical structure of PEPITEM and 
important amino acids within its sequence. We employ Biacore binding assays to 
investigate potential interactions of PEPITEM or 14-3-3ζ with CDH15 and TSP-1. 
Finally, we attempt to develop a high-throughput assay for measuring the effect of 
PEPITEM.  
Here, evidence is presented suggesting that PEPITEM is an unstructured 
peptide with no individually crucial amino acids. Our data may indicate that PEPITEM 
and 14-3-3ζ do not interact directly with CDH15 or thrombospondin-1 in our in vitro 
binding assays, and PEPITEM was not capable of eliciting a measurable intracellular 
calcium response in EC. 
 
4.2. Results  
4.2.1. Exploring the structure of PEPITEM using NMR. 
 
Our current knowledge of PEPITEM portrays this peptide as 14-amino acids 
long, some residues of which are charged. However we are not currently aware if this 
peptide has any secondary structure, or consistent conformations following release 
from 14-3-3ζ. 
To examine the structure of PEPITEM, we utilised NMR spectroscopy to study 
the possible conformation of PEPITEM in vitro. Initially, the protons in each amino 
 89 
 
acid were “assigned” i.e. associated to their unique chemical shift (ppm) using the 
TOCSY spectra. Each point labelled in Figure 4.1 represents a proton within 
PEPITEM. The labelsdenote the amino acid which the proton is assigned to (e.g. 
9Leu is Leucine at 9th amino acid position). Next, the TOCSY and ROESY spectra 
were overlaid allowing discrimination between intra-residue cross peaks and inter-
residue signals, and providing structural information. Stronger cross peaks in the 
spectra indicate closer proximity of protons. Intra-residue cross peaks illustrated in 
Figure 4.1 are displayed as the assignment and the proton (H) detected in that 
residue, followed by the intra-residue proton it interacts with respectively. (e.g. 5GlnH, 
Hba). Where necessary, proton nomenclature (e.g. a/α, b/β, g/γ) represents their 
position in the amino acid residue, and where there are two protons attached to a 
heavy atom they are differentiated  by a following “a” or “b”. Inter-residue cross peaks 
are labelled as the proton assigned to the amino acid, followed by the proton in 
another residue it interacts with e.g. 9LeuH 7AlaHb. 
 
In the overlaid TOCSY and ROESY spectra, we observed amide proteins 
along the x-axis with cross peaks to the aliphatic Hα protons on the y-axis between 
3.6 and 4.5 ppm. Methyl protons were located between 0.5 and 1.3 ppm on the y-
axis, with the rest of the protons located in the central portion between 1.4 and 3.4 
ppm. Many intra-residue assignments were made, for example between protons in 
Glu at the 13th residue (13GluH,Hbb - x=8.2ppm y=2.0ppm). Some inter-residue 
NOEs were noted, for example between the 2nd and 5th residues (5GlnH 2ValHgb - 
x=8.4ppm y=0.5ppm). These are better illustrated in Figure 4.2, which maps all inter-
residue distance restraints within the PEPITEM sequence. No long range ROEs were 
seen between amino acids more than 3 residues apart, however the presence of  
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Figure 4.1. 2D 1H NMR spectrum of PEPITEM acquired at 600MHz. 
A region within the overlaid TOCSY (blue) and ROESY (red, tm=200ms) 
spectra of PEPITEM showing cross-peaks between amide protons in the 
x-dimension and aliphatic protons between 3.6-4.5ppm, and methyl 
assignments between 0.5-1.3ppm in the y dimension. The TOCSY 
spectrum gives inter-residue peaks and the ROESY spectrum gives both 
intra and inter-residue peaks via through space interactions. 1H chemical 
shift is reported in the x and y dimensions as parts per million (ppm). 
Labelling represents the position and amino acid assigned to the proton 
followed by an associated proton. * = methyl groups with 3 equivalent 
protons. 
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ROEs between the residues 2 and 5, and 10 and 12 may suggest the existence of 
hinge-like structure, which roughly corresponds to the loop regions in 14-3-3ζ. 
  
With NMRpipe software,we next produced 100 predicted conformers of 
PEPITEM which met the NMR-derived structural information obtained in figure 4.1. 
We then performed structural alignments using PyMOL softwareof the 20 lowest 
energy structures defined by chemical characteristics of the NMR data. Initially, we 
aligned the conformers along the whole length of the peptide (Figure 4.3a), in which 
conformer structure was fairly inconsistent throughout. Alignment of the first 5 N-
terminal residues demonstrated random movement and considerable flexibility in the 
20 conformers (Figure 4.3b). Finally, we aligned PEPITEM with the last 5 C-terminal 
residues (Figure 4.3c). These residues aligned reasonably well, and flexibility of the 
rest of the chain could then be seen.  
The root mean squared deviation (RMSD) for these 20 structures was 
calculated by pairwise alignment of conformers, followed by calculation of the 
distance of each atom from the mean structure. This was squared, rooted, and the 
sum of distances of each conformer was divided by the total number of atoms giving 
the RMSD for PEPITEM. The average RMSD was 2.945 Å for the backbone atoms 
and 4.157 Å for all atoms, showing little convergence of the 20 structures. 
We further interrogated the structure of PEPITEM by examining whether 
particular amino acids in the PEPITEM structure could be attributed to its function. 
We performed single alanine substitutions along the length of the peptide sequence, 
as alanine is a charge-neutral amino acid, and charged residues often impart  
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Figure 4.3. 3D alignment of PEPITEM conformers. 
Structural alignment of 20 conformers with the lowest energy was 
performed using PyMOL software. Alignment was performed (a) along the 
whole length of PEPITEM, (b) using the first 5 N-terminal residues of 
PEPITEM, or (c) using the final 5 C-terminal residues. Each separate colour 
is representative of each individual conformer of the peptide which were in 
agreement with the NMR data. 
a) 
c) 
b) 
C-terminus 
N-terminus 
C-terminus 
Reasonable 
alignment 
Random movement 
and chain flexibility 
Chain flexibility 
Inconsistent 
conformer 
structure 
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structure and therefore function. We then screened each peptide at 20ng/ml for 
function using the in vitro migration assay. Alanine substitution at position 7 
represents native PEPITEM as it has an alanine residue naturally at this position. 
None of these PEPITEM variants significantly affected PBL adhesion (Figure 4.4). 
Interestingly, the closer the alanine substitution to the C-terminus, the more 
PEPITEM function was reduced, however this was not statistically significant 
compared to residue 7, and all peptides retained inhibitory function of between 21 - 
45%.  
These data confirmed the absence of secondary structure of PEPITEM, and 
lack of singly crucial residues. 
 
 
Figure 4.4. The effect of alanine substitutions on PEPITEM function. 
PEPITEM versions were synthesised with the substitution of alanine at each of 
the 14 amino acid residues in turn, except residue 7 which has a naturally 
occurring alanine and therefore represents native PEPITEM. Peptides were 
tested at 20ng/ml for inhibitory function using the in vitro migration assay. Data 
is expressed as percentage inhibition of transmigrated PBL. ns = not statistically 
significant analysed by one way ANOVA with Dunnett’s post- test. N=3-6. 
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4.2.2. Examining the interactions of PEPITEM, 14-3-3ζ, CDH15 and 
TSP-1 in Biacore binding assays. 
 
A role for CDH15 in the PEPITEM paradigm was recently demonstrated by 
Chimen et al. (2015). Previous binding experiments warranted further interrogation 
and validation. Therefore, we sought to perform additional binding assays to 
elucidate any binding interactions in vitro between PEPITEM, 14-3-3ζ, CDH15 or 
TSP-1 using the Biacore 3000 system. 
N-terminal biotinlyated PEPITEM and scrambled control peptide were bound 
to a streptavidin-coated CM5 Sensor chip, and increasing concentrations of CDH15 
were flowed over for 1 minute (Figure 4.5). While an increase in RU was observed 
during the injection of all concentrations of CDH15 over the PEPITEM-immobilised 
flow-cell, this was also the case for injections over flow cells immobilised with 
scrambled peptide or streptavidin alone. Figure 4.5a illustrates the increase and 
subsequent drop in response units (RU) seen on the Biacore sensorgram across all 
flow cells after injection of the highest concentration of CDH15 (100μg/ml). Following 
the injection and initial increase in RU, all conditions dropped almost back to 
baseline, although remained slightly higher. SPR for PEPITEM was 0.87 RU before 
injection of 100μg/ml CDH15, and 4.27 RU after (Figure 4.5b). 
TSP-1 has been previously identified as a potential binding partner of 
PEPITEM in addition to CDH15. We investigated the involvement of TSP-1 in the 
binding of PEPITEM to the EC surface. First, we flowed TSP-1 over immobilised 
PEPITEM. Similar to CDH15, we saw an increase in RU after the initial injection, 
 96 
 
followed by a decrease almost back down to baseline (Figure 4.6a) and this trend 
was also seen in control (SA and Scr) conditions (Figure 4.6b). 
Next, we investigated whether TSP-1 and PEPITEM interact with CDH15 as a 
complex. Therefore, we initially promoted potential complex formation between TSP-
1 and a PEPITEM using concentration ratios of 1:5 (10µg/ml TSP-1 with 50µg/ml 
PEPITEM) or 5:1 (50µg/ml TSP-1 with 10µg/ml PEPITEM). After injection of either 
solution, the trend of increasing RU following followed by a decrease back to roughly 
baseline was seen again (Figure 4.7a). On closer examination of the RU, injection of 
50μg/ml TSP-1: 10μg/ml PEPITEM induced some non-specific interaction with the 
blank flow cell (Figure 4.7b). 
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RU: Before After 
SA 1.66 7.74 
PEPITEM 0.87 4.27 
Scr 0.32 5.24 
 
 
 
 
 
Figure 4.5. Studying in vitro interactions between immobilised 
PEPITEM and CDH15. 
N-terminal biotinlyated PEPITEM, scrambled peptide (Scr) or streptavidin 
alone (SA) was immobilised to a CM5 Sensor Chip. Between 12.5-100µg/m 
(equivalent to 0.10-0.82µM)l recombinant CDH15 was injected (a) 
Representative Biacore sensorgram following injection of 100µg/ml CDH15 
and (b) quantification of response units (RU) before (grey) and after (white) 
injection of 100μg/ml CDH15. Data represents 1 experiment 
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RU: Before After 
SA 1.11 29.68 
PEPITEM 0.35 5.97 
Scr 0.47 2.00 
 
 
 
 
Figure 4.6. Investigating PEPITEM interactions with TSP-1 using Biacore. 
N-terminal biotinlyated PEPITEM, scrambled peptide (Scr) or streptavidin 
alone (SA) was immobilised to a CM5 Sensor Chip. 50μg/ml (equivalent to 
0.30μM) TSP-1 was flowed over for 1 minute. (a) Representative Biacore 
sensorgram following injection of 50µg/ml TSP-1 and (b) quantification of 
response units (RU) before (grey bar) and after (white bar) TSP-1 injection. 
Data represents 1 experiment. 
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RU: Before After  RU: Before After 
Blank 3.08 1.19 Blank 1.61 6.28 
CDH15 0.84 0.68 CDH15 1.36 0.88 
 
 
 
 
 
 
 
Figure 4.7. Examination of CDH15 interactions with TSP-1-PEPITEM 
complexes in vitro. 
PEPITEM and TSP-1 at concentration ratios of 1:5 (10µg/ml TSP-1 
equivalent to 0.06µM with 50µg/ml PEPITEM equivalent to 33.33µM), or 
5:1 (50µg/ml TSP-1 equivalent to 0.30µM with 10µg/ml PEPITEM 
equivalent to 6.7µM) were flowed over immobilised CDH15 or a blank 
flow-cell for 1 minute. (a) Representative Biacore sensorgram following 
injection of PEPITEM-TSP-1 solutions (b) quantification of response 
units (RU) before (grey bar) and after (white bar) injection. Data 
represents 1 experiment. 
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Finally, as 14-3-3ζ is the parent protein of PEPITEM, we investigated the 
potential interaction of 14-3-3ζ with CDH15 or TSP-1. The N-term biotinlyated 
PEPITEM had previously been checked for function in vitro (Chimen et al., 2015), 
demonstrating that biotinlyation did not affect receptor interactions. However, to 
investigate 14-3-3ζ interactions, we utilised a histidine-tagged 14-3-3ζ protein (14-3-
3ζ-His). Initially, we investigated what effect this may have upon the inhibition of PBL 
transmigration, since PEPITEM can be enzymatically cleaved from the parent protein. 
Surprisingly, while 14-3-3ζ-His did not affect adhesion, we saw a significant decrease 
in PBL transmigration from 27% in the control to 17% with 14-3-3ζ-His treatment 
(Figure 4.8). Clearly this finding may be important in elucidating the molecular 
mechanism behind PEPITEM function, and requires addressing in subsequent 
chapters. 
 
 
 
 
 
 
Figure 4.8. The effect of histidine tagging of 14-3-3ζ on PBL 
transmigration. 
20ng/ml Scrambled peptide (Scr), PEPITEM or 14-3-3𝜁-His was tested in the 
in vitro migration assay to assess its effect on PBL transmigration across 
cytokine-stimulated endothelium. Data represents mean ± SEM of 5 
independent experiments. ***P≤0.001 using one way ANOVA followed by 
Dunnett’s post-test. Ns = not significant.  
Control  PEPITEM   Scr    14-3-3ζ-His Control  PEPITEM    Scr   14-3-3ζ-His 
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Following the realisation that recombinant 14-3-3ζ-His inhibits PBL 
transmigration, we immobilised 14-3-3ζ-His to a nickel chip and injected TSP-1 or 
CDH15. Figure 4.9a shows the Biacore sensorgram following injection of the highest 
concentrations of TSP-1 (100µg/ml) and CDH15 (200μg/ml). In keeping with previous 
Biacore observations, there was an increase followed by a decrease in RU after each 
injection, however when quantified, this returned to a higher RU value than prior to 
injection in both blank and 14-3-3ζ-His immobilised flow cells (Figure 4.9b). 
Together, these data implied that while 14-3-3ζ-His can inhibit PBL 
transmigration, no interactions between PEPITEM, 14-3-3ζ or CDH15 and TSP-1 
were evident. 
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RU: Before After  RU: Before After 
Blank 1.68 21.02  Blank 24.34 752.74 
14-3-3ζ 1.72 27.74  14-3-3ζ 23.40 352.07 
Figure 4.9. Exploring 14-3-3ζ interactions with CDH15 and TSP-1.  
50-100μg/ml (0.30-0.60µM) TSP-1 or 50-200µg/ml (0.80-1.60µM) CDH15 
were flowed over immobilised 14-3-3ζ-His or a blank flow cell. (a) 
Representative Biacore sensorgram following injections of 100µg/ml TSP-
1 followed by 200μg/ml CDH15 and (b) quantified response units (RU) 
prior to (grey) and after (clear) injections. Data represents 1 experiment. 
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4.2.3. Development of a high-throughput assay for measuring 
PEPITEM function. 
 
The current use of the migration assay requires multiple blood donations, PBL 
isolation and lengthy data-analysis. We initially investigated the potential of using 
Jurkat T cells, an immortalised T cell line, as a substitute for PBL to reduce 
experiment time, reagents, and to standardise our assays.  
Jurkat T cells were examined for adhesion and transmigration across cytokine-
stimulated EC. Initial observations under control conditions were unexpected (Figure 
4.10a). It was immediately obvious that substantially more Jurkat T cells were surface 
adherent compared to PBL from a healthy donor. Upon quantification of adhesion 
and transmigration (Figure 4.10b), indeed a significantly higher level of Jurkat T cells 
were adherent (4120 cells/mm2/1x106) compared to previous observations, which 
were usually in the low hundreds. Furthermore, very few Jurkat T cells transmigrated 
(less than 1% transmigrated cells), and this was unaffected by treatment with 
PEPITEM. These data strongly suggested the inappropriateness of the use of Jurkat 
T cells to examine the function of PEPITEM. 
We next sought to exploit S1P-induced intracellular calcium flux as a 
secondary effect of PEPITEM to indirectly measure its function. To investigate 
whether calcium flux was a viable means to use as a read-out of PEPITEM function, 
we employed a simple plate-reader based assay in 96-well format using the 
fluorescent calcium indicator Fluo-4. Here, calcium flux would be detected as an 
increase in relative fluorescence units (RFU) in response to different concentrations 
of ligand. We first tested the calcium response of HDBEC in this assay using 
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Figure 4.10. The use of Jurkat T cells to study PBL transmigration in 
vitro. 
Jurkat T cells were added to cytokine-stimulated HDBEC before washing, 
fixing and imaging. Some Jurkat T cells were pre-incubated with 10µg/ml 
adiponectin (AQ) 1 hour prior to migration, or some wells were treated with 
20ng/ml PEPITEM or scrambled (Scr) immediately before migration. (a) 
Images acquired by phase contrast microscopy were used to compare control 
conditions between Jurkat T cells and freshly isolated PBL. (b) Adherent and 
transmigrated Jurtkat T cells were counted. Data is from 1 experiment. 
Jurkat T cells Fresh PBL 
a) 
b) 
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calcium ionophore, an agent known to causes mass intracellular calcium release. In 
the raw traces, responses were seen above 10-9M, and at 10-6M the response was 
almost saturated (Figure 4.11a). When we converted this to percentage increase in 
RFU compared to baseline, increasing calcium ionophore concentrations positively 
correlated with an increase in the maximal RFU response (4.11b), and the deviation 
from zero was statistically significant. 
As a positive control, we then confirmed that S1P was a viable ligand to 
induce calcium flux in HDBEC. Indeed, S1P elicited an obvious increase in RFU 
responses above 10-1M (Figure 4.12a), and again we observed positive correlation of 
S1P concentration with maximal RFU response which was statistically significant 
from zero (Figure 4.12b). 
Subsequently, we tested the ability of PEPITEM (Figure 4.13a) or scrambled 
control (Figure 4.13b) to induce calcium flux in HDBEC. No obvious increase in RFU 
was noticeable at any concentrations in the raw traces even at the highest 
concentration of 10-2mg/ml PEPITEM or scrambled peptide. Unexpectedly, 
scrambled peptide treatment of HDBEC induced a statistically significant increase in 
RFU when calculated as percentage increase, but not PEPITEM treatment (Figure 
4.13c), however the differences between the slopes were not statistically significant. 
Notably, negligible percentage increases in RFU between 8% and 14% were 
detected and seemed to increase at higher concentrations of either peptide. 
These data suggested that PEPITEM did not induce high enough levels of 
S1P to induce a measurable calcium flux. 
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Figure 4.11. Calcium ionophore-induced intracellular calcium flux 
Cytokine-stimulated HDBEC were loaded with Fluo-4 calcium dye prior to 
treatment with 0-10-6M calcim ionophore. Calcium flux was measured using a 
FlexStation plate reader over 180 seconds. (a) Representative trace of 
calcium flux following calcium ionophore treatment. (b) Percentage maximal 
increase in RFU following treatment with calcium ionophore (P≤0.0001). Data 
is mean ± SEM of 4 independent experiments with linear regression analysis.  
0 50 100 150 200
0
10000
20000
30000
40000
50000
Time (s)
R
e
la
ti
v
e
 f
lu
o
re
s
c
e
n
c
e
 (
R
F
U
)
10-6M
10-7M
10-8M
10-9M
10-10M
10-11M
10-12M
0M
a) 
b) 
10-13 10-12 10-11 10-10 10-9 10-8 10-7 10-6 10-5
0
100
200
300
400
Log concentration (M)
In
c
re
a
s
e
 in
 R
F
U
(%
 o
f 
b
a
s
e
lin
e
)
 107 
 
   
 
0 50 100 150 200
10000
15000
20000
25000
Time (s)
R
e
la
ti
v
e
 f
lu
o
re
s
c
e
n
c
e
 (
R
F
U
)
Flex Raw S1P
10-1M
10-2M
10-3M
10-4M
10-5M
10-6M
10-7M
0M
10-8 10-7 10-6 10-5 10-4 10-3 10-2 10-1 100
0
50
100
150
Log concentration (M)
In
c
re
a
s
e
 i
n
 R
F
U
(%
 o
f 
b
a
s
e
li
n
e
)
a) 
b) 
Figure 4.12. Calcium flux in HDBEC following S1P treatment. 
Cytokine-stimulated HDBEC were loaded with Fluo-4 calcium dye prior to 
treatment with 0-10-1M S1P. (a) Representative trace of calcium flux following 
S1P treatment. (b) Percentage maximal increase in RFU following treatment with 
S1P. Data is represented as mean ± SEM of 4 independent experiments. Linear 
regression analysis was performed, P≤0.0001. 
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Figure 4.13. Intracellular calcium flux in response to PEPITEM treatment. 
Cytokine-stimulated HDBEC were loaded with Fluo-4 dye and treated with 
increasing concentrations of PEPITEM or Scrambled peptide. Fluorescent 
signal measured using a FlexStation plate reader over 190 seconds. 
Representative traces of calcium flux following (a) PEPITEM or (b) Scrambled 
peptide treatment. (c) Percentage maximal increase in RFU following 
PEPITEM (P=0.0655) or Scrambled treatment (P=0.03). N=4. Mean ± SEM. 
Data was analysed by linear regression. P=0.6434 between slopes. 
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4.3. Discussion 
 
Due to the novelty of PEPITEM, little information about its function is available 
in the literature, and nothing has been published about its structure other than as part 
of 14-3-3ζ. Additionally, there are no known published interactions of PEPITEM 
except with CDH15, but this requires further investigation. In this chapter, we 
examined PEPITEM structure using NMR, and investigated binding interactions 
using Biacore. Finally, we assessed the potential of developing a higher throughput 
assay for PEPITEM function utilising Jurkat T cells, or intracellular calcium flux 
indirectly induced by PEPITEM.  
We employed the use of NMR to determine the structure of PEPITEM. TOCSY 
and ROESY spectra identified several inter-residue interactions between amino acids 
one, two and three residues away. However absence of consecutive adjoining of Hα 
protons to HN (amide protons) 3 residues apart confirmed a lack of alpha helices, and 
indeed there was no evidence of secondary structure. 
The 14 residues corresponding to the PEPITEM sequence in 14-3-3ζ are 
located between the second and third alpha helices of the protein, and are prominent 
on the surface of the protein (Figure 1.5). Interestingly, some medium-range 
interactions at either end of the sequence between residues 2 and 5, and residues 10 
and 12 roughly corresponded to these loop regions in 14-3-3ζ, however not enough 
NOEs were measured to be certain of this association. Perhaps these regions have 
some importance in the cleavage of PEPITEM from its parent protein. 
Modelling of the top 20 conformers demonstrated some structure at the C 
terminus when the last 5 residues were aligned. This was because there were slightly 
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more NOEs detected in this region, meaning that the structure is slightly better 
defined. Despite these residues aligning reasonably well, the rest of the chain 
appeared highly flexible. Calculation of the average RMSD demonstrated that there 
is little convergence of the top 20 conformers, and supported observations of very 
little secondary structure within the peptide.  
Possibly the biggest limitation was one which was unavoidable. PEPITEM is a 
small peptide of approximately 1.5kDa. Often, short peptides are indeed linear and 
can take many conformations affected by the environment they are in. Moreover, 
PEPITEM may only adopt a stable conformation upon receptor binding. Here, we 
used a pH 6 buffer for investigations for good signal to noise ratio, as lower pH 
reduce the exchange rate of HN. While pH 6 does not resemble in vivo conditions, 
since the blood has a pH of 7.35-7.45 (NHS, 2015) and this is the environment where 
T cells begin trans-endothelial migration, using pH in this range would likely only give 
very small signals from the HN, compromising our analysis. Therefore, it is difficult to 
accurately predict the conformation PEPITEM will take in vivo. 
Alanine substitution at any given residue did not reveal any significant 
differences in the inhibitory function of PEPITEM, determined using the in vitro 
migration assay. This suggests that no amino acids are individually essential for 
function. However, a subtle reduction in inhibitory function was noted towards the C-
terminus. This was an interesting observation because there are several charged 
residues at this terminus absent from the N-terminus, and NMR spectroscopy 
suggested more structure in this region. Perhaps more than one residue must be 
substituted to significantly alter PEPITEM function. It would be exciting to investigate 
whether alanine substitution of all charged residue simultaneously at the C-terminus 
abrogates PEPITEM function.  
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Together, these data tells us that there is no secondary structure, besides 
possible hinge regions at either end corresponding with loops in 14-3-3ζ.  
 
Biacore binding assays can provide information about molecular interactions 
by measuring differences in SPR. Interaction of CDH15 and PEPITEM was 
suggested by Chimen et al. (2015) and briefly investigated using a Biacore T200 
system.  
An increase in RU during the injection of all molecules was observed across 
experiments, and was followed by a prompt decrease. This is due to the injection of 
increased protein or peptide concentrations and buffer components giving signal 
during injection. This signal was not accumulating in the flow cell and therefore the 
signal dropped off again at the end of injection. Equivalent signals were observed 
over all flow cells in each experiment, indicative of no specific binding interactions, 
and any rises in RU were negligible. In some investigations, control flow cells 
demonstrated the highest increase in RU after injection, again supporting a lack of 
binding interactions. Therefore, it can be concluded that no interactions were 
observed between CDH15, PEPITEM, 14-3-3ζ and TSP-1 in these investigations. 
Chimen et al. (2015) reported a key role for CDH15 in PEPITEM function, 
however Biacore experiments were not comprehensive in that study. The binding 
assays were performed using a Biacore T200 system, whereas here, a Biacore3000 
system was employed, and may not be as sensitive to small changes in SPR. It is 
also possible that a lack of interaction between PEPITEM or 14-3-3ζ with CDH15 and 
TSP-1 was due to the use of recombinant proteins, which, depending on expression 
models used in production, may mis-fold or aggregate. If this is the case, binding 
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interactions would be hindered by protein conformations unrecognisable to their 
ligands. Membrane preparations are commonly used in Biacore studies to investigate 
interactions between membrane proteins, which take on particular conformations in 
the lipid bilayer and facilitate interactions. When studying PEPITEM interactions in 
the future, it would be advisable to consider membrane preparations as an alternative 
to recombinant proteins. 
Buffer choice can also affect protein conformation. The same buffer conditions 
used by Chimen et al. (2015) were also employed in our studies. However this may 
not mimic in vivo conditions occurring during PEPITEM binding to EC, and therefore 
a range of buffers must be tested during further investigations. 
We considered the possibility of binding interactions at the EC surface 
occurring as part of a larger complex, and therefore tested different concentration 
ratios of PEPITEM with TSP after incubation at 37oC. We saw no indication of 
specific binding interactions. If repeated, molar ratios of PEPITEM and TSP-1 should 
be used as PEPITEM is much smaller than TSP-1 and equivalent concentrations 
would not yield an equivalent number of molecules. 
Surprisingly, 14-3-3ζ-His inhibited PBL transmigration to the same extent as 
PEPITEM, and this requires further investigate to confirm that this wasn’t due to the 
presence of a histidine tag. 
 
Finally we investigated the use of a high-throughput assay to measure 
PEPITEM function in vitro. When we substituted PBL for Jurkat T cells, adhesion and 
transmigration was not comparable to previous data using PBL. Substantially higher 
numbers of Jurkat T cells became surface adherent, but did not transmigrate. Other 
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people have shown migration of Jurkat T cells in vitro, but those studies typically 
employed the use of chemotactic chambers or transwell filters for longer periods of 
time, in the presence of chemotactic agents (Kitani et al., 1998, Ma and Ma, 2014, 
Ticchioni et al., 2002). Furthermore, Jurkat T cells have been reported to possess a 
defect in the integrin LFA-1 (Mobley et al., 1994), required for T cell firm adhesion 
and subsequent transmigration. Indeed since they are a cancer cell line, it is 
questionable how much they resemble in vivo primary T cells. We therefore turned 
our attention to exploiting indirect S1P-induced intracellular calcium flux in EC as a 
measurement of PEPITEM function. PEPITEM was found at 1.5ng/ml in the serum of 
healthy donors by Chimen et al. (2015) and we have demonstrated inhibitory function 
at 20ng/ml in vitro.  While calcium ionophore and S1P were able to induce dose-
dependent calcium flux in EC, PEPITEM did not do so even at levels much higher 
than those seen in human serum or used in vitro. The low percentage increases in 
RFU in PEPITEM and scrambled treatments was likely due to an increase in optical 
path-length as a result of the addition of these substances into the assay plate. This 
is probably the case as no such increases were observed in the raw data traces at 
any concentration. 
Since the synthesis of S1P has been suggested by Chimen et al. (2015) as a 
result of PEPITEM binding, we can conclude that intracellular calcium flux indirectly 
induced by PEPITEM was not measurable, and perhaps the assay was not sensitive 
enough. Indeed Chimen et al. (2015) demonstrated significant inhibition of PBL 
transmigration by S1P at 10-7M, however no intracellular calcium flux was detected at 
this concentration in vitro, highlighting these sensitivity issues. It is possible that the 
concentration of S1P that PEPITEM induces is small as it acts locally, since high 
concentrations would be detrimental due to pleotropic effects elsewhere in the body.  
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To utilise calcium flux as a measurement of PEPITEM function, the sensitivity of the 
assay needs to be greatly improved.  The sensitivity of the assay is ultimately 
determined by the dissociation constant (Kd) of the dye for calcium. Therefore, 
another possible approach might be to use a dye with a lower Kd than Fluo-4. 
Alternatively, since calcium signalling can be specifically localised within a cell, 
changes can sometimes be detected using confocal microscopy but not using the 
FlexStation. Using confocal microscopy, however, would not be as high-throughput. 
Alternatively, other features leading to S1P production such as SPHK1 activity could 
be measured following PEPITEM treatment and evaluated as a means to assess 
PEPITEM function.  
 
4.4. Conclusions 
 
In this chapter, we confirmed that PEPITEM is a simple, unstructured linear 
peptide with high flexibility, and no individually essential amino acids. While we 
revealed a lack of interaction between PEPITEM or 14-3-3ζ and CDH15 or TSP-1 in 
vitro, Chimen et al. (2015) demonstrated a key role for CDH15 and this requires 
further investigation. The measurement of PEPITEM function by way of indirect S1P-
induced intracellular calcium flux was not sensitive enough to detect changes in 
intracellular calcium following PEPITEM treatment, and we remain unsure about the 
levels of S1P induced. Development of a high throughput assay would be 
advantageous to PEPITEM research as it would provide an invaluable means of 
testing large numbers of PEPITEM derivatives which may hold therapeutic use in the 
future. Moreover, investigations into EC surface interactions which occur following 
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PEPITEM binding would prove key to a comprehensive understanding of this novel 
paradigm. 
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CHAPTER 5: THE PHARMACOKINETICS OF 
PEPITEM AND ITS DERIVATISED PEPTIDES 
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5.1. Introduction 
 
Autoimmunity, Crohn’s disease, multiple sclerosis, type I diabetes (T1D), 
atherosclerosis and rheumatoid arthritis (RA) are just a handful of examples of 
chronic inflammatory diseases, which usually are T cell driven. For example in T1D 
and RA, T cell infiltration occurs in the pancreas and joint synovium respectively 
(Imagawa et al., 1999, Komatsu and Takayanagi, 2012) and is followed by tissue 
destruction. Since PEPITEM is a potent inhibitor of T cell trafficking, it represents an 
attractive agent with therapeutic potential. PEPITEM has been tested in a range of 
animal models of disease including peritonitis and uveitis (Chimen et al., 2015) and 
demonstrated reduced T cell trafficking into inflamed tissues. However, there are 
currently several obstacles in front of the development of PEPITEM for therapeutic 
use. The pharmacokinetics of PEPITEM are currently unknown, including its plasma 
concentration across the population, and the amount released by B lymphocytes 
under adiponectin stimulation. Furthermore, the optimal dose of PEPITEM in vivo has 
not yet been fully established. 
Peptides are an attractive prospect for drug therapies and arguably have 
several advantages, including higher affinity to their target and lower toxicity 
compared to small molecule drugs typically less than 500 Daltons (Da) in size, which 
have more side effects and lower specificity due to their small size (Craik et al., 2013). 
However, there are some problems which restrict the use of peptides as drug 
therapeutics.  
Here, we use the word “protease” to define enzymes which break down both 
proteins and peptides, and this term is recognised as interchangeable with the term 
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“peptidase” (Barrett and McDonald, 1986). Proteases hydrolyse peptide bonds and 
are ubiquitous in vivo. Numerous proteases have important function in a range of 
biological processes from digestion to apoptosis (Potempa and Pike, 2009). Small 
peptides are particularly vulnerable to proteases owing to their typically 
uncomplicated structure, and can undergo enzymatic degradation in the blood, 
kidneys or liver (Werle and Bernkop-Schnurch, 2006). 
Moreover, small peptides of approximately of 5kDa or less experience renal 
clearance in vivo, as the glomerular cut off is usually between 30-70kDa, although 
this has been widely debated and studies have suggested that other molecular 
properties such as net charge and molecular dimensions influence this (Duncan, 
2003, Fox et al., 2009, Ohlson et al., 2001, Oliver et al., 1992, Ruggiero et al., 2010).  
Generally, this means that peptides are likely to have a short in vivo half- life. 
Indeed the size of PEPITEM is just 1.5kDa and this presents a major problem, as 
effective therapeutic agents require significant availability and exposure for 
substantial effectiveness. This is particularly important in the treatment of chronic 
inflammatory disease, where inflammation is persistent. 
 
Pharmaceutical modifications have been used to increase peptide stability and 
half-life in vivo. Common modifications include the addition of polyethylene glycol 
(PEG) polymers to peptides, which can promote increased water solubility and can 
even reduce immunogenicity (Veronese and Pasut, 2005). PEG repeats can also 
increase the molecular weight (MW) of peptides reducing the likelihood of renal 
filtration. Addition of N or C terminal PEG repeats can also provide some relief from 
exopeptidases by blocking the termini, further increasing stability (Veronese and 
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Pasut, 2005, Werle and Bernkop-Schnurch, 2006). It is possible that the addition of 
PEG to a peptide may hinder its function, and it is therefore important to test PEG 
derivatives. 
N-terminal acetylation or C-terminal amidation can also prevent degradation 
by endopeptidases and exopeptidases, and the usage of uncommon amino acids, for 
example, in their D-isomeric form, can also prevent protease recognition and 
subsequent degradation, increasing stability (Landon et al., 2004, Werle and 
Bernkop-Schnurch, 2006). An advantage of D-isomerisation of all amino acids but in 
reversed sequence (reverse D-isomerisation, RDI) can reduce recognition by 
proteases but retain receptor-ligand interactions through maintaining the position of 
the adjuncts of each residue. Again these modifications may change the peptide’s 
biological activity. 
  
To determine the action of agents in vivo, appropriate mouse models of 
chronic inflammation must first be used. The apolipoprotein E-deficient (apoE -/-) 
mouse is a commonly used mouse model of atherosclerosis (Meir and Leitersdorf, 
2004). This is due to similarities between atherosclerosis in humans, and induced 
disease in mice, with comparable morphology and progression (Nakashima et al., 
1994, Plump et al., 1992). High fat diet (HFD) can also be used to accelerate disease 
progression in this model. We now know that atherosclerosis is an inflammatory 
disease exacerbated by T cells (Reviewed in section 1.5.4). Previous studies 
suggested the alleviation of disease by certain anti-inflammatory drugs (Paul et al., 
2000, Reis et al., 2000).  Furthermore, transfer of CD4+ T cells from apoE-/- mice into 
apoE-/-/SCID-/- mice accelerated atherosclerotic lesion progression (Zhou et al., 2000), 
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suggesting a role for T cells in the establishment of atherosclerosis. Chimen et al. 
(2015) demonstrated inhibition of CD4+ T cells by PEPITEM, but PEPITEM has not 
yet been tested in a mouse model of atherosclerosis. 
 
In this chapter, we examine whether common pharmacological modifications 
affect PEPITEM function in vitro before investigating the pharmacokinetics and 
localisation of the native form in vivo. We also assess the ability of PEPITEM to 
reduce plaque burden in an apoE-/- model of atherosclerosis. 
Here, we provide evidence that common pharmaceutical modifications do not 
affect PEPITEM function in vitro and may be useful further down the line in 
development. In agreement with literature of short peptides to date, PEPITEM has a 
short circulating half -life and is cleared by the kidneys. Finally, we find that 
intraperitoneal (IP)-treatment of apoE-/- mice on HFD with PEPITEM for 6 weeks did 
not reduce plaque severity. 
 
5.2. Results 
5.2.1. Assessing the effect of common pharmaceutical 
modifications on PEPITEM function in vitro. 
 
To assess the effect of common pharmaceutical modifications on the function 
of PEPITEM, derivitised peptides were synthesised by way of a small-scale epi-scan 
array, yielding crude, unpurified peptides. Such arrays, though more economically 
viable for the production of large variations of peptides, can leave behind impurities 
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or contaminants as a result of the synthesis process. Modifications included the 
addition of N- or C- terminal 352MW PEG repeats (N- or C- PEG), N and C terminal 
acetylation and amidation (N/C block), and reverse D-isomerisation (RDI). 
 
Initially we compared the function of purified and crude native PEPITEM in the 
in vitro migration assay. Both pure and crude peptides demonstrated no significant 
difference in function, with 20ng/ml of pure and crude PEPITEM significantly reducing 
PBL transmigration to 23% and 22% respectively, compared to the control (37%, 
Figure 5.1a). After testing each peptide modification at 20ng/ml, we saw no effect on 
PBL adhesion, and none of the modifications significantly enhanced or hindered 
PEPITEM function in vitro, exhibiting between 30 and 35% inhibition of PBL 
transmigration (Figure 5.1b). 
These data suggest that PEPITEM can be modified to improve its stability in 
vivo without reducing its efficacy. 
 
 
5.2.2. Investigating the in vivo pharmacokinetics of PEPITEM. 
 
Small peptides are known for having short half-lives in vivo. To establish the 
longevity of exogenous PEPITEM in the circulation, we first needed to be able to 
detect it in plasma. A tritiated version of PEPITEM (3H PEPITEM) was synthesisd 
allowing the detection of PEPITEM through the measurement of radioactivity. 
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Figure 5.1. The effect of PEPITEM modifications on the inhibition of PBL 
transmigration. 
Peptide derivatives were synthesised by crude array and assessed using the in 
vitro migration assay. (a) Native PEPITEM synthesised by crude array was 
compared to native PEPITEM synthesised more purely at 2-200ng/ml (b) 
modified peptides were assessed for PEPITEM function at 20ng/ml. *P<0.05, 
**P=0.01, ns= not significant analysed by way ANOVA with Dunnett’s post-test. 
Data represent mean ± SEM of 3 independent experiments. 
 
a) 
b) 
Control  Pure    Pure    Pure    Crude   Crude  Crude 
                  2         20       200         2          20        200 
 
ng/ml: 
 
   Native   N-term  C-term    N/C      RDI 
PEPITEM   PEG    PEG     BLOCK 
 
   Native   N-term  C-term    N/C      RDI 
PEPITEM   PEG    PEG     BLOCK 
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We first performed a dilution of 3H PEPITEM from 0.1ng to 10ng in increasing 
volumes of scintillant liquid to determine optimal conditions for the detection of 
radioactivity by scintillation counting (Figure 5.2a). No differences were observed in 
radioactivity counts (Disintegrations per minute, DPM1) between different volumes of 
scintillant, and radioactivity remained detectable at all concentrations. Therefore, to 
utilise a minimal amount of radioactive substance while maintaining sensitivity, 1ng 
3H PEPITEM and 2ml scintillant was chosen for future experiments. 
Cardiac puncture is an appropriate method for ex-vivo assessment of the 
blood. Occasionally, red blood cells may become lysed during cardiac 
exsanguination and centrifugation, causing the release of haemoglobin. Due to the 
presence of double bonds in haemoglobin molecules, the potential for signal quench 
during scintillation counting was possible. To check whether RBC lysis affected the 
detection of radioactivity, mouse plasma samples with and without visible amounts of 
haemoglobin were spiked with 0.1ng or 1ng 3H PEPITEM (Figure 5.2b). The 
presence of visible haemoglobin did not hinder the detection of radioactivity by 
scintillation counting, confirming the reliability of the signal between samples. 
After establishing optimal conditions for the detection of radioactivity in plasma, 
1ng/g 3H PEPITEM was injected into mice via the tail vein for 2 to 60 minutes, and 
plasma was examined for radioactivity by scintillation counting. After 2 minutes, only 
1062 DPM1 was detected compared to 20046 DPM1 at 0 minutes, representing a 
significant decrease in radioactivity (Figure 5.3). Radioactivity counts further 
decreased to 332 DPM1 and 266 DPM1 after 30 and 60 minutes respectively. These 
data therefore imply rapid clearance and low retention of PEPITEM in circulation 
following IV injection. 
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With PEPITEM being much smaller than the renal filtration cut off, we 
investigated whether this short circulating half-life could be attributed to clearance by 
the kidneys. PEPITEM was conjugated to alexafluor-680 fluorescent dye to enable us 
to track it in vivo via fluorescence. Upon testing the fluorescently-labelled PEPITEM 
(PEPITEM-AF680) in vitro utilising the migration assay, we confirmed that 
PEPITEM-AF680 did not affect PBL adhesion and retained the ability to inhibit T cell  
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Figure 5.2. Determining optimal conditions for the detection of 
radioactive PEPITEM in serum. 
(a) Initially, 0.1-10ng 3H PEPITEM was spiked into 0.5-2ml scintillant. (b) The 
effect of haemoglobin on the reliability of the signal of 0.1 or 1ng radioactive 
PEPITEM was then confirmed. Radioactivity was detected using a 
scintillation counter and signal is expressed as DPM1. Data represents 1 
experiment. 
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trafficking significantly, and PBL transmigration was reduced from 30% in the control 
to 16% (Figure 5.4).  This level of inhibition was similar to PEPITEM (18% PBL 
transmigration). 
We established the optimal concentration of 100µg/ml for the detection of 
PEPITEM-AF680 imaging using the In Vivo Imaging System (IVIS), (data not shown). 
100µg/ml of PEPITEM-AF680 was injected into BALB/c mice for 15 minutes to allow 
enough time for a detectible PEPITEM-AF680 fluorescent signal to accumulate in 
any given organ(s). Animals were sacrificed and organs were excised for ex-vivo 
imaging using the IVIS. Localised fluorescence was clearly observable in the kidneys, 
stomach and gut 15 minutes post-injection of PEPITEM-AF680 (Figure 5.5), and 
when quantified, kidney fluorescent intensity was 7.1x107p/s/cm2/sr in control mice,  
Figure 5.3. The in vivo pharmacokinetics of PEPITEM. 
1ng/g 3H PEPITEM was injected via the tail vein of C57BL/6 mice. Blood 
was extracted after 2, 30 or 60 minutes and assessed for radioactivity by 
scintillation counting. Radioactivity at 0 minutes was determined by spiking 
1ng/g 3H into collected blood before centrifugation and measurement of 
radioactivity. Data expressed as radioactive counts (DPM1), and represents 
mean ± SEM of 3-6 mice. P≤0.001 by one way ANOVA followed by 
Dunnett’s post-test. 
 126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Inhibition of PBL transmigration by a PEPITEM-AF680 
conjugate. 
PEPITEM was conjugated to Alexa-fluor 680 dye via the amide bond. 20ng/ml 
PEPITEM-AF680 was tested alongside 20ng/ml native PEPITEM or Scrambled 
for function in the in vitro migration assay. Data represents mean ± SEM of 8 
independent experiments, and was analysed by one way ANOVA with Dunnett’s 
post-test. ***P≤0.001, ns=not significant. 
PEPITEM -AF680 
  
Figure 5.5. IVIS imaging of organs following injection of PEPITEM-AF680 
into BALB/C mice  
(a) PBS control or (b) 100µg/ml PEPITEM-AF680 was injected IV into BALB/c 
mice. Organs were imaged ex-vivo after 15 minutes. Representative images 
taken using the IVIS Spectrum Imager, with 3 mice per group. Fluorescence is 
expressed radiant efficiency (p/s/cm2/sr). 
Control (PBS) 
Kidneys Kidneys 
Heart 
Heart 
Gut Gut 
Stomach Stomach 
Spleen 
Spleen 
Lungs Lungs 
Liver Liver 
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and 1.9x109p/s/cm2/sr in PEPITEM-AF680-treated mice, and was significantly 
different (Figure 5.6). Higher levels of fluorescence were also observed in the spleen, 
lungs and heart of PEPITEM-AF680-treated mice, but these increases were much 
smaller than that seen in the kidneys. High levels of autofluorescence were notable in 
the stomach and gut of the control group, however the fluorescent intensity was not 
higher in PEPITEM-AF680-treated mice. Calculation of the percentage increase in 
fluorescence following PEPITEM-AF680 treatment compared to the PBS control mice 
revealed the largest increase in fluorescent signal localised mainly in the kidney, and 
the lack of increase in the stomach and gut (Figure 5.7). This is indicative of rapid 
renal clearance of PEPITEM from the circulation in vivo. 
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Figure 5.6. Organ fluorescence following injection of PEPITEM-AF680 
into BALB/c mice. 
100µg/ml PEPITEM-AF680 or PBS control was injected IV into BALB/C 
mice. After 15 minutes, organs were excised and imaged for fluorescence. 
Mean fluorescence intensity of each organ was measured representing the 
average fluorescent counts divided by the number of pixels in each ROI. 
*P≤0.05 and ns=not significant by unpaired t-test. N=3 mice per group. 
Data expressed as mean ± SEM. 
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Figure 5.7. The organ distribution of PEPITEM-AF680 in vivo. 
PEPITEM-AF680 or PBS control was injected IV into BALB/c mice. After 
15 minutes, organs were excised and imaged for fluorescence. The 
increase in fluorescence of each organ from mice treated with PEPITEM-
AF680 was calculated from the data in Figure 5.6, by dividing the 
increase in fluorescence by the fluorescence in PBS control mice. N=3. 
 130 
 
5.2.3. Investigating the effect of PEPITEM in a mouse model of 
atherosclerosis. 
 
Atherosclerosis is characterised by plaque formation in the artery wall in an 
inflammatory environment, and T cells have been shown to exacerbate it. We 
investigated whether treatment of apoE-/- mice with PEPITEM administered via 
intraperitoneal (IP) injection could reduce atherosclerotic plaque burden in vivo. We 
selected C-terminal PEG PEPITEM for increased stability as it demonstrated no 
significant difference in inhibitory function in in vitro migration assays, and may aid 
stability of the C-terminus which alanine substitution data suggested might be 
important for function. 
Mice on HFD were treated twice a week with 1.75mg/ml PEPITEM or 
scrambled control for 6 weeks. Hearts were isolated and the aortic root was 
examined for plaque burden. Mice in both control and PEPITEM groups 
demonstrated plaque formation in the aortic root bicuspid valves (Figure 5.8a). 
However, plaque burden did not differ between groups, exhibiting 11.8% and 11.9% 
plaque burden for control and PEPITEM treatment respectively. Since previous 
studies reported inflammation and steatosis in the liver of apoE-/- mice on HFD, we 
examined the liver of control and PEPITEM-treated mice. No signs of inflammation or 
steatosis were seen in either group (Figure 5.9).  
These experiments suggested that PEPITEM treatment for 6 weeks did not 
alleviate plaque burden in a mouse model of atherosclerosis. 
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Scrambled control PEPITEM-PEG 
Figure 5.8. Plaque burden in apoE-/- mice on HFD following treatment 
with PEPITEM-PEG. 
C57BL/6 mice were treated for 6 weeks with PEPITEM-PEG or scrambled 
control. (a) Heart sections were observed for plaque formation in the aortic 
root, imaged by light microscopy. (b) Percentage plaque burden (stained red 
with Oil red O) was quantified using image J. Data represent mean ± SEM of 
2 and 3 mice for scrambled control and PEPITEM-PEG groups respectively. 
a) 
b) 
Scrambled     PEPITEM-PEG 
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Aortic 
lumen 
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Control 
PEPITEM-PEG 
Figure 5.9. Liver histology of apoE-/- mice on HFD following 6 weeks of 
PEPITEM-PEG treatment. 
Representative H&E-stained liver sections from C57BL/6 mice treated for 6 
weeks with scrambled control or PEPITEM-PEG. Images were acquired by 
brightfield microscopy. 
Hepatocytes 
 
Bile duct 
Hepatic portal vein 
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5.3. Discussion 
 
The high potency of PEPITEM and its specificity to memory T cells (Chimen et 
al., 2015) make PEPITEM a desirable candidate for development into a therapeutic 
agent against a wide range of T cell-mediated chronic inflammatory diseases.  
There are numerous ways available for peptide modification and this is 
common practice in the pharmaceutical industry.  We tested several common 
modifications in this chapter to examine any effects on PEPITEM function and thus 
their plausible use to increase peptide stability during future development. None of 
the modifications significantly affect the ability of PEPITEM to inhibit PBL 
transmigration in vitro. Initially we tested the effect of the addition of N or C terminal 
352Da PEG repeats, as larger PEGs become increasingly expensive and we were 
unsure what effect addition of synthetic polymers to these termini would have on 
function. The fact that addition of PEG to either termini did not affect function means 
their use is a possibility in the future as a strategy to increase solubility or stability if 
necessary. Additionally, adjusting the size of PEG is an option if increased molecular 
weight is required. N-terminal acetylation and C-terminal amidation of PEPITEM 
could also be employed as a preventative measure for recognition by exopeptidases. 
The reverse D-isomerised peptide, representing the PEPITEM amino acid sequence 
in reverse order using D-amino acids, represents the use of amino acid isomers rare 
in nature which are not easily recognised by proteases, again preventing degradation. 
Similarly, this variant did not affect PEPITEM function. 
These data suggested that PEPITEM can be modified to improve its stability in 
vivo without reducing its effectiveness at inhibiting PBL transmigration. This could 
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prove valuable further down the line in development for increasing peptide half-life, or 
for studying PEPITEM biology, for example by conjugation to a fluorescent dye as 
utilised in this chapter. Economically, crude synthesis of large numbers of modified 
peptides did not affect PEPITEM function and remains a cost-effective option for 
screening large numbers of modified peptides. 
 
Besides degradation by proteases, PEPITEM faces potential clearance from 
the circulation by the kidneys due to its small size of just 14 amino acids (1.5kDa). 
We employed the use of radiolabelled PEPITEM to measure PEPITEM presence in 
plasma. Disappointingly but perhaps expectedly, 3H PEPITEM demonstrated rapid 
clearance from the circulation of C57BL/6 mice, the majority of which occurred in 
under 2 minutes. The bi-exponential reduction observed was similar to results 
obtained following injection of inulin, a fructose polymer of approximately 5kDa (Qi et 
al., 2004) . A further decline in the presence of 3H PEPITEM occurred at 30 minutes. 
However, residual radioactivity remained after 60 minutes suggesting that PEPITEM 
may be held in a compartment interchangeable with the plasma, such as organs. The 
cardiac output in mice is 5-10ml/min and is approximately 20 times faster than in 
humans. Therefore, we cannot be certain how fast PEPITEM clearance from the 
circulation would occur in humans, but in light of these data, it is likely to be cleared 
quickly and probably by the kidneys. 
To investigate the endpoint of PEPITEM in vivo and confirm our suspicion of 
renal clearance, we conjugated PEPITEM to AF680 and initially checked for function 
in vitro. Unsurprisingly, since earlier modifications to either termini did not affect 
PEPITEM function, PEPITEM-AF680 still significantly inhibited PBL transmigration. 
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We next investigated the endpoint of PEPITEM in vivo. Baseline levels of 
fluorescence were present in all organs after 15 minutes, demonstrated by the 
control group. Furthermore, high levels of autofluorescence were detected in the 
organs of the GI tract, with the stomach exhibiting the highest levels of fluorescence 
of any organ including the kidneys in both control and PEPITEM-AF680-treated 
groups. This did not differ between groups, however since the autofluorescence was 
so high, it may not have been possible to detect smaller increases in fluorescent 
signal above this. Therefore we are unable to conclude if PEPITEM enters the 
stomach or gut in vivo. High levels of autofluorescence in these organs was most 
likely due to the chow diet, which consists highly of alfalfa and thus autofluorescent 
chlorophyll (Inoue et al., 2008). This was confirmed by imaging a chow pellet, which 
was highly fluorescent (data not shown). Higher fluorescence levels was also seen in 
the heart, spleen and lungs of PEPITEM-AF680 treated animals compared to the 
control group. This was in agreement with the pharmacokinetic data, which 
suggested the sequestration of small levels of radioactivity in, probably in plasma-
interchangeable tissue. 
The most dramatic difference in autofluorescence was seen in the kidneys of 
PEPITEM-AF680 treated mice. These data were highly suggestive of the majority of 
PEPITEM-AF680 being cleared from the circulation by the kidneys. We suspected 
this was highly likely, as peptides <5kDa are often rapidly cleared and PEPITEM is 
only 1.5kDa. The second largest difference in fluorescence was noted in the lungs. 
Other than the kidneys, the lungs receive a significant fraction of the cardiac output. 
This may explain the presence of fluorescence in the lungs of PEPITEM-AF680 
treated mice, however the mechanism of PEPITEM absorption by the lungs is 
unknown. Unfortunately, it is possible that some of the dye molecules may have been 
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cleaved off. To confirm this in the near future, radioactivity will be measured in all 
major organs collected following the pharmacokinetics experiment, and 3H PEPITEM 
organ distribution will be compared to PEPITEM-AF680 distribution. 
Together, these data imply that PEPITEM has a short in vivo half-life, leaving 
the circulation rapidly mainly due to renal clearance, however some residual 
PEPITEM may be retained in other organs. 
The half-life of PEPITEM must be increased in order to deliver a suitable 
therapeutic agent for the treatment of T cell-mediated chronic inflammatory diseases. 
This can be achieved by increasing its molecular weight, perhaps using higher 
molecular weight PEG or conjugation to larger inexpensive proteins such as albumin, 
which is not readily filtered by the kidneys (Leger et al., 2004). The issue of stability 
may then be addressed using the modifications tested in this chapter. One example 
where drug modification has led to a successful increase in in vivo half-life is the 
erythropoiesis-stimulating drug Hematide, which is modified with PEG (Stead et al., 
2006). Additionally, conjugation to albumin has extended the half-life of a glucagon-
like peptide 1(GLP-1) analogue termed CJC-1131, in clinical trials (Giannoukakis, 
2003). 
 
We next investigated the effect of intra-peritoneal delivery of native PEPITEM 
in an apoE-/- mouse model of atherosclerosis through examination of atherosclerotic 
changes in the aortic root. In these preliminary data, no difference in plaque burden 
in the aortic root was observed in mice receiving PEPITEM treatment compared to 
control groups. Chimen et al. (2015) had previously demonstrated the ability of 
PEPITEM to alleviate T cell trafficking in mouse models of Salmonella infection and 
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Sjögren's syndrome, by delivering PEPITEM to mice at 100µg/day IP for up to 4-5 
days. We therefore chose a dose of 700µg/week, and separated this into two 350µg 
injections in order to observe effects after 6 weeks HFD, whist complying with animal 
ethics. However two injections per day may not have been as efficient as daily 
delivery. It is unclear whether the similarities in plaque burden between groups is 
because the model is not sensitive to PEPITEM, or because of low therapeutic 
coverage resulting from two doses per week compared to daily doses. Furthermore, 
while we now know PEPITEM undergoes rapid clearance from the circulation, it is 
uncertain if delivery into the peritoneum makes PEPITEM susceptible to peptidases 
in the tissue.  
 
PEPITEM specifically inhibits the trans-endothelial migration of memory T cells 
(Chimen et al., 2015). Stemme et al. (1992) reported that 64% of T cells located in 
plaques are of the CD45RO+ memory phenotype, but it was unclear if these cells 
were differentiating into memory cells in the tissue, or whether they were being 
selectively recruited from the blood. While atherosclerosis involves a T cell element, it 
is also recognised as a multifactorial disease, with complex involvement of other cell 
types such as monocytes (Reviewed by Hansson et al. (2002)). Plaque formation 
occurred in our mouse model of atherosclerosis, but it is unclear if the model used 
was sensitive enough to detect small differences in treated mice as a result of 
inhibiting T cell trafficking into the plaque. Indeed the extent of involvement of T cells 
in atherosclerosis has been questioned for some time. Zhou et al. (2000) reported 
recruitment of CD4+ T cells to atherosclerotic lesions following allogenic transfer to 
apoE-/-/Scid-/- mice. The presence of CD4+ T cells exacerbated plaque burden in this 
model. Conversely, while Dansky et al. (1997) confirmed the presence of T cells in 
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atherosclerotic lesions, they concluded that lymphocytes play only a minor role in 
atherosclerosis and are not essential for atheroma formation in apoE-/- mice.  
 
High fat diet can be used to accelerate atherosclerosis in apoE-/- mice. 
However, placing mice on a high fat diet also induces steatosis, with studies 
reporting the deposit of lipids and inflammation in the liver as early as 7 weeks post-
high fat feeding (Schierwagen et al., 2015, Tous et al., 2005). Interestingly, while 
mice experienced plaque formation, no lipid deposits or abnormal morphology was 
observed in either group after 6 weeks of HFD. It is possible that 6 weeks of HFD 
feeding may not be sufficient to induce chronic lipid deposition, and perhaps may 
lead us to not see any difference in plaque burden following PEPITEM treatment, as 
atherosclerosis might not have been severe enough to demonstrate any potential 
effects of inhibition of T cell trans-endothelial migration with PEPITEM in this context. 
In summary, these experiments suggested that after 6 weeks of PEPITEM 
treatment, there was no difference in plaque burden. Small group numbers limited 
this investigation and unfortunately, one individual was also culled due to health 
issues. As there is much variability among living things, a repeat of this experiment 
with greater animal numbers is necessary, perhaps with an extended high-fat feeding 
time, and a revised treatment plan after establishing a peptide with a longer in vivo 
half-life. 
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5.4. Conclusion 
 
Effective therapeutics have long half-lives in vivo. They are not rapidly cleared 
by the kidneys, and are not degraded readily by proteases. PEPITEM is a good 
candidate as a therapeutic agent for the treatment of chronic inflammatory disease, 
and has potential for modification to address any stability issues it may have. 
However, its current use as a therapeutic is hampered by fast renal clearance 
reducing its availability and exposure, and therefore its effectiveness as a treatment.  
Many diseases are T cell mediated or have a T cell element which may 
exacerbate symptoms, including RA, atherosclerosis, and T1D. PEPITEM function 
was not altered by modification in vitro, but it didn’t last long in circulation and was 
cleared by the kidneys within minutes, with lesser amounts residing in other organs. 
We must now focus on increasing the in vivo half-life of PEPITEM by 
investigating methods used previously by others to produce successful drug 
treatments. These new versions of PEPITEM must then be tested in vitro for function, 
and in vivo for effectiveness using appropriate mouse models of chronic inflammation. 
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CHAPTER 6: THE ROLE OF 14-3-3ζ IN THE 
PEPITEM PARADIGM 
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6.1. Introduction 
 
Present in all eukaryotes, 14-3-3 proteins are highly conserved. They are 
capable of dimer formation and interaction with more than 200 ligands (Pozuelo 
Rubio et al., 2004). 14-3-3 has been identified as a modulator of numerous cellular 
processes required for the normal function of cells (reviewed in section 1.6.4), and 
has been associated with a range of diseases, particularly neurological conditions, 
for example Alzheimer’s disease (Berg et al., 2003). 14-3-3 proteins are primarily 
considered as intracellular trafficking proteins with numerous functions (Fu et al., 
2000). However some studies report 14-3-3 being present in extracellular 
environments. For example, 14-3-3 isoforms have been detected in cerebrospinal 
fluid (CSF) of patients suffering from Creutzfeld–Jakob disease (CJD) (Zerr et al., 
1998). Despite several associations with disease, a direct role for 14-3-3 in 
inflammation remains elusive and there is no clear biological function for extracellular 
14-3-3 isoforms.  
Recently, 14-3-3ζ and other isoforms of the 14-3-3 family of proteins were 
identified in the exosomes of B cells (Buschow et al., 2010). Exosomes are cell-
derived vesicles, containing cargo of proteins, lipids and RNA (Raposo and 
Stoorvogel, 2013). Having such important roles in other cellular functions, we 
considered whether 14-3-3 plays a role in the homeostatic mechanism identified by 
Chimen et al. (2015), involving B cell production of PEPITEM. PEPITEM represents 
amino acids 28 to 41 of the 27kDa 14-3-3ζ protein. Enzymatic release of PEPITEM 
from 14-3-3ζ protein has been demonstrated in Chapter 3. We also showed that 14-
3-3-His can inhibit PBL transmigration to the same extent as PEPITEM, however it 
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was not clear if that effect was due to 14-3-3ζ alone, or interference from the histidine 
tag. 
Though Chimen et al. (2015) demonstrated the presence of PEPITEM in B cell 
supernatants following AQ stimulation, it remains unclear how PEPITEM is released 
by B cells, or whether it is released first as 14-3-3ζ, and then subsequently cleaved 
into PEPITEM extracellularly by proteases. 
 
In this chapter, we examine the role of 14-3-3ζ in the function of PEPITEM. 
Initially, 14-3-3ζ recombinant protein was tested it in the in vitro migration assay for 
the ability to inhibit PBL transmigration in the absence of the histidine tag. Preliminary 
investigations were undertaken to examine the protein and mRNA expression of 
14-3-3ζ in B cells and EC. Ultimately, we investigated the role of proteases in the 
inhibitory function of 14-3-3ζ. 
Here, we describe the ability of 14-3-3ζ to inhibit PBL transmigration 
independent of B cells. We provide evidence that suggests B cells secrete 14-3-3ζ 
constitutively, and that matrix metalloproteases (MMPs) may play an important role in 
the release of PEPITEM from its parent protein, adding an additional layer of 
complexity to this already multifaceted homeostatic paradigm. 
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6.2. Results 
 
6.2.1. The effect of 14-3-3ζ protein on PBL transmigration in vitro. 
 
Since PEPITEM can be enzymatically released from 14-3-3ζ, and 14-3-3ζ-His 
elicited inhibitory function, we investigated whether using 14-3-3ζ recombinant 
protein in our in vitro migration assay would yield similar results compared to treating 
EC with PEPITEM. No difference in PBL adhesion was observed (Figure 6.1), 
however the addition of 14-3-3ζ in the migration assay showed significant ability to 
inhibit the transmigration of PBL across EC, reducing it from 25% in the control, to 
14%. This was comparable to PBL transmigration seen following PEPITEM treatment 
(12%). 
We considered the involvement of B cells in the effect of 14-3-3ζ, perhaps as 
the source of proteases releasing PEPITEM from 14-3-3ζ, and leading to the 
inhibition of PBL transmigration. To determine whether the effect of 14-3-3ζ required 
the presence of B cells, B cells were depleted from PBL preparations through 
negative selection. Flow cytometry was used to confirm the purity of samples post-
depletion. PBL were first gated on by size using SSC and FSC (Figure 6.2a). Next, 
doublets were removed (Figure 6.2b) and CD3+ T cells or CD19+ B cells were gated 
on (Figure 6.2c and 6.2d). Typically, CD3+ T cells made up the majority of the sample, 
with B cells representing approximately 3% of total PBL (Figure 6.3a). However post-
depletion, CD3+ T cells were enriched, and the presence of less than 1% CD19+ B 
cells was deemed acceptable (Figure6.3b). Typically, T cell purity was 99.5%. 
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Figure 6.1. Inhibition of PBL transmigration by 14-3-3ζ. 
PBL were added to cytokine-stimulated-EC with 20ng/ml 14-3-3ζ, PEPITEM or 
scrambled peptide (Scr). Adherent and migrated cells were assessed by phase 
contrast microscopy. Data represents mean ± SEM of 9 independent 
experiments, and was analysed by one way ANOVA with Dunnett’s post-test. 
***P<0.001, ns= not significant. 
Control PEPITEM   Scr     14-3-3ζ Control PEPITEM   Scr     14-3-3ζ 
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Figure 6.2. Gating strategy for the identification of PBL and PBMCs by 
flow cytometry. 
Representative flow cytometry plots demonstrating the gating approach for the 
assessment of T or B cells. PBL or PBMC were isolated from healthy donors. 
(a) Initially, the PBL populations were gated on based on size using forward 
scatter (FSC-H) and side scatter (SSC-H). (b) Doublet cells were gated out 
using FSC-H against Pulse width. (c ) T cells were identified as a CD3+ 
population, while (d) B cells were identified as CD19+ cells. 
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After depletion 
CD3 CD19 
CD3 CD19 
Figure 6.3. Assessment of B cell depletion from PBL preparations 
using flow cytometry. 
Representative flow cytometry plots illustrating the gating strategy 
employed to confirm B cell absence. B cells were depleted from isolated 
PBL by negative selection magnetic beads. Flow cytometry was used to 
assess T cell enrichment (a) before and (b) after B cell depletion. 
Preparations containing <1% B cells were deemed acceptable, however 
typically there were <0.5%. 
a) 
b) 
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After establishing an enriched T cell population consisting of less than 1% B 
cells, the in vitro migration assay was repeated using 20ng/ml 14-3-3ζ recombinant 
protein. Again, no difference was seen in adhesion. However interestingly, 14-3-3ζ 
retained its ability to inhibit PBL transmigration in the absence of B cells (Figure 6.4). 
Control conditions exhibited 27% transmigration, and 14-3-3ζ treatment reduced this 
to 15%, which was similar to PEPITEM treatment (14%). 
We next investigated whether the inhibitory effects of 14-3-3ζ were dependent 
on direct interaction with PBL in the in vitro migration assay. 14-3-3ζ recombinant 
protein was pre-incubated for 1 hour on cytokine-stimulated EC before washing and 
performing the migration assay with fresh PBL. Interestingly, while no differences 
were seen in adhesion, pre-treatment of EC with 14-3-3ζ inhibited PBL transmigration 
(Figure 6.5). Control conditions saw 30% transmigration, while treatment with 
PEPITEM, 14-3-3ζ, or pre-incubation with 14-3-3ζ reduced this to 20, 20 and 21% 
migration respectively. 
These data suggest that 14-3-3ζ can inhibit PBL transmigration. Whether this 
is directly as a protein or indirectly as PEPITEM remains unknown. 
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Figure 6.4. The effect of 14-3-3ζ on PBL transmigration following B cell 
depletion. 
B cells were depleted using magnetic beads and purity was confirmed by flow 
cytometry. PBL and 20ng/ml 14-3-3ζ, PEPITEM or Scrambled peptide (Scr) 
were simultaneously added to cytokine-stimulated EC and recruitment and 
migration were observed. **P<0.01 analysed by one way ANOVA with 
Dunnett’s post-test. Ns = not statistically significant. Data representative mean 
± SEM of 4 separate experiments. 
Figure 6.5. The effect of 14-3-3ζ pre-incubation with EC on PBL 
transmigration. 
Cytokine-stimulated EC were pre-incubated with 20ng/ml 14-3-3ζ for 1 hour 
before EC were washed and the migration assay performed. Data was analysed 
by one way ANOVA with Dunnett’s post-test, and represent 7 independent 
experiments.  ****P<0.001, ns=not statistically significant. Data expressed as 
mean ± SEM. 
Control PEPITEM   Scr     14-3-3ζ Control PEPITEM   Scr     14-3-3ζ 
Control PEPITEM  Scr   14-3-3ζ  14-3-3ζ 
                                                        (pre- 
                                                   incubation) 
Control PEPITEM  Scr   14-3-3ζ  14-3-3ζ 
                                                        (pre- 
                                                   incubation) 
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6.2.2. 14-3-3ζ expression by lymphocytes and endothelial cells. 
 
Chimen et al. (2015) demonstrated the presence of PEPITEM in B cell 
supernatants following B cell stimulation with AQ. However, the mechanisms of 
PEPITEM production from B cells remain unknown, and it is not clear whether 
PEPITEM is secreted as 14-3-3ζ before extracellular processing into PEPITEM. We 
performed preliminary investigations to identify whether B cells secrete 14-3-3ζ in 
response to AQ stimulation.  
B cells were first enriched from PBL by depleting CD19- cells. Flow cytometric 
analysis of processed samples was conducted, and B cell enrichment was confirmed 
(Figure 6.6). B cell purity of at least 95% was deemed acceptable, however purity 
was typically 96%. 
Following 1 hour incubation of B cells with or without AQ, B cell supernatants 
were lyophilised and examined for the presence of 14-3-3ζ protein via western blot. 
Recombinant 14-3-3ζ protein confirmed specificity of the antibody, and HeLa cell 
lysates of unknown protein concentration were used as an additional positive control. 
Interestingly, 14-3-3ζ protein was detectable in supernatants from both unstimulated 
and AQ stimulated samples (Figure 6.7a). Upon quantification of protein signal 
intensity by densitometry, 14-3-3ζ appeared to be produced in equivalent amounts in 
both unstimulated and AQ stimulated B cells (Figure 6.7b). 
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Figure 6.6. Confirmation of B cell enrichment from PBMC. 
Representative flow cytometry plots demonstrating the enrichment of B 
cells. PBMC were isolated from healthy blood and B cells were depleted. 
Flow cytometry was performed and the purity of CD19+ cells measured. B 
cell purity >96% was deemed acceptable. 
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Figure 6.7. 14-3-3ζ protein expression in B cell supernatants. 
B cells enriched from PBMC were stimulated with or without 10µg/ml 
adiponectin for 1 hour. Cells were pelleted and supernatants interrogated 
for 14-3-3ζ protein by western blotting. (a) blotting for 14-3-3ζ (b) 
densitometry of western blot using area under the curve method. Data is 
from 1 experiment. 
a) 
b) 
      14-3-3ζ          HeLa           B cell           B cell 
recombinant        cell    supernatants  supernatants 
      protein        lysates  unstimulated AQ- stimulated 
 10ng 14-3-3ζ      HeLa           B cell               B cell 
 recombinant       cell      supernatants   supernatants 
      protein         lysates  unstimulated  AQ- stimulated 
Lane:          1             2                3                 4 
34kDa   - 
14-3-3ζ  - 
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We subsequently assessed mRNA expression in lymphocytes and endothelial 
cells. Preliminary data showed the relative expression of 14-3-3ζ in B cells to be 
much higher than in HeLa cells, B cell-depleted PBL, or HDBEC (Relative expression 
to 18s: 866, 72, 54 and 23 respectively, Figure 6.8a). 14-3-3ζ expression did not 
substantially increase in B cells following AQ stimulation (Figure 6.8b), and was not 
significantly increased in cytokine-treated HDBEC (Figure 6.8c). Stimulated EC also 
demonstrated the presence of 14-3-3ζ protein assessed by confocal microscopy 
(Figure 6.9), which appeared highly expressed throughout the cells but not the nuclei. 
These preliminary results imply that EC and B cells express 14-3-3ζ protein, 
and it is possible that 14-3-3ζ is constitutively secreted by B cells. B cells, B cell-
depleted PBL and EC also express low levels of 14-3-3ζ mRNA, but B cells express it 
more highly. 
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Figure 6.8. Assessment of 14-3-3ζ gene expression in lymphocytes 
and HDBEC by qPCR 
(a) 14-3-3ζ mRNA expression in B cells, B cell-depleted PBL and EC. 
HeLa mRNA was used as a positive control (n=1). (b) 14-3-3ζ expression 
in isolated B cells stimulated with or without 10µg/ml AQ (n=1). (c) 14-3-
3ζ expression in HDBEC stimulated with or without TNF-α + IFN-γ (n=4, 
ns= not significant by Mann-Whitney t-test). 
a) 
b) 
c) 
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bisBenzimide             FITC                 MERGE 
Figure 6.9. Expression of 14-3-3ζ protein HDBEC. 
EC were grown in Ibidi µ-slides, cytokine-stimulated and fixed with 
formaldehyde. 14-3-3ζ was stained using mouse anti-human 14-3-3ζ 
primary antibody, followed by an anti-mouse-FITC secondary. Nuclei were 
stained with bisBenzimide and images were acquired using an inverted 
Zeiss LSM-510 UV confocal microscope. 
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6.2.3 Investigating the role of proteases in 14-3-3ζ function. 
 
The suggestion from preliminary data that B cells may constitutively secrete 
14-3-3ζ protein suggests that the regulation of PEPITEM production may be 
mediated by extracellular proteases from PBL or EC. Therefore, we investigated the 
role of proteases in 14-3-3ζ-mediated inhibition of PBL transmigration.  
MMPs are an abundant family of proteases expressed by a variety of cells, 
including PBL and EC (Abraham et al., 2005, Di Girolamo et al., 1998, Hanemaaijer 
et al., 1993). The role of MMPs in T cell migration has been reported in several 
studies (Brundula et al., 2002, Faveeuw et al., 2001, Marracci et al., 2002). We 
investigated the role of MMPs in the paradigm using a broad spectrum protease 
inhibitor, GM6001. Following pre-treatment of both PBL and EC with the inhibitor, the 
in vitro migration assay was performed, and surface adherent and transmigrated PBL 
were subsequently analysed. 
A small reduction in adhesion was noted following treatment with the 
GM6001+ 14-3-3ζ or GM6001+ PEPITEM, but not following treatment with the 
inhibitor alone (Figure 6.10). PEPITEM and 14-3-3ζ significantly inhibited PBL 
transmigration, and excitingly, this inhibition was lost following treatment with the 
GM6001+ 14-3-3ζ or GM6001+ PEPITEM. PBL transmigration was comparable to 
the control which was 41%, compared to 36.6% or 37.2% in 14-3-3 and PEPITEM 
treated conditions respectively. 
We next submitted the amino acid sequence of 14-3-3ζ to PROSPER, an 
online database to identify predicted proteases in silico (Figure 6.11a, Song et al. 
(2012)). Of the proteases that did not cleave in the centre of the PEPITEM sequence,  
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Figure 6.10. The effect of MMP inhibition on 14-3-3ζ and PEPITEM function. 
EC and PBL were treated with MMP broad-spectrum inhibitor, GM6001 (10nM) 
for 1 hour prior to performing migration assay. Immediately before migration, 
PEPITEM, scrambled peptide (Scr) or 14-3-3ζ (all 20ng/ml) were added to PBL. 
Data represents mean ± SEM of 6 independent experiments, analysed by one 
way ANOVA with Dunnett’s post-test. *P≤0.05, ** P≤0.01, P≤0.001. 
PEPITEM   -      +      -      -      -      -      -      + 
    Scr         -       -     +      -      -      -      -       - 
14-3-3ζ       -       -      -     +      -      -      +      - 
DMSO        -       -      -      -      +     -       -      - 
GM6001     -       -      -      -      -      +      +     + 
                                                         
PEPITEM   -      +      -      -      -      -      -      + 
    Scr         -       -     +      -      -      -      -       - 
14-3-3ζ       -       -      -     +      -      -      +      - 
DMSO        -       -      -      -      +     -       -      - 
GM6001     -       -      -      -      -      +      +     + 
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Figure 6.11. In silico analysis of predicted protease cleavage sites in 14-3-3ζ 
protein. 
(a) Human 14-3-3ζ protein sequence was entered into PROSPER, and analysed 
for the presence of protease cleavage sites. (b) Alignment of the seven 14-3-3ζ 
isoforms, highlighting conserved protease cleavage sites. The original PEPITEM 
sequence is highlighted in white, with the new 17aa product designated by a black 
box. 
a) 
b) 
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matrix metalloproteinase 9 (MMP-9, yellow residues) was identified as a potential 
protease involved in the release of PEPITEM from its parent protein. Proteases 
predicted to cleave within the PEPITEM sequence included cathepsin G (red 
residues) and glutamyl peptidase I (green residues). Furthermore, when we 
submitted all 14-3-3 isoforms to PROSPER, we noticed that several cleavage sites 
were conserved at the same residues between 14-3-3 family members (Figure 6.11b). 
While MMP-9 and cathepsin G cleavage sites were present in all 14-3-3 isoforms, 
glutamyl peptidase I was present in four family members. The relevance of these 
apparently conserved protease recognition sites is currently unknown. 
Together these results suggested a role for MMPs in the PEPITEM paradigm, 
however confirmation of the involvement of MMP-9 and the role of the other identified 
proteases is required. 
 
6.3. Discussion 
 
After the surprising finding that 14-3-3ζ-his inhibits PBL transmigration in vitro, 
we investigated the role of 14-3-3ζ in the PEPITEM paradigm. 
We first tested whether the inhibition of PBL migration by 14-3-3ζ-His was due 
to the presence of a histidine tag. Indeed 14-3-3ζ significantly inhibited PBL migration 
to the same extent as PEPITEM. We considered whether the 14-3-3ζ protein itself 
was inhibiting PBL trafficking, or whether 14-3-3ζ was first being processed into 
PEPITEM, maybe by B cells. Chimen et al. (2015) previously demonstrated the 
release of PEPITEM by B cells. In the view that extracellular 14-3-3ζ inhibits PBL 
 159 
 
transmigration, the processing of 14-3-3ζ is likely to be occurring outside of B cells to 
give rise to the PEPITEM detected in B cell supernatants, and not intracellularly. 
14-3-3ζ was used at 20ng/ml (0.72nM) in the migration assay, where we 
observed significant inhibition of PBL transmigration. Although the same 
concentration of PEPITEM was used, PEPITEM is much smaller in size than 14-3-3ζ 
protein. This means that there would have been fewer molecules of 14-3-3ζ but more 
molecules of PEPITEM, where 20ngml PEPITEM is equivalent to 13.3nM, and yet 
inhibition was observed with both treatments. PEPITEM significantly inhibits PBL 
transmigration at concentrations as low as 0.1ng/ml, equivalent to 0.07nM (Chimen 
et al., 2015). This may explain why 20ng/ml 14-3-3ζ still induced inhibition of PBL 
transmigration.  
We next investigated whether 14-3-3ζ-mediated inhibition of PBL required the 
presence of B cells, since PEPITEM was found in supernatants of isolated B cells, 
suggesting that they can process 14-3-3ζ into PEPITEM independently of other cell 
types. We depleted B cells from PBL preparations and examined transmigration in 
vitro. Indeed the presence of B cells was not necessary for 14-3-3ζ mediated 
inhibition of PBL transmigration. Assuming that 14-3-3ζ is processed into PEPITEM 
extracellularly, these data suggested that EC or T cells may also facilitate this 
process.  
Chimen et al. (2015) demonstrated that 1 hr pre-incubation with PEPITEM on 
EC before performing the migration assay inhibited PBL transmigration. We 
considered whether this was also true for 14-3-3ζ, and certainly it was. These results 
imply that extracellular 14-3-3ζ is capable of inhibition of PBL transmigration by first 
interacting directly with the EC. Perhaps the involvement of EC proteases was 
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required for the release of PEPITEM from 14-3-3ζ protein. Unfortunately while these 
investigations suggested that extracellular 14-3-3ζ inhibits PBL transmigration, they 
do not tell us whether EC is processing 14-3-3ζ into PEPITEM itself, or if PBL are 
affecting 14-3-3ζ after their addition to the EC.  
 
In preliminary investigations, we examined the secretion of 14-3-3ζ by B cells 
following stimulation with AQ.  14-3-3ζ protein expression in B cell supernatants in 
both unstimulated and AQ-stimulated conditions was detected by western blot. 
Interestingly, 14-3-3ζ is known to dimerise (Fu et al., 2000). However due to western 
blot methodology, we were unable to determine whether 14-3-3ζ in B cell 
supernatants was a monomer or a dimer, but this can be confirmed in future using 
native, SDS-free conditions. Quantification of protein by densitometry suggested 
similar protein levels in the supernatant of stimulated and unstimulated B cells, 
implying constitutive secretion of 14-3-3ζ protein of less than 10ng in 1 hour, as this 
was the concentration of recombinant 14-3-3ζ protein ran as a positive control. While 
there is a chance that 14-3-3ζ was found in B cell supernatants as a consequence of 
release following apoptosis, this is unlikely as experiments performed by other 
members of our lab have previously confirmed that B cells do not undergo apoptosis 
after 1 hour at room temperature.  
The 14-3-3 family of proteins including the 14-3-3ζ isoform have been 
detected in the exosomes of B cells (Buschow et al., 2010), suggesting that 
externalisation of 14-3-3ζ proteins represents an active secretory mechanism in 
immunity. However this requires careful investigation, as the B cells used in the study 
in question were an Epstein–Barr virus-transformed human B-cell line RN (HLA-
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DR15), and it is unclear how closely these cells resemble healthy human B cells. 
Exosomes from B cells isolated from healthy donors must now be examined for the 
presence of 14-3-3ζ, to evaluate the likelihood of 14-3-3ζ export from B cells via 
exosomes.  
Upon preliminary analysis of 14-3-3ζ expression in mRNA isolated from 
negatively selected B cells, PBL preps following B cell depletion or EC, B cells 
expressed 14-3-3ζ more highly, supporting our hypothesis that B cells are the cell 
type responsible for 14-3-3ζ secretion and therefore PEPITEM production in this 
paradigm, although this requires further validation due to the small sample size. In 
addition to 14-3-3ζ mRNA, endothelial cells were also seen to express 14-3-3ζ 
protein diffusely. Again this demonstrated the specificity of the process of 14-3-3ζ 
secretion by B cells, as EC have the potential for 14-3-3ζ secretion, yet they do not 
autoregulate this pathway and therefore must not secrete 14-3-3ζ. 
AQ stimulation did not increase 14-3-3ζ production by B cells, suggesting that 
B cells are constitutively expressing 14-3-3ζ. If this is indeed the case, the release of 
PEPITEM from 14-3-3ζ may well be regulated by proteases, under AQ control. MMPs 
are a family of proteases which are known to degrade extracellular matrix molecules. 
14-3-3 proteins have been identified in the literature as up-regulators of MMPs, and 
have been associated with inflammatory diseases. For example, 14-3-3σ has been 
shown to upregulate MMP-1 in fibroblasts (Asdaghi et al., 2012, Ghahary et al., 
2004), and levels of extracellular 14-3-3η in the joints and serum of RA patients 
correlated positively with MMP expression (Maksymowych and Marotta, 2014). 
Furthermore, numerous studies have reported the involvement of MMPs in T cell 
migration both in vitro and in vivo (Brundula et al., 2002, Faveeuw et al., 2001, 
Marracci et al., 2002).  
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We examined the involvement of MMPs in the inhibitory function of 14-3-3ζ 
using the broad spectrum MMP inhibitor GM6001. A reduction in adhesion following 
treatment with the inhibitor and 14-3-3ζ or PEPITEM was noted. It is possible that the 
GM6001 inhibitor exhibited a minor effect on PBL recruitment, as the conditions 
treated with it represented the lowest adhesion. Even so, transmigration was 
expressed as a percentage of adherent cells to account for this discrepancy. Pre-
incubation of EC and PBL with GM6001 abolished function of 14-3-3ζ, suggesting the 
requirement of MMPs for subsequent processing into PEPITEM for the inhibition of 
PBL transmigration. Unexpectedly, MMP inhibition also abrogated the ability of 
PEPITEM to inhibit PBL transmigration. In silico analysis using the online protease 
specificity prediction server, PROSPER, identified potential protease cleavage sites 
within 14-3-3ζ. MMP-9 cleavage sites flanked the PEPITEM sequence and were 
absent within the PEPITEM sequence itself.  Indeed studies have demonstrated the 
expression of MMPs, including MMP-9, in human B cells, as well as T cells (Abraham 
et al., 2005, Di Girolamo et al., 1998, Trocmé et al., 1998). Furthermore, MMP-9 
expression has been reported in endothelial cells (Taraboletti et al., 2002), and is 
upregulated following stimulation with TNF-α (Hanemaaijer et al., 1993, Mackay et al., 
1992, Nelimarkka et al., 1998). If MMP-9 does indeed cleave 14-3-3ζ into PEPITEM, 
this may explain why EC pre-treatment with 14-3-3ζ was able to significantly inhibit 
PBL transmigration. 
 
The peptidases cathepsin G and glutamyl peptidase I were predicted to cleave 
at sites located within the PEPITEM sequence. The broad spectrum MMP inhibitor 
does not inhibit cathepsin G or glutamyl peptidase I, yet both 14-3-3ζ and PEPITEM 
function was abrogated following treatment with the broad spectrum inhibitor. This 
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implies that MMPs are required for initial cleavage of 14-3-3ζ, but subsequent 
proteases, potentially cathepsin G or glutamyl peptidase I, may also be involved 
which require the initial cleavage from 14-3-3ζ into smaller peptides, recognisable by 
these proteases, to yield functional peptide(s). Indeed glutamyl peptidase I is an 
endopeptidase highly expressed in epithelial cells of the intestine and kidney, but 
also by vascular endothelium (Lojda and Gossrau, 1980). Cathepsin G on the other 
hand is expressed primarily by cells of the myeloid lineage (Grisolano et al., 1994), 
which were excluded in our assays, however one study has reported cathepsin G 
activity associated with T lymphocytes (Delgado et al., 2001). If glutamyl peptidase I 
is in fact responsible for further PEPITEM processing, it may explain why it requires 
initial degradation of 14-3-3ζ to recognise its substrate, since this endopeptidase 
recognises specific motifs at the N-terminus. 
Our data suggests an MMP, conceivably MMP-9, is responsible for initial 
cleavage of 14-3-3ζ into PEPITEM. However the MMP-9 cleavage sites would in fact 
yield a 17 amino acid product, providing the sequence MKSVTEQGAELSNEERN. 
Since mass spectrometric methodology involved peptide fragmentation, which 
always occurs uniformly due to the integral properties of the amino acids within the 
sequence, it is possible that the 14 amino acids detected previously were actually 
part of a larger 17 amino acid peptide sequence, MKSVTEQGAELSNEERN. 
Assuming this cleavage product is yielded from 14-3-3ζ by MMPs, the final possible 
peptide products cleaved by cathepsin G would be MK, SVTEQGAEL or SNEERN. 
Potential products yielded by glutamyl peptidase I would be MKSVTE and 
QGAELSNEERN, and if both proteases were involved, MK, SVTE, QGAEL or 
SNEERN could be cleaved. Therefore, it is possible that 14-3-3ζ, after initial cleavage 
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into PEPITEM, is subsequently processed into smaller pharmacophore(s). We must 
now evaluate which of these peptides are functional in vitro. 
Many proteins and peptides are known to undergo cleavage into smaller 
active forms, mediated by proteases. Several examples of this are evident in 
immunity. A number of different isoforms of the chemokine IL-8 have been identified 
(Yoshimura et al., 1989), and processing of these isoforms by a number of proteases 
including MMP-9, increase the activity of IL-8 (Van den Steen et al., 2000). 
Chemerin, like IL-8, is a chemoattractant protein with immunological function. It too 
can be cleaved by several proteases, including cathepsin G, into both active and 
inactive peptides (Kastin, 2013). 
 
14-3-3ζ is the only family member possessing the PEPITEM motif. However, 
rather interestingly, when all 14-3-3ζ isoforms are aligned, the PEPITEM sequence 
appears highly conserved with only a few amino acids varying in the sequence. 
Moreover, predicted MMP-9 protease sites appear conserved among family 
members, all giving rise to 17 amino acid peptide products following excision. 
Cathepsin G protease sites also appear conserved between family members, and 
this may have implications in vivo where cells of the myeloid lineage such as 
neutrophils are present. It raises important questions as to whether PEPITEM is in 
fact a member of a larger family of peptides derived from the 14-3-3 family of proteins. 
These peptides, like PEPITEM, may also have biological function, but whether this is 
in immunity is unknown. 
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The data presented in this chapter suggests that extracellular processing of 
14-3-3ζ must occur via initial involvement of MMPs in the processing of B cell-derived 
extracellular 14-3-3ζ into PEPITEM, and this initial step appears essential to 
subsequently yield functional peptides which inhibit PBL transmigration. It is now 
possible that PEPITEM is a 17 amino acid peptide subsequently processed into 
smaller peptides, and similar processing steps can be seen elsewhere in 
inflammation such as in IL-8 or chemerin production. 
 
6.4. Conclusion 
 
The importance of 14-3-3ζ and how it is regulated is now recognised as an 
integral part of the PEPITEM paradigm. Indeed both 14-3-3ζ and MMPs have been 
implicated in inflammatory diseases. 
The experiments performed in this chapter suggested the secretion of 14-3-3ζ 
by B cells, as well as an important role for MMPs and other proteases in the 
PEPITEM paradigm, representing another level of regulation of T cell trafficking. In 
order to fully comprehend this complex homeostatic pathway, we must now 
investigate which proteases are involved in the processing of 14-3-3ζ into PEPITEM, 
and what is their source. 
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CHAPTER 7 – GENERAL DISCUSSION 
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7.1 General discussion 
In this thesis, I examine the biological and chemical nature of PEPITEM, and 
investigate the involvement of proteases in the adiponectin-PEPITEM axis. 
I initially demonstrated the reproducibility of previous work conducted by 
Chimen et al. (2015) on the ability of adiponectin, and therefore PEPITEM, to inhibit 
T cell transmigration in vitro. I confirmed the simple structure of PEPITEM using NMR, 
but was unable to demonstrate any binding interactions with CDH15 or TSP-1 using 
Biacore binding assays. I showed the inability of PEPITEM to elicit measurable 
calcium flux in endothelial cells, and revealed the short circulating half-life of 
PEPITEM in vivo for the first time. This was found to be mainly due to renal filtration, 
and highlighted the requirement for further peptide modification in order to develop 
PEPITEM as a suitable therapeutic for chronic inflammatory diseases. Finally, I 
uncovered the significance of the 14-3-3ζ protein in the PEPITEM paradigm through 
demonstration of its secretion by B cells, and the requirement of MMPs for PEPITEM 
function. 
The PEPITEM-adiponectin axis represents a novel, exciting finding and 
provides insight into the molecular mechanisms underlying the regulation of T cell 
trafficking. However, due to its novelty, the underlying molecular mechanisms remain 
to be firmly established. The importance of understanding such mechanisms is 
highlighted in chronic inflammatory dieses such as T1D and RA, where this 
homeostatic regulatory pathway is impaired, and T cell trafficking becomes 
dysregulated. 
Current therapies used in the treatment of chronic inflammatory diseases often 
include the use of antibodies. Rituximab is monoclonal antibody currently used in the 
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treatment of RA, and is being investigated for the treatment of a range of other 
chronic inflammatory diseases (Gürcan et al., 2009). Through the recognition of 
CD20, it specifically depletes B cells believed to exacerbate disease through 
antibody production. This is interesting as Chimen et al. (2015) demonstrated B cell-
mediated inhibition of T cell trafficking across inflamed EC. However, Chimen et al. 
(2015) also demonstrated that B cell adiponectin receptor expression, required to 
elicit PEPITEM production, is impaired in chronic inflammatory diseases including RA 
and T1D. It has been suggested that certain B cell subsets promote T cell 
recruitment in mice models of diabetes (Ryan et al., 2010) but it is not known which 
subsets Rituximab targets (Browning, 2006). PEPITEM is secreted in higher 
quantitates by plasma cells (Chimen et al., 2015), suggesting plasma cells play a 
critical role in the regulation of T cell trafficking, however the role of Bregs in this 
context requires further attention. 
Anti-CD3 therapies including the monoclonal antibody Teplizumab (Sherry et 
al., 2011) have been tested in clinical trials and target T cells in T1D, thought to be 
responsible for the infiltration and subsequent destruction of beta cells in the 
pancreatic islets. The monoclonal antibody Infliximab is used to target soluble and 
membrane-bound TNF-α (Scallon et al., 2002), a pro-inflammatory cytokine 
responsible for the activation and subsequent recruitment of many immune cell types. 
TNF-α blockers such as Infliximab are currently used in the treatment of number of 
chronic inflammatory diseases including Crohn’s disease and RA. 
Unfortunately, the success of these antibody-based therapies has been 
somewhat limited. Aside from being highly expensive to produce, undesirable side-
effects and issues with recurrent infections can occur with these treatments, along 
with disappointing results over long-term treatment (Chatenoud et al., 1994, Herold et 
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al., 2002, Keymeulen et al., 2005, Pescovitz et al., 2009). There is clearly a 
requirement for more effective and more specific therapeutic agents. 
 
T cells are involved in a large range of chronic diseases. AQ and S1P are able 
to inhibit T cell transmigration through the paradigm shared with PEPITEM, however 
the therapeutic use of these molecules in the inhibition of T cell trafficking is 
unsuitable, with the exception of the S1P analogue fingolimod, which was approved 
by the FDA in 2010 for the treatment of multiple sclerosis (MS), (FDA, 2010). Both 
adiponectin and S1P have pleotropic effects on metabolism and T cell migration 
respectfully, and are therefore likely to lead to undesirable off-target effects. On the 
other hand, PEPITEM represents a different therapeutic strategy for the treatment of 
T cell mediated disease, owing to its specificity to T cells and potency at low 
concentrations (Chimen et al., 2015). Additionally, as a peptide, it would be more 
cost effective than current antibody therapies. So far, no toxicity has been associated 
with PEPITEM in short-term animal studies conducted both here and by Chimen et al. 
(2015), however its long term toxicity is unknown and must be validated. 
Unfortunately, like many therapeutics, the use of PEPITEM as a therapeutic 
agent has limitations highlighted by research presented in this thesis. Perhaps the 
biggest hurdle for the development of PEPITEM as a therapeutic agent is its rapid 
renal clearance from the circulation. An effective therapeutic agent requires a long in 
vivo half-life to maximise exposure to its target, and exert intended effects. Many 
successful therapeutic agents have undergone modification to become appropriate 
medications, including the erythropoiesis-stimulating drug Hematide, and the 
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glucagon-like peptide 1 (GLP-1) analogue CJC-1131 (Giannoukakis, 2003, Stead et 
al., 2006).  
When designing a drug, it is important to consider the intended method of 
delivery. Oral therapy is the most desirable method as it allows non-invasive dosage, 
which can be managed by the patient. Absorption by the gut and entrance into the 
blood stream must be considered when modifying PEPITEM to ensure it is efficiency. 
For certain T cell-mediated skin conditions such as psoriasis, topical treatment with 
PEPITEM is an option and may require minimal modification for success, facing no 
opposition from rapid renal clearance. Indeed we must now further modify PEPITEM 
to suit its requirements in vivo, and screen modified peptides in vitro using a suitable 
high-throughput assay. Optimal doses of these modified peptides must then be 
established using in vivo models of chronic inflammation. 
 
The 14-3-3 family of proteins have only briefly been associated with 
lymphocyte trafficking to date. In the current literature, a role for 14-3-3σ in the 
regulation of integrin activation in fibroblasts and lymphocytes has been described 
(Nurmi et al., 2006). Indeed it is intriguing since neither 14-3-3ζ protein nor PEPITEM 
have been associated with lymphocyte trans-endothelial migration in the literature, 
and certainly have not been linked to S1P production by endothelial cells. 
The evidence presented in this thesis provides new insights into the novel 
immunological role of extracellular 14-3-3ζ protein. These data suggest that 14-3-3ζ 
is released from B cells, and PEPITEM is subsequently excised from the parent 
protein extracellularly by MMP-9. It is likely that PEPITEM undergoes further 
proteolytic cleavage into smaller bioactive peptides, however this step requires initial 
 171 
 
excision of PEPITEM from 14-3-3ζ. Numerous studies have reported the involvement 
of MMPs in T cell migration both in vitro and in vivo, however MMP-9-mediated 
degradation of 14-3-3ζ into a functional immunological peptide is a novel observation. 
Fascinatingly, in other 14-3-3 family members, the respective PEPITEM 
sequence differs only by a few amino acids. In silico analysis revealed conserved 
predicted MMP-9 cleavage sites present in all 7 14-3-3 family members, at the same 
residues flaking the PEPITEM-like motifs, all of which were 17 amino acids in length. 
This remarkable similarity suggests that the other PEPITEM-like sequences, once 
excised, may also have biological activity. It is possible that proteolytic cleavage of 
the 14-3-3 family members represents an evolutionary trait for the systematic release 
of functional peptides key to other regulatory paradigms, perhaps associated with 
their diverse range of functions. 
3D constructions of the 14-3-3ζ protein structure demonstrate PEPTEM 
residues exposed on the protein surface. Presumably, this facilitates cleavage of 
these residues from 14-3-3ζ. The NMR data presented in this thesis suggested 
potential hinge regions at either end of PEPITEM, roughly corresponding to the 
helices which flank the sequence. This flexibility may indeed allow interaction with 
proteases, and it would be interesting to see if this feature is also present at 
corresponding residues in the other 14-3-3 isoforms. 
It is now clear that 14-3-3ζ signifies yet another level of homeostatic regulation 
of T cell trafficking in the PEPITEM paradigm, necessary for the prevention of chronic 
inflammatory disease. The cellular source of proteases and the underlying 
mechanisms controlling their function must now be investigated. 
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Chimen et al. (2015) studied the effects of PEPITEM on T cell migration and 
showed that PEPITEM inhibits CD4+ and CD8+ T cells, but not neutrophils or 
monocytes. Within PBL, B cells were shown to secrete this agent, however other 
potential sources of PEPITEM were not explored. The research presented in chapter 
6 demonstrated the ability of several cell types including epithelial cells (HeLa) and 
endothelial cells (HDBEC) to express the parent protein 14-3-3ζ. This raises the 
question of which other cell types may also be able to produce PEPITEM and thus 
regulate the immune response, and requires more attention. 
In summary, this research provides us with additional knowledge about T cell 
trafficking and the current model of the PEPITEM paradigm, which is illustrated in 
Figure 7.1. However, many questions remain to be addressed, listed in section 7.2. 
Understanding the molecular mechanisms underlying this regulatory process 
and identifying crucial motifs within the PEPITEM sequence will facilitate the design 
of modified peptides for therapeutic use. Additionally, although much more 
complicated than originally comprehended, complete elucidation of the PEPITEM 
paradigm will prove invaluable to the field of T cell immunology, as it represents a 
significant homeostatic mechanism crucial for the prevention of disease and appears 
central to the regulation of T cell trafficking into inflamed tissues.  
Our observations to date add to our current understanding of PEPITEM, and 
with subsequent investigation, the prospect of exploiting PEPITEM for the treatment 
of T cell-mediated chronic disease looks hopeful. 
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7.2 Future investigations: 
 
Whist significant findings have been made in this thesis regarding the 
PEPITEM paradigm, much remains to be understood about this fascinating and 
unique pathway. Here, I summarise questions highlighted by this thesis requiring 
further investigation for a comprehensive understanding of the biology of PEPITEM, 
and to facilitate therapeutic development. 
 
 Investigations into PEPITEM function 
Is PEPITEM a 17 amino acid peptide, and does it undergo further processing? 
A 17-amino acid sequence is now suspected to represent PEPITEM and must be 
synthesised and tested in the in vitro migration assay for function. We can further 
investigate its function through the use of inhibitors for glutamyl peptidase I, which we 
suspect is responsible for further cleavage into smaller pharmacophore. We must 
also synthesis these shorter peptide sequences and assess them for the ability to 
inhibit PBL transmigration in vitro. 
How does PEPITEM interact with CDH15 on the endothelial cell surface? 
We must study the interactions occurring at the endothelial cell surface, and how 
CDH15 is functioning as the PEPITEM receptor. The use of CDH15, 14-3-3ζ, MMP-9 
and TSP-1 as “bait” to “fish” for interacting proteins may allow us to determine 
whether a complex of proteins assemble at the endothelial cell surface. Microarray 
data may elucidate how the endothelial transcriptome is affected by PEPITEM 
binding, as this is currently unknown.  
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How can we screen for PEPITEM function rapidly? 
The in vitro migration assay has been central to this thesis but consists of many time-
consuming elements unsuitable for high-throughput screening of PEPITEM function. 
It is important to develop a high-throughput assay as the measurement of calcium 
flux via a plate reader-based assay was not feasible. We must investigate the 
possibility of utilizing more sensitive calcium dyes or confocal microscopy to measure 
intracellular calcium flux. Alternatively, we can investigate the use commercially 
available kits for measuring sphingosine kinase 1 activity in endothelial cells. 
Are other cell types capable of PEPITEM production? 
While Chimen et al. (2015) demonstrated the ability of B cells to inhibit T cell 
transmigration via the production of PEPITEM, the potential for other cell types to 
produce PEPITEM has not been excluded.  We must now determine which other cell 
types which express 14-3-3ζ can also produce PEPITEM, and what may be 
regulating its production. 
 
 Assessing the role of 14-3-3ζ in the PEPITEM paradigm 
Is 14-3-3ζ secreted specifically by B cells? 
Preliminary results suggest that 14-3-3ζ is expressed in, and in fact secreted by B 
cells in vitro. However, these experiments must be repeated to ascertain validity. The 
presence or absence of 14-3-3ζ in the supernatants of EC or isolated T cells must 
also be confirmed. Since 14-3-3ζ dimerization can facilitate interaction with ligands, B 
cell-secreted 14-3-3ζ must be assessed for the presence of dimers using native 
western blotting. To confirm the in vivo relevance of 14-3-3ζ function in the context of 
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the PEPITEM paradigm, the generation of a B cell-specific 14-3-3ζ knock out mouse 
could be employed in in vivo mouse models of inflammatory diseases.  
What mechanisms lead to14-3-3ζ export in B cells? 
Our data suggested that 14-3-3ζ is released extracellularly by B cells, and this may 
be occurring via B cell exosomes. This mode of active export of 14-3-3ζ requires 
characterising, and the exosomes from B cells isolated from heathy donors must be 
assessed for the presence of 14-3-3ζ ex-vivo. Confirmation of the involvement of B 
cell exosomes in the release of extracellular 14-3-3ζ can be confirmed using 
commercially available exosome-specific inhibitors. 
What is the role of other 14-3-3 family members in immunity?  
The 14-3-3 family of proteins exhibited conserved protease recognition sites within 
the same residues corresponding to the location of PEPITEM. It is likely that the 
other peptide products resulting from cleavage at these sites have biological activity. 
We must examine whether these peptides are involved, like PEPITEM, in the 
inflammatory response, or whether they represent parts of other regulatory pathways.  
 
 Characterising the proteases involved in 14-3-3ζ processing 
Which protease(s) are involved in 14-3-3ζ processing? 
To identify the involvement of specific proteases in the production of PEPITEM and 
derived peptides, the gene expression of proteases including MMP-9 and glutamyl 
peptidase I must be assessed in isolated T and B cell preparations, and in EC. 
Supernatants from these isolated cell types must be examined for protein expression 
of extracellular MMP-9 and glutamyl peptidase I by western blotting. Furthermore, the 
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role of AQ in the control of PEPITEM production must be explored, since AQ was 
previously shown to lead to the release of PEPITEM in B cell supernatants. 
What is the source of proteases and how are they regulated? 
While we have elucidated a role for proteases in the production of PEPITEM, we 
have not yet ascertained the cell type(s) responsible for them. The use of specific 
MMP-9 and glutamyl peptidase I inhibitors in the migration assay will establish 
protease involvement. By incubating either PBL or T cells with specific protease 
inhibitors, we will be able to narrow down the source of these proteases. Once the 
protease(s) and source(s) are defined, subsequent investigations into their regulation 
should be conducted. The use of MMP-9-/- mice, which are commercially available, 
will facilitate investigations into the importance of these protease(s) in the PEPITEM 
paradigm in vivo. 
 
 Development of PEPITEM as therapeutic agent 
How can we increase PEPITEM half-life? 
It is essential that the half-life of PEPITEM is increased for successful use in the 
treatment of T cell-mediated chronic diseases. Pharmacological modifications, 
including the addition of higher molecular weight PEG and conjugation to albumin, 
must be synthesised and screened for functionality using the in vitro migration assay. 
Subsequent investigations must follow to assess in vivo half-life and 
pharmacokinetics. After the identification of suitable peptide modifications, in vivo 
models of chronic inflammatory disease must be employed to validate the 
effectiveness of PEPITEM as a therapeutic agent. 
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